



OPEN ACCESS

Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload

Christina W Obiero ,^{1,2} Phoebe Williams,^{1,3} Sheila Murunga,¹ Johnstone Thitiri,¹ Raymond Omollo,⁴ Ann Sarah Walker,⁵ Thaddaeus Egondi,⁴ Borna Nyaoke,⁴ Erika Correia,⁶ Zoe Kane,⁷ Silke Gastine,⁷ Karin Kipper,^{8,9} Joseph F Standing,⁷ Sally Ellis,⁶ Mike Sharland,¹⁰ James Alexander Berkley ,^{1,3,11} for the NeoFosfo Study Group

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/archdischild-2021-322483>).

For numbered affiliations see end of article.

Correspondence to

Dr James Alexander Berkley, Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi 80108, Kenya; jberkley@kemri-wellcome.org

Received 18 May 2021

Accepted 24 December 2021

Published Online First

25 January 2022

ABSTRACT

Objective To assess pharmacokinetics and changes to sodium levels in addition to adverse events (AEs) associated with fosfomycin among neonates with clinical sepsis.

Design A single-centre open-label randomised controlled trial.

Setting Kilifi County Hospital, Kenya.

Patients 120 neonates aged ≤ 28 days admitted being treated with standard-of-care (SOC) antibiotics for sepsis: ampicillin and gentamicin between March 2018 and February 2019.

Intervention We randomly assigned half the participants to receive additional intravenous then oral fosfomycin at 100 mg/kg two times per day for up to 7 days (SOC-F) and followed up for 28 days.

Main outcome(s) and measure(s) Serum sodium, AEs and fosfomycin pharmacokinetics.

Results 61 and 59 infants aged 0–23 days were assigned to SOC-F and SOC, respectively. There was no evidence of impact of fosfomycin on serum sodium or gastrointestinal side effects. We observed 35 AEs among 25 SOC-F participants and 50 AEs among 34 SOC participants during 1560 and 1565 infant-days observation, respectively (2.2 vs 3.2 events/100 infant-days; incidence rate difference -0.95 events/100 infant-days (95% CI -2.1 to 0.20)). Four SOC-F and 3 SOC participants died. From 238 pharmacokinetic samples, modelling suggests an intravenous dose of 150 mg/kg two times per day is required for pharmacodynamic target attainment in most children, reduced to 100 mg/kg two times per day in neonates aged < 7 days or weighing < 1500 g.

Conclusion and relevance Fosfomycin offers potential as an affordable regimen with a simple dosing schedule for neonatal sepsis. Further research on its safety is needed in larger cohorts of hospitalised neonates, including very preterm neonates or those critically ill. Resistance suppression would only be achieved for the most sensitive of organisms so fosfomycin is recommended to be used in combination with another antimicrobial.

Trial registration number NCT03453177.

What is already known on this topic?

- ⇒ Antimicrobial resistance poses a threat to neonatal survival and there is an urgent need for affordable new treatment options.
- ⇒ Intravenous fosfomycin presents a significant sodium load and oral fosfomycin preparations contain a large amount of fructose, but limited safety data exist in neonates.
- ⇒ Paediatric and neonatal dosing recommendations for intravenous fosfomycin are divergent and there are no published oral dosing regimens.

What this study adds?

- ⇒ Intravenous and oral fosfomycin had no evidence of impact on serum sodium or gastrointestinal side effects at 100 mg/kg two times per day, respectively.
- ⇒ Intravenous fosfomycin 150 mg/kg two times per day is likely required for pharmacodynamic target attainment in most children, reduced to 100 mg/kg two times per day in neonates aged < 7 days or weighing < 1500 g.
- ⇒ Fosfomycin has potential for affordable treatment of neonatal sepsis in combination with other antimicrobials while sparing carbapenems in the context of increasing antimicrobial resistance.

INTRODUCTION

Antimicrobial resistance (AMR) disproportionately impacts populations in low-income and middle-income countries (LMICs). Reductions in mortality have been less in neonates than older children, and at least one-quarter of neonatal deaths are attributable to infection.¹ AMR contributes to this burden, with multidrug-resistant (MDR) pathogens accounting for $\sim 30\%$ of global neonatal sepsis deaths.²

WHO recommends ampicillin, penicillin or cloxacillin (if *Staphylococcus aureus* infection is suspected) plus gentamicin (first-line), and



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

To cite: Obiero CW, Williams P, Murunga S, et al. *Arch Dis Child* 2022;**107**:802–810.

third-generation cephalosporins (second-line) for empiric treatment of neonatal sepsis.³ With spread of extended spectrum β -lactamase (ESBL) and carbapenemase enzymes,⁴ clinical isolates are commonly reported non-susceptible to this regimen.⁵ Carbapenem-sparing is important in controlling MDR,⁶ and reintroduction of legacy antibiotics has been advocated to address the lack of new affordable antibiotics.⁷

Fosfomycin is an off-patent phosphonic acid derivative identified as 'critically important' by WHO.⁸ Fosfomycin is bactericidal⁹ and exhibits activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant *S. aureus*, vancomycin-resistant *Enterococcus* spp, ESBL producers and may penetrate biofilms.¹⁰ Fosfomycin demonstrates in vitro synergy with aminoglycosides and carbapenems^{11 12} and is commonly used for MDR urinary tract infections in adults.¹³

Current paediatric intravenous fosfomycin dosing recommendations are divergent, ranging between 100 and 400 mg/kg/day, without published oral dosing regimens. Four neonatal studies estimate an elimination half-life of 2.4–7 hours following 25–50 mg/kg intravenously.^{14 15} Protein binding was minimal and maximum concentration was in-line with adult data.^{16 17} Bactericidal effects are thought to correlate with either time above the minimum inhibitory concentration (MIC)¹⁶ or area under the curve (AUC):MIC ratio.^{18 19}

Case reports totalling 84 neonates treated with intravenous fosfomycin 120–200 mg/kg/day suggest it is well-tolerated.^{20–24} Toxicity among adults and older children appears low.²⁵ However, parenteral fosfomycin contains 14.4 mmol/330 mg sodium per gram—a potential safety concern in neonates whose sodium reabsorption is inversely proportional to gestational age (GA).²⁶ Furthermore, oral fosfomycin contains a high fructose load (~1600 mg/kg/day), which may predispose to gastrointestinal side effects and impact fluid balance.^{27 28}

We aimed to assess pharmacokinetics (PK) and changes to sodium levels in addition to adverse events (AEs) associated with intravenous followed by oral fosfomycin in neonates with clinical sepsis.

METHODS

Participants and study design

We conducted an open-label randomised controlled trial of standard-of-care (SOC) antibiotics alone, versus SOC plus intravenous then oral fosfomycin, in neonates with clinical sepsis at Kilifi County Hospital (KCH), Kenya.

Screening and eligibility

All neonates admitted to KCH were screened. Inclusion criteria were: age ≤ 28 days, weight > 1500 g, gestation > 34 weeks and meeting criteria for intravenous antibiotics per WHO³ and Kenyan²⁹ guidelines. Neonates were excluded if requiring cardiopulmonary resuscitation, grade 3 hypoxic ischaemic encephalopathy,³⁰ sodium ≥ 150 mmol/L, creatinine ≥ 150 μ mol/L, jaundice requiring exchange transfusion, allergy or contraindication to fosfomycin, a specific indication for another antibiotic class, admitted from another hospital or not residing within Kilifi county (figure 1).

Participants were enrolled within 4 hours of the first dose of SOC antibiotics, until September 2018 when a protocol amendment extended this to within 24 hours to include overnight admissions.

Enrolment and randomisation

A randomisation schedule with random block sizes was used to assign participants (1:1) to continue SOC antibiotics only or

receive SOC plus (up to) 7 days of fosfomycin (SOC-F) (online supplemental figure S1). Concealment was by sequentially numbered opaque sealed envelopes.

Study treatment

SOC entailed ampicillin or cloxacillin (if staphylococcal infection was suspected) plus gentamicin as first-line antibiotics, or third-generation cephalosporins (eg, ceftriaxone) as second-line antibiotics according to WHO and Kenya paediatric guidelines.^{3 29} Participants randomised to SOC-F also received intravenous fosfomycin for at least 48 hours, switching to oral when tolerating feeds sufficiently to presume adequate absorption of oral medications. Fosfomycin (intravenous or oral) was administered for 7 days or until discharge, whichever occurred first. Fomicyt 40 mg/mL fosfomycin sodium solution for intravenous infusion (Infectopharm, Germany) and Fosfocina 250 mg/5 mL fosfomycin calcium suspension for oral administration (Laboratorios ERN, Spain) were given at 100 mg/kg/dose two times per day.

Follow-up, safety monitoring and outcomes

Participants were followed-up for 28 days. All participants were cared for in the same high dependency unit to standardise AE monitoring. Complete blood count and biochemistry (including sodium) were done at admission, days 2 and 7, and were repeated if clinically indicated. AEs were coded according to MedDRA V.22.0. Severity was classified according to DAIDS V.2.1. AEs were followed up until clinical resolution or judged to be chronic and stable while receiving care. 'Anticipated' AEs were defined a priori as those expected to occur commonly in this population, including likely deteriorations of conditions present at birth (trial protocol in online supplemental file 1).

Pharmacokinetics

Patients allocated to SOC-F were randomly assigned to one early (5, 30 or 60 min) and one late (2, 4 or 8 hours) PK sample after both the first intravenous and first oral fosfomycin doses. A non-systematic fifth sample was collected for participants still hospitalised on day 7. Opportunistic cerebrospinal fluid (CSF) samples were collected from clinically indicated lumbar punctures (LP). Sample processing and fosfomycin measurement are described in online supplemental file 2.

Statistical methods

We reviewed admission data between 2015 and 2016 and calculated a mean sodium of 139 mmol/L (SD 7.6, range 106–198) among 1785 neonates weighing > 1500 g. Excluding 132 neonates who had serum sodium of > 150 mmol/L (our exclusion criteria) resulted in a mean sodium of 137 mmol/L (SD 5.2) among the remaining 1653 neonates. A sample size of 45 per arm was subsequently calculated to ensure a 5 mmol/L difference in plasma sodium at day 2 could be determined with $> 85\%$ power based on local prior sodium distribution data.

For PK, a sample size of 45 provided $> 85\%$ power to estimate PK parameters for clearance, volume of distribution and bioavailability with 95% CIs with precision of $\geq 20\%$ using simulation-estimation. For this, an adult disposition model, with age and size scaling to neonates with added first-order absorption and assumed bioavailability was used.³¹ To




Figure 1 Trial flow chart. This original figure was created by CWO for this manuscript. CPR, cardiopulmonary resuscitation; HIE, hypoxic ischaemic encephalopathy; IV, intravenous; SOC, standard of care; SOC-F, standard of care plus fosfomycin. *Reasons include mother postcaesarean section (46) or seriously ill (6), absconded from hospital (3), discharged against advice (3), abandoned by mother (1) and already enrolled into another study (1). †One SOC-F participant died after completing follow-up (on day 106).

allow for missed samples, we aimed to recruit 60 neonates per arm.

Differences in baseline parameters were tested using χ^2 test, Student's t-test or Wilcoxon rank-sum test. Differences in sodium, potassium, creatinine and alanine aminotransferase at day 2 and 7 were tested using analysis of covariance adjusting for baseline values. For AEs, serious adverse events (SAEs) and adverse drug reactions, we estimated incidence rate ratios (IRR) and rate differences (IRD) between arms with two-sided exact CIs using STATA V.15.1 (StataCorp, College Station, Texas, USA).

Model-based estimation of PK parameters was undertaken using first-order conditional estimation with interaction in

NONMEM V.7.4.³² Full details of PK model development and simulations are provided elsewhere.³²

Ethical review and oversight

DNDi/GARDP undertook on-site monitoring and an independent Data Safety and Monitoring Board provided oversight.

RESULTS

Enrolment

Between 19 March 2018 and 6 February 2019, 120 neonates (61 SOC-F, 59 SOC) were enrolled (figure 1), 42 (35%) before the protocol amendment. Median (IQR) age, weight and GA were

Table 1 Baseline characteristics

	SOC (n=59)	SOC-F (n=61)	All (n=120)	P value (SOC vs SOC-F)
Age (days)	1 (0–4)	1 (0–3)	1 (0–3)	
Gestational age (weeks)	38 (37–40)	40 (38–40)	39 (38–40)	0.079
Sex				
Female	24 (41)	24 (39)	48 (40)	0.881
Male	35 (59)	37 (61)	72 (60)	
Anthropometry				
Weight (g)	2700 (2080–3200)	2800 (2500–3230)	2750 (2370–3215)	0.154
Head circumference (cm)	34.0 (32.5–36.0)	34.7 (33.6–36.0)	34.6 (33.0–36.0)	0.173
Length (cm)	48.0 (44.4–49.5)	48.0 (46.0–49.5)	48.0 (45.0–49.5)	0.371
Admitted from				
KCH maternity	24 (41)	28 (46)	52 (43)	0.846
Other health facility	20 (34)	19 (31)	39 (33)	
Home	15 (25)	14 (23)	29 (24)	
Clinical symptoms				
Fever	21 (36)	22 (36)	43 (36)	0.957
Difficulty in breathing	39 (66)	40 (66)	79 (66)	0.951
Difficulty feeding	10 (17)	11 (18)	21 (18)	0.876
Seizures	8 (14)	11 (18)	19 (16)	0.502
Vomiting	1 (1.7)	1 (1.6)	2 (1.7)	0.981
Clinical signs				
Axillary temperature (°C)	36.8 (36.3–37.4)	37 (35.7–37.6)	36.9 (35.9–37.5)	0.580
Heart rate (bpm)	147 (136–161)	147 (138–158)	147 (138–159)	0.471
Respiratory rate (bpm)	54 (45–68)	56 (48–68)	56 (48–68)	0.953
Oxygen saturation (%)	96 (86–97)	95 (88–98)	96 (88–98)	0.484
Capillary refill time ≥ 2 s	12 (20)	14 (23)	26 (22)	0.728
Respiratory distress*	43 (73)	37 (61)	80 (67)	0.156
Jaundice	6 (10)	11 (18)	17 (14)	0.217
Skin lesions†	4 (6.8)	3 (4.9)	7 (5.8)	0.664
Abdominal distension	5 (8.5)	1 (1.6)	6 (5.0)	0.086
Impaired consciousness‡	2 (3.4)	9 (15)	11 (9.2)	0.031
Abnormal posture	1 (1.7)	3 (4.9)	4 (3.3)	0.223
Abnormal tone	8 (14)	13 (21)	21 (18)	0.264
Bulging fontanel				
Agitated	9 (15)	11 (18)	20 (17)	0.683
Lethargic	10 (17)	17 (28)	27 (23)	0.152

Data are n (%) or median (q25–q75).

*Nasal flaring, lower chest wall indrawing and/or grunting.

†Pustules, vesicles, petechiae and/or cellulitis.

‡Responsive to pain only or unresponsive.

KCH, Kilifi County Hospital; SOC, standard of care; SOC-F, standard of care plus fosfomycin.

1 day (IQR 0–3), 2750 g (2370–3215) and 39 weeks (38–40), respectively. Baseline characteristics and laboratory parameters are presented in table 1 and online supplemental table S1.

Two neonates had detected bacteraemia (online supplemental table S2). Two of 55 neonates who underwent an LP had laboratory-confirmed meningitis (*Streptococcus agalactiae* bacteraemia with CSF leucocytes ≥ 20 cells/ μ L (SOC-F); positive CSF antigen test for *Streptococcus pneumoniae* and CSF leucocytes ≥ 20 cells/ μ L (SOC)).

Treatment fidelity and follow-up

One SOC-F neonate erroneously received only SOC antimicrobials and was excluded from PK analyses. Two SOC-F and one SOC neonate withdrew consent—data are included up to withdrawal. All except two SOC participants (cloxacillin plus gentamicin (n=1) and ceftriaxone (n=1)) received ampicillin plus gentamicin at admission. Online supplemental table S3 shows antibiotic combinations administered in participants who received antibiotics other than ampicillin plus gentamicin at

admission or following change of treatment. Ten SOC-F participants switched to second-line therapy due to clinical deterioration or meningitis, five prior to the fourth PK sample (online supplemental table S3). Overall, 60 participants received at least one intravenous fosfomycin dose and 58 at least one oral dose.

Six (four SOC-F, two SOC) participants died in hospital (figure 1). One SOC participant died 3 days postdischarge (day 22). One SOC-F participant missed follow-up and was later found to have died on day 106 (outside the study follow-up period); data were included up to day 28. Three SOC-F infants were lost to follow-up. Total infant/days of observation were 1560 and 1565 for SOC-F and SOC, respectively, of which 422 and 314 were in hospital.

Biochemical safety

On day 2, the mean (SD) plasma sodium values were 137 mmol/L (4.6) in SOC-F vs 136 mmol/L (3.7) in SOC participants; mean difference +0.7 mmol/L (95% CI –1.0 to +2.4). On day 7, mean (SD) sodium values were 136 mmol/L (4.2) vs

Table 2 Descriptive summary of blood chemistry parameters by randomised treatment arm

Parameter	Statistic	Day 0		Day 2		Day 7	
		SOC (n=59)	SOC-F (n=61)	SOC (n=59)	SOC-F (n=61)	SOC (n=6)	SOC-F (n=7)
Sodium (mmol/L)	Range (min-max)	126–145	125–149	126–143	126–149	136–144.8	128–141
	Mean (SD)	135.4 (4.1)	136.4 (5.3)	135.7 (3.8)	136.6 (4.6)	138.6 (3.3)	135.7 (4.2)
	Median (IQR)	136 (132–138)	136 (133–140)	136 (133.5–138)	136 (134–140)	137.9 (136–139)	136 (134–139)
	n (missing)	59 (0)	61 (0)	48 (11)	54 (7)	6 (0)	7 (0)
Creatinine (µmol/L)	Range (min-max)	32–147	35–142	39–135	33–122	40–77	40–74
	Mean (SD)	92.3 (28)	88.5 (24.1)	73.7 (24.1)	72.2 (20)	59.2 (12.7)	62 (11.4)
	Median (IQR)	96.5 (70–113)	89 (74–109)	72 (54.5–87)	70 (57–83)	59.5 (53–66)	65 (57–72)
	n (missing)	58 (1)	61 (0)	52 (7)	55 (6)	6 (0)	7 (0)
Potassium (mmol/L)	Range (min-max)	2.9–6.2	2.7–6.2	2.8–5.7	2.3–4.8	2.5–4.9	2.9–5.2
	Mean (SD)	4.3 (0.6)	4.3 (0.7)	3.9 (0.7)	3.5 (0.7)	4.1 (0.9)	3.9 (0.9)
	Median (IQR)	4.3 (3.9–4.6)	4.2 (3.8–4.7)	3.9 (3.4–4.4)	3.5 (3–4)	4.3 (3.8–4.9)	4 (3–4.4)
	n (missing)	59 (0)	61 (0)	48 (11)	55 (6)	6 (0)	7 (0)
Alanine transaminase (U/L)	Range (min-max)	23–238	25–244	15–475	16–152	44–83	23–64
	Mean (SD)	90.6 (58.4)	81.8 (46.5)	73.1 (78.3)	59.9 (32.5)	64.8 (18.3)	44.7 (14.2)
	Median (IQR)	74 (54–99)	68 (45–115)	51 (38.5–70)	56.5 (35–77)	66 (49.5–80)	46.5 (35–53)
	n (missing)	37 (22)	46 (15)	48 (11)	50 (11)	4 (2)	6 (1)

n, number; SOC, standard of care; SOC-F, standard of care plus fosfomycin.

139 mmol/L (3.3); mean difference -2.9 mmol/L (95% CI -7.5 to $+1.8$) (table 2).

On day 2, mean (SD) potassium concentration was marginally (yet not clinically significantly) lower in SOC-F than SOC infants: 3.5 mmol/L (0.7) vs 3.9 mmol/L (0.7), difference -0.4 mmol/L (95% CI -0.7 to -0.1). There was no evidence of difference between arms in other laboratory parameters (table 2).

Adverse events

We observed 35 AEs in 25 SOC-F participants and 50 AEs in 34 SOC participants; 2.2 events/100 infant-days and 3.2 events/100 infant-days, respectively: IRR 0.7 (95% CI 0.4 to 1.1), IRD -0.9 events/100 infant-days (95% CI -2.1 to $+0.2$, $p=0.11$).

Twelve SAEs occurred among 11 SOC-F participants and 14 SAEs among 12 SOC participants (0.8 events/100 infant-days in SOC vs 1.0 events/100 infant-days; IRR 0.8 (95% CI 0.4 to 1.8), IRD -0.2 events/100 infant-days (95% CI -0.9 to $+0.5$, $p=0.59$). Hypoglycaemia was the most common AE (five SOC-F and six SOC); four cases in each arm were grade 3 or 4 (online supplemental table S4). Three SOC-F and four SOC participants had moderate or severe thrombocytopenia and were well at day 28 without platelet transfusion. AEs classified as ‘anticipated’ occurred in 13 SOC-F and 13 SOC participants (online supplemental table S5). Three SOC participants were re-admitted to hospital (pneumonia (n=2) and febrile illness of unknown origin (n=1)); all were discharged home alive. One SOC-F participant had a mild perineal rash and another SOC-F participant experienced moderate diarrhoea 13 days postdischarge; both resolved without sequelae. Excluding mortality, 50 AEs resolved while 27 were either resolving, had not changed or had resolved with sequelae (online supplemental table S6). No AEs were related to study medication.

Pharmacokinetics

Sixty participants had at least one intravenous PK sample collected. Fifty-five participants contributed complete sets of four samples, and five participants had partial sets. Six participants had a sample collected on day 7. Overall, 238 plasma (119 for intravenous and 119 for oral fosfomycin) and 15 CSF samples were analysed. No sample had fosfomycin levels below the limit of quantification.³²

Population PK model development and simulation results are described in detail elsewhere.³² Briefly, a two-compartment PK disposition model with an additional CSF compartment provided a good fit to the data, with clearance and volume at steady-state for a typical participant (weight (WT) 2805 g, postnatal age (PNA) 1 day, postmenstrual age (PMA) 40 weeks) being 0.14 L/hour (0.05 L/hour/kg) and 1.07 L (0.38 L/kg), respectively. In addition to fixed allometric and expected PMA maturation based on renal function,³¹ PNA was associated with increasing clearance over the first week of life. The model-based population estimate of oral bioavailability was 0.48 (95% CI 0.35 to 0.78) and CSF/plasma ratio was 0.32 (95% CI 0.27 to 0.41).

Simulated steady-state plasma concentration-time curves are illustrated in online supplemental figure S2. Probability of target attainment (PTA) for AUC:MIC thresholds for bacteriostasis, 1-log kill and resistance suppression is given in figures 2 and 3 for the studied population (weight >1500 g), and extrapolated using data from smaller neonates. Given the rapid increase in clearance over the first week of life, simulations were further stratified by PNA (online supplemental table S7).

Resistance suppression could not be consistently achieved with any simulated dosing regimens for organisms with MIC >0.5 mg/L (figures 2 and 3). For 100 mg/kg two times per day intravenously, bacteriostasis could be achieved with 100% PTA for an MIC of 32 mg/L in all four simulated strata (figure 2). Regarding 1-log kill, PTA for 100 mg/kg two times




Figure 2 Probability target attainment for intravenous fosfomycin dosing. Neonatal subpopulations. Group 1: WT >1.5 kg +PNA ≤7 days (n=4391), group 2: WT >1.5 kg +PNA >7 days (n=2798), group 3: WT ≤1.5 kg +PNA ≤7 days (n=1534), group 4: WT ≤1.5 kg +PNA >7 days (n=1277). Groups 1 and 2 represent patients similar to those fitting our inclusion criteria. Groups 3 and 4 represent an extrapolation to preterm neonates that were not studied in our population. This original figure was created by ZK for this manuscript. BID, two times per day; IV, intravenous; MIC, minimum inhibitory concentration; PNA, postnatal age; WT, weight.

per day intravenously for an MIC of 32 mg/L was 0.84 and 0.96 for groups 1 and 3 with PNA ≤7 days, but PTA was lower at 0.19 and 0.60 for groups 2 and 4 with PNA >7 days. At 150 and 200 mg/kg two times per day intravenously, PTA for 1-log kill was 0.64 and 0.90 in group 2, and 0.91 and 0.98 in group 4, respectively.

Oral dosing with 100 mg/kg two times per day in groups 2 and 4 yielded PTA values for bacteriostasis of 0.85 and 0.96, respectively (figure 3), and PTAs for groups 1–4 were 0.15, 0.004, 0.41 and 0.05, respectively for 1-log kill at an MIC of 32 mg/L.

DISCUSSION

We provide evidence for the use of fosfomycin in infants at 100 mg/kg/dose two times per day, without evidence of plasma sodium disturbance (intravenous) or osmotic diarrhoea (oral) when compared with SOC. Our primary safety objective, to detect differences in plasma sodium levels between the two treatment arms on day 2, was adequately powered. Although our sample size was too small to determine group differences for other safety events, all neonates were closely monitored, and events reported contribute towards evidence supporting the potential use of fosfomycin as an




Figure 3 Probability target attainment for oral fosfomycin dosing. Neonatal subpopulations. Group 1: WT >1.5 kg +PNA ≤7 days (n=4391), group 2: WT >1.5 kg +PNA >7 days (n=2798), group 3: WT ≤1.5 kg +PNA ≤7 days (n=1534), group 4: WT ≤1.5 kg +PNA >7 days (n=1277). Groups 1 and 2 represent patients similar to those fitting our inclusion criteria. Groups 3 and 4 represent an extrapolation to preterm neonates using external data that were not studied in our population. This original figure was created by ZK for this manuscript. BID, two times per day; MIC, minimum inhibitory concentration; PNA, postnatal age; PO, oral; WT, weight.

alternative empiric treatment for sepsis in this vulnerable group. However, confirmation of these results in larger and sicker cohorts will be important.

We aimed to enrol neonates aged ≤28 days and did not selectively include suspected early onset sepsis. However, 86% neonates were hospitalised within the first week of life, confirming the high burden of early neonatal morbidity reported in similar LMICs.^{33–36} High levels of resistance of pathogens causing early onset and late-onset sepsis (including ESBL *Escherichia coli* and *Klebsiella pneumoniae*) to empiric antimicrobials have been observed,^{37–39} potentially acquired in the maternity department. Broad-spectrum antimicrobial coverage that includes fosfomycin as first-line treatment in such settings may improve outcomes and spare the use of carbapenems.

In common with many antimicrobials,⁴⁰ PNA was a key covariate in describing fosfomycin clearance. This effect was distinct from GA and weight and represents rapid glomerular filtration maturation

postnatally. Locally, 90% of invasive Enterobacterales had fosfomycin MIC ≤32 µg/mL¹⁵ and for neonates aged >7 days it is likely that >100 mg/kg/dose intravenously is required for bactericidal activity (figure 2). For a 32 µg/mL target, 150 mg/kg two times per day is suggested for intravenous treatment if PNA >7 days. Once stabilised and if there is a requirement to move to oral fosfomycin, doses can be selected with consideration of a neonate's WT, PMA, PNA and the likely pathogen MIC but should take into account the bioavailability reported here. Studies are needed to further assess the safety profile and efficacy of this higher dose recommended by our PK model.

Current guidance on neonatal parenteral fluid and electrolyte intake suggests limiting sodium supplementation to 2–3 mmol/kg/day with PNA >3 days, with preterm neonates requiring up to 5 mmol/kg/day.⁴¹ The studied fosfomycin intravenous formulation, at 100 mg/kg/dose two times per day, provides 2.8 mmol/kg/day sodium. SOC-F neonates achieved median sodium levels

<140 mmol/L with only one neonate exceeding 145 mmol/L (149 mmol/L). Sodium intake using this fosfomycin formulation at 150 mg/kg two times per day is calculated at 4.2 mmol/kg/day. Thus, higher doses as per revised European Medicines Agency recommendations⁴² will require monitoring electrolytes to confirm safety. In addition, studies are needed in neonates with shock or renal failure who need close monitoring of electrolytes and fluid balance and will likely require dose adjustment.

Since resistance suppression could only be achieved for the most sensitive of organisms, and fosfomycin-inactivating enzymes may exist in transferrable plasmids,⁴³ fosfomycin is recommended to be used in combination with another antibiotic. The potential utility of fosfomycin plus amikacin for neonatal sepsis was recently studied by assessing in vitro activity and pharmacodynamic interactions using checkerboard assays and a 16-arm dose-ranged hollow-fibre infection model.⁴⁴ This combination had enhanced bactericidal activity, prevented the emergence of resistance, and achieved sterility with lower combination exposures, compared with monotherapy with either antibiotic. This study concluded that fosfomycin plus amikacin combination is suitable for further clinical assessment. Simulation-based PK/pharmacodynamic assessments of ampicillin and gentamicin on 373 residual samples collected from 59 SOC-F participants suggested good Gram-positive cover (MIC ≤ 0.25 mg/L) but poor coverage against Enterobacterales (MIC ≤ 2 mg/L), underscoring the need for alternative antibiotic combinations in settings with high resistant rates. Although analysis of fosfomycin interaction with ampicillin, gentamicin or ceftriaxone was not done in this study, previous studies have shown that it has synergistic activity with β -lactams, aminoglycosides and cephalosporins.⁴⁵

Trials evaluating fosfomycin combinations in neonatal sepsis are urgently needed⁴⁶ and our data provide the basis on which to evaluate efficacy within a combination in multiple settings compared with current SOC, either empirically or to treat microbiologically confirmed MDR infections. We are planning a multisite randomised clinical trial to assess novel antimicrobial combinations (including fosfomycin) for optimal treatment of sepsis in settings with high AMR rates and variable SOC antimicrobial choices.⁴⁷ This trial will be preceded by a run-in confirmatory PK study of fosfomycin at the higher dose identified in the current study and will generate further data on fosfomycin safety in a large population of neonates at moderate to high risk of mortality across different LMIC settings. Robust evidence of sepsis epidemiology and management in infants aged <60 days from a recently concluded observational study (NCT03721302) is contributing towards the design of this trial.

Limitations include single-centre recruitment and exclusion of the sickest neonates at enrolment, which was judged important given the very limited prior information. Our narrow eligibility criteria excluded neonates at highest risk of poor outcomes, including very preterm neonates or those critically ill or with conditions likely to cause hypernatraemia such as severe hypoxic ischaemic encephalopathy. Future trials need to include these vulnerable groups that may benefit most from optimal antibiotic treatment.

Our sample size was not intended to determine antimicrobial efficacy or comprehensively establish safety. Enrolment rate increased (42 enrolled/519 screened vs 79/505) after extension of recruitment window from 4 to 24 hours, based on guidelines on clinical evaluation of antimicrobial agents for AMR.⁴⁸ We believe that this did not impact our results. Our study highlights challenges faced by researchers conducting early phase clinical trials in resource-limited settings including difficulties in obtaining informed consent from parents/guardians of vulnerable neonates. We implemented strategies to optimise consent such as ensuring that key decision

makers within each family were involved during the process. The small CSF dataset provides evidence of appreciable concentrations in CSF; however, further data are required for firm dosing recommendations for meningitis.

Strengths of our trial include a low loss to follow-up, standardised observational data, a high ascertainment of PK samples and robust timing and dosing information—a logistically challenging exercise in neonates in any setting.⁴⁹ Total observation days for neonates in both treatment arms were similar and sufficient number of neonates with available day 2 plasma sodium samples and complete sets of four PK samples contributed to this analysis, despite unbalanced losses due to consent withdrawals, loss to follow-up or deaths.

Increasing AMR in a population who may die rapidly due to inadequate antimicrobial coverage is concerning given limited new antibiotics in the pipeline. Fosfomycin offers significant potential as part of a safe, easily administered and affordable regimen.

Author affiliations

¹Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

²Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands

³Nuffield Department of Medicine, University of Oxford, Oxford, UK

⁴Global Antibiotic Research and Development Partnership, Nairobi, Kenya

⁵MRC Clinical Trials Unit, University College London, London, UK

⁶Global Antibiotic Research and Development Partnership, Geneva, Switzerland

⁷Great Ormond Street Institute of Child Health, University College London, London, UK

⁸Institute of Chemistry, University of Tartu, Tartu, Estonia

⁹Analytical Services International (ASI) Ltd, St George's – University of London, London, UK

¹⁰Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, University of London, London, UK

¹¹The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya

Acknowledgements We thank the DSMB (Professor Johannes van den Anker (Chair), Professor Gilbert Kokwaro, Professor Rachel Musoke) for their support in reviewing study data. We thank the trial participants and their parents/guardians for their contribution to this trial. In addition, we acknowledge and thank KEMRI-Wellcome Trust Research Programme nurses and clinical staff, and DNDi staff. This manuscript is published with the permission of the Director of KEMRI.

Contributors CWO, PW, ASW, KK, JFS, SE, MS and JAB contributed to the study design. CWO, PW, SM, JT, BN, EC, SE and JAB contributed to the planning, conduct and reporting of the trial. SM developed the database. CWO, SM, RO, TE and JAB had full access to all the data in the study, performed the clinical data analysis and take responsibility for the integrity of the data and the accuracy of the data analysis. KK undertook analysis of PK samples. ZK, SG and JFS analysed the PK data. CWO, PW and JAB prepared the draft manuscript, and all authors contributed to and reviewed the manuscript. JAB provided oversight of the trial. JAB is the guarantor of the trial.

Funding The trial was sponsored by DNDi/GARDP with funding from German Federal Ministry of Education and Research (BMBF), German Ministry of Health, South African Medical Research Council, Department for International Development (DFID) UK, Médecins Sans Frontières and Ministry of Health, Welfare and Sport of the Netherlands. The trial was materially supported by the Wellcome Trust (203077_Z_16_Z). JFS was supported by UK Medical Research Council (MRC) Fellowship (M008665) and ZK, SG and JFS received institutional level support from the Great Ormond Street NIHR Biomedical Research Centre. JAB was supported by the MRC/DFID/Wellcome Joint Global Health Trials scheme (MR/M007367/1). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The protocol was approved by the KEMRI Scientific and Ethical Review Unit (KEMRI/SERU/CGMRC/097/3513), Kenya Pharmacy and Poisons Board (PPB/ECCT/17/10/01/2017(200)) and Oxford Tropical Research Ethics Committee (26-17). Written informed consent was sought by trained field assistants in the carer's preferred language. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Trial datasets are deposited at <https://dataverse.harvard.edu/dataset/kwtrp> and are available on request through the KEMRI/Wellcome Trust Research Programme Data Governance Committee dgc@kemri-wellcome.org.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Christina W Obiero <http://orcid.org/0000-0002-9321-0183>

James Alexander Berkley <http://orcid.org/0000-0002-1236-849X>

REFERENCES

- Lawn JE, Blencowe H, Oza S, *et al*. Every newborn: progress, priorities, and potential beyond survival. *Lancet* 2014;384:189–205.
- Laxminarayan R, Matsoso P, Pant S, *et al*. Access to effective antimicrobials: a worldwide challenge. *Lancet* 2016;387:168–75.
- WHO. *Pocket book of hospital care for children: guidelines for the management of common childhood illnesses*. 412. 2 edn. World Health Organization, 2013.
- Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. *MMWR Morb Mortal Wkly Rep* 2013;62:165–70.
- Downie L, Armiento R, Subhi R, *et al*. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics—systematic review and meta-analysis. *Arch Dis Child* 2013;98:146–54.
- Moxon CA, Paulus S. Beta-Lactamases in Enterobacteriaceae infections in children. *J Infect* 2016;72 Suppl:S41–9.
- Folgori L, Ellis SJ, Bielicki JA, *et al*. Tackling antimicrobial resistance in neonatal sepsis. *Lancet Glob Health* 2017;5:e1066–8.
- The World Health Organization. Critically important antimicrobials for human medicine. 3rd Revis, 2011. Available: <https://apps.who.int/iris/bitstream/10665/255027/1/9789241512220-eng.pdf> [Accessed 19 Nov 2020].
- Kahan FM, Kahan JS, Cassidy PJ, *et al*. The mechanism of action of fosfomycin (phosphonomycin). *Ann NY Acad Sci* 1974;235:364–86.
- Hendlin D, Stapley EO, Jackson M, *et al*. Phosphonomycin, a new antibiotic produced by strains of *Streptomyces*. *Science* 1969;166:122–3.
- Souli M, Galani I, Boukovalas S, *et al*. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing *Klebsiella pneumoniae* and protection of resistance development. *Antimicrob Agents Chemother* 2011;55:2395–7.
- Falagas ME, Kastoris AC, Kapaskelis AM, *et al*. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. *Lancet Infect Dis* 2010;10:43–50.
- Raz R. Fosfomycin: an old—new antibiotic. *Clin Microbiol Infect* 2012;18:4–7.
- Guggenbichler JP, Kienel G, Frisch H. Fosfomycin, a new antibiotic drug (author's transl). *Pediatr Padol* 1978;13:429–36.
- Molina MA, Olay T, Quero J. Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period. *Chemotherapy* 1977;23 Suppl 1:217–22.
- Bergan T, absorption Dof. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. *Infection* 1990;18 Suppl 2:S65–9.
- Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin trometamol. *Chemotherapy* 1993;39:297–301.
- Lepak AJ, Zhao M, VanScoy B, *et al*. In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2017;61. doi:10.1128/AAC.00476-17. [Epub ahead of print: 24 05 2017].
- Docobo-Pérez F, Drusano GL, Johnson A, *et al*. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. *Antimicrob Agents Chemother* 2015;59:5602–10.
- Taylor CG, Mascarós E, Román J, *et al*. Enteropathogenic *E. coli* $\leq$ i> Gastroenterocolitis in Neonates Treated with Fosfomycin. *Chemotherapy* 1977;23:310–4.
- Rossignol S, Regnier C. [Fosfomycin in severe infection in neonatology]. *Ann Pediatr* 1984;31:437–44.
- Guillois B, Guillemin MG, Thoma M. [Neonatal pleuropulmonary staphylococcal infection with multiple abscesses of the liver]. *Ann Pediatr* 1989;36:681–4.
- Gouyon JB, Francois C, Semama D. [Nosocomial Staphylococcus epidermidis and Staphylococcus aureus septicemias in neonates]. *Ann Pediatr* 1990;37:21–5.
- Algubaisi S, Bühner C, Thomale U-W, *et al*. Favorable outcome in cerebral abscesses caused by *Citrobacter koseri* in a newborn infant. *IDCases* 2015;2:22–4.
- Iarikov D, Wassel R, Farley J, *et al*. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. *Infect Dis Ther* 2015;4:433–58.
- Nash PL. Potassium and sodium homeostasis in the neonate. *Neonatal Netw* 2007;26:125–8.
- Akcam M. Oral fructose solution as an analgesic in the newborn: a randomized, placebo-controlled and masked study. *Pediatr Int* 2004;46:459–62.
- Bueno M, Yamada J, Harrison D, *et al*. A systematic review and meta-analysis of non-sucrose sweet solutions for pain relief in neonates. *Pain Res Manag* 2013;18:153–61.
- MOH. *Basic paediatric protocols for ages up to 5 years*. 4 edn, 2016.
- Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. *Arch Neurol* 1976;33:696–705.
- Rhodin MM, Anderson BJ, Peters AM, *et al*. Human renal function maturation: a quantitative description using weight and postmenstrual age. *Pediatr Nephrol* 2009;24:67–76.
- Kane Z, Gastine S, Obiero C, *et al*. Iv and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. *J Antimicrob Chemother* 2021;76:1855–64.
- Obiero CW, Mturi N, Mwarumba S, *et al*. Clinical features to distinguish meningitis among young infants at a rural Kenyan Hospital. *Arch Dis Child* 2021;106:130–6.
- Dandona R, Kumar GA, Bhattacharya D, *et al*. Distinct mortality patterns at 0–2 days versus the remaining neonatal period: results from population-based assessment in the Indian state of Bihar. *BMC Med* 2019;17:140.
- Irimu G, Aluvaala J, Malla L, *et al*. Neonatal mortality in Kenyan hospitals: a multisite, retrospective, cohort study. *BMJ Glob Health* 2021;6:e004475.
- Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. *Lancet Glob Health* 2016;4:e752–60.
- Okomo U, Akpalu ENK, Le Doare K, *et al*. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. *Lancet Infect Dis* 2019;19:1219–34.
- Blomberg B, Jureen R, Manji KP, *et al*. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar ES Salaam, Tanzania. *J Clin Microbiol* 2005;43:745–9.
- Mohsen L, Ramy N, Saied D, *et al*. Emerging antimicrobial resistance in early and late-onset neonatal sepsis. *Antimicrob Resist Infect Control* 2017;6:63.
- Germovsek E, Kent A, Metsvaht T, *et al*. Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. *Antimicrob Agents Chemother* 2016;60:4869–77.
- Jochum F, Moltu SJ, Senterre T, *et al*. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: fluid and electrolytes. *Clin Nutr* 2018;37:2344–53.
- European Medicines Agency. Product information as Approved by the CHMP on 26 March 2020, pending endorsement by the European Commission, 2020. Available: https://www.ema.europa.eu/en/documents/referral/fosfomycin-article-31-referral-annex-iii_en.pdf [Accessed 18 Jun 2020].
- Wang H, Min C, Li J, *et al*. Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant *Klebsiella pneumoniae* strains from two tertiary hospitals in China. *BMC Microbiol* 2021;21:109.
- Darlow CA, Docobo-Perez F, Farrington N, *et al*. Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. *Antimicrob Agents Chemother* 2021;65:e0029321.
- Kastoris AC, Rafailidis PI, Vouloumanou EK, *et al*. Synergy of fosfomycin with other antibiotics for gram-positive and gram-negative bacteria. *Eur J Clin Pharmacol* 2010;66:359–68.
- Li G, Standing JF, Bielicki J, *et al*. The potential role of fosfomycin in neonatal sepsis caused by multidrug-resistant bacteria. *Drugs* 2017;77:941–50.
- Li G, Bielicki JA, Ahmed ASMNU, *et al*. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. *Arch Dis Child* 2020;105:26–31.
- Japanese Pharmaceuticals and Medical Devices Agency. Report on clinical evaluation of antimicrobial agents for AMR, 2019. Available: <https://www.pmda.go.jp/files/000233507.pdf> [Accessed 18 Jun 2020].
- O'Hara K, Martin JH, Schneider JJ. Barriers and challenges in performing pharmacokinetic studies to inform dosing in the neonatal population. *Pharmacy* 2020;8:16.

Randomised Controlled Trial of Fosfomycin Safety and Pharmacokinetics in Neonatal Sepsis

Supplement 1

This supplement contains the following items:

1. Original protocol and final protocol
2. Informed consent forms



**Intravenous and Oral Fosfomycin in Hospitalized Neonates with Clinical Sepsis:
an open-label safety and pharmacokinetics study
(neoFosfo)**

Short title	Neo-Fosfo
Name of product(s)	Fosfomycin oral and IV formulations
Drug Class	Antibiotic
Indication	
Protocol Number	Neo-Fos-001
EudraCT	Not applicable
Study Sponsor	DNDi Tetezi Towers, 3rd Floor George Padmore Rd Kilimani PO BOX 21936-00505 Nairobi KENYA +254 20 3995 000 Head Office: Chemin Louis Dunant, 15, 1202 GENEVA Switzerland Phone: +41 22 906 9230
Principal Investigator	Professor James A Berkley
Coordinating Institutions	KEMRI/Wellcome Trust Research Programme PO Box 230, Kilifi, 80108, Kenya University of Oxford, University Offices, Wellington Square, Oxford, OX1 2JD, UK

Clinical Trial Protocol Version / Date	Version 1.1 dated 23 rd August 2017
Protocol Amendment Number / Date	Not applicable

The information contained in this document is confidential. It is to be used by investigators, potential investigators, consultants, or applicable independent ethics committees. It is understood that this information will not be disclosed to others without written authorization from DNDi, except where required by applicable local laws

CLINICAL TRIAL PROTOCOL SIGNATURE PAGE

Statistician

Signature		
		Date of Signature (DD/MMM/YY)
Name	Sarah Walker	
Title	Professor	
Institution	MRC Clinical Trials Unit	
Address	University College London, London, UK	

Principal Investigator

Investigator Signature		
		Date of Signature (DD/MMM/YY)
Name	Prof James A Berkely	
Title	Professor	
Institution	KEMRI/Wellcome Trust Research Programme	
Address	PO Box 230, Kilifi, 80108, Kenya	

Investigators Signature Page

I have read this protocol and agree that it contains all necessary details for carrying out this trial. I will conduct the trial as outlined herein and will complete the trial within the time designated.

I will provide copies of the protocol and all pertinent information to all individuals responsible to me who assist in the conduct of this trial. I will discuss this material with them to ensure they are fully informed regarding the drug and the conduct of the trial.

I will use only the informed consent form approved by the sponsor or its representative and will fulfil all responsibilities for submitting pertinent information to the Institutional Review Board/Independent Ethics Committee (IRB/IEC) responsible for this trial if required by national law.

I agree that the sponsor or its representatives shall have access to any source documents from which case report form information may have been generated.

Table of Contents

<i>Title of the Project</i>	7
<i>Investigators and Institutional Affiliations</i>	7
<i>Lay summary</i>	8
<i>Abstract</i>	10
<i>Abbreviations</i>	11
<i>Introduction / Background</i>	13
<i>Justification for the study</i>	17
<i>State the Null Hypotheses</i>	17
<i>Objectives</i>	17
a) General Objectives	17
b) Specific Objectives.....	17
<i>Study Design</i>	18
<i>Study site:</i>	18
<i>Definition of Study Population:</i>	18
<i>Rationale for animal use and justification for animal species chosen</i>	19
<i>Sampling</i>	19
<i>i. Sample size determination:</i>	19
i. For Pharmacokinetics:.....	19
<i>Procedures:</i>	20
<i>Clinical Trial Governance:</i>	25
<i>Safety reporting</i>	25
i) Assessment of Safety:.....	25
ii) Laboratory examinations	26
iii) Adverse event definitions and reporting.....	26
<i>Withdrawal criteria:</i>	30
<i>Data Safety Monitoring Board:</i>	30
<i>Quality Assurance and Quality Control Procedures</i>	31
A) Investigator's file:	31
B) Case report forms (CRFs):	31
C) Source documents:	31
E) Monitoring, audits and inspections:.....	31
F) Protocol Amendments:	32
<i>Data Management and Analysis:</i>	Error! Bookmark not defined.
<i>Data Sharing</i>	32
<i>Intellectual property</i>	32
<i>Time Frame/Duration of the Project</i>	32
<i>Ethical Considerations</i>	33
<i>Expected Application of the Results</i>	35
<i>References</i>	36
<i>Budget</i>	Error! Bookmark not defined.

Justification of the Budget.....**Error! Bookmark not defined.**

Appendices**Error! Bookmark not defined.**

Appendix D: Further Information Regarding Study Treatment (Fosfomycin):Error! Bookmark not defined.

1. Mechanism of Action of IMP:.....**Error! Bookmark not defined.**

2. Standard of Care treatment.....**Error! Bookmark not defined.**

3. IMP dosing and treatment regimens:.....**Error! Bookmark not defined.**

5. Storage.....**Error! Bookmark not defined.**

Title of the Project

Intravenous and oral fosfomycin in hospitalized neonates with clinical sepsis: An open-label safety and pharmacokinetics study.

*Investigators and Institutional Affiliations***KEMRI CGMR-C**

James Berkley (PI)

Phoebe Williams

Christina Obiero

Neema Mturi

Claire Gordon

Joseph Waichungo

Johnstone Thitiri

Mwanamvua Boga

Sheila Murunga

KEMRI CCR

Martin Ogas

Non-KEMRI*:

Mike Sharland: St George's Hospital, University of London, UK

Julia Anna Bielicki: St George's Hospital, University of London, UK

Karin Kipper: St George's Hospital, University of London, UK

Joseph Standing: University College, London, UK

Sarah Walker: Medical Research Council Clinical Trials Unit at University College London, UK

*Curriculum Vitae of non-KEMRI investigators attached, see appendix E.

Lay summary

A study measuring the levels of an additional antibiotic (fosfomycin) to treat severe infections in newborns.

What is the problem?

Among babies presenting with signs of serious infection, or who develop these signs whilst in hospital, bacterial resistance to the antibiotics that are normally used is increasing. This means that babies with infections may be at a higher risk of dying. In Africa, alternative antibiotics are often expensive and may themselves cause the bacteria to become resistant. Therefore, new treatment strategies are needed. Fosfomycin is a potentially inexpensive antibiotic that is licensed for use in children in Europe and may be useful to resource-poor countries. It has a good safety profile in children and is expected to be effective against infections that do not respond to the currently used antibiotics. However, more information is needed to inform how fosfomycin should be used in babies in Kenya.

What questions are we trying to answer?

We want to find out what doses of fosfomycin would be most suitable for sick newborns in Kenya in order to optimize its use in an effective and safe way. We also want to find out how well local bacteria that have been previously found (and stored) from patients at Kilifi County Hospital are able to be killed by fosfomycin.

Where is the study taking place?

The study will take place in Kilifi County Hospital, Kilifi, Kenya.

How many people does it involve?

For the study measuring the levels of antibiotics in newborn babies, we will include 120 babies admitted to the hospital with presumed infection. 60 of these babies will be given fosfomycin in addition to standard treatment and drug levels measured; the other 60 will receive standard treatment.

How are these people selected?

We will ask parents and guardians of all babies aged 28 days or less who are admitted to Kilifi County Hospital with signs of infection to participate, unless they are being transferred from another hospital, already received other antibiotics by injection, are very sick or premature, or have abnormally high salt (sodium) levels in their blood.

What does the study involve for those who are in it?

After providing information and answering any questions, informed consent will be requested from the child's parent or guardian. A doctor or study clinical officer will examine the baby and take the usual admission investigations, then prescribe the two antibiotics that are currently recommended by the WHO for the treatment of presumed infection in babies (ampicillin and gentamicin).

Half of the babies will be selected randomly to receive intravenous fosfomycin *as well as* the standard antibiotics. The nurse or clinical officer will then take two blood samples to check fosfomycin levels. After a minimum of four doses of intravenous (IV) fosfomycin (over 48 hours), when their condition is improved and they are tolerating feeds by mouth, the baby will then be changed on to oral fosfomycin. A further two blood samples will be collected after the first oral dose of fosfomycin, including one to check the kidney and liver function and level of salts in the blood (which is currently a routine investigation). Each of these blood samples is 0.5ml, giving a total for this research of 2.5ml (half a teaspoon) for checking the drug levels, and a further 1ml (a quarter of a teaspoon) for checking the level of salts in their blood.

For all babies, a blood test will be taken (which is normally part of routine care) at around 48 hours to check the blood count, kidney and liver function and level of salts in the blood. If a baby has a lumbar puncture as part of their normal treatment (if their doctor is concerned about an infection in their brain), the fosfomycin level in the fluid surrounding their brain will also be checked.

The babies will be closely followed by the study team, working together with the hospital staff to provide the best care available in the hospital. On day 7, any babies who remain as inpatients will have a blood test to check their kidney and liver function and level of salts in the blood (and 0.5ml drawn for fosfomycin levels in the group receiving this antibiotic). Breastfeeding and health counselling will be given according to national guidelines. All

babies will be followed up in our outpatients' clinic 28 days after their presentation to hospital and parents/guardians may also phone the study team directly on a study-specific mobile phone or bring the baby to the ward prior to that review, in case of health concerns.

What are the benefits and risks/costs of the study for those who are involved?

Additional staff (clinical officers and nurses) will be recruited to undertake study duties and assist in general care on the ward, adding to the staff available. Training will be enhanced for all paediatric ward staff on the treatment of babies presenting with infections, and on the prevention of infections within the hospitals. We will also make available additional antibiotics as needed, should a baby continue to have signs of infection despite treatment or remain unwell. Drawing a blood sample carries the potential risks of bruising to the vein or infection, and careful training on procedures will help to prevent these. There may be a small risk of the baby having high levels of salt (sodium) in their blood due to the salt content of the fosfomycin injection. Improved monitoring of kidney function and blood salt levels will offset these risks.

How will the study benefit society?

This study is leading up to a large clinical trial assessing how effective fosfomycin is to treat babies with infections, and if it is effective, will support efforts to make fosfomycin available at low cost for Kenya and other countries. This will help babies to be more effectively treated when bacteria are resistant to the currently used antibiotics.

When does the study start and finish?

The study aims to start as soon as scientific and ethical approval is granted and is expected to continue for 18 months (including analysis and write-up).

Abstract

Antimicrobial resistance (AMR) has become a major issue in global health. Despite progress in the reduction of under 5 mortality rates in recent decades, the proportion of neonatal deaths occurring within this age group has increased, with almost one quarter of all neonatal deaths occurring due to serious bacterial infection. Common bacteria causing neonatal sepsis are now exhibiting widespread resistance to several classes of antibiotics. There is an urgent need to discover new, effective treatments and re-evaluate existing therapeutic agents to treat infections potentially caused by multi-drug resistant (MDR) pathogens. Gram-negative bacteria (GNB) predominate as the cause of neonatal sepsis and are increasingly associated with high rates of resistance to the currently recommended WHO empirical therapy regimen of ampicillin/penicillin and gentamicin. There is therefore a need to develop an updated empiric regimen with improved efficacy in the context of increasing MDR sepsis in neonates. New antimicrobials under development will be expensive once licensed, and there are currently virtually no planned trials to assess their efficacy in neonates in low- and middle-income countries (LMICs).

One potential strategy is utilizing an existing off-patent (and therefore affordable) antibiotic available in intravenous and oral formulations – fosfomycin. Fosfomycin has a wide spectrum of activity against Gram-positive and Gram-negative bacteria causing neonatal sepsis. It is mainly used for resistant urinary tract infections in adults but has licensed neonatal and paediatric doses in Europe (though dosing regimens vary between countries). Both oral and IV formulations are available. A large clinical trial to assess the efficacy of a fosfomycin plus an aminoglycoside combination (compared to the current WHO recommended ampicillin and gentamicin) is anticipated, including sites in Kenya. The ultimate aim is for fosfomycin to be included in the WHO Essential Medicines List for children (EMLc) and be available for use in developing countries, where rates of resistance to ampicillin and gentamicin have been estimated at over 40%. The first steps before this trial are to clarify the pharmacokinetics (PK) and safety profile of fosfomycin in neonates, as well as generating further information regarding local patterns of bacterial susceptibility to fosfomycin. The aim of this study is to fulfil both these steps. Fosfomycin (IV and oral) PK will be investigated among 60 babies admitted to hospital and being treated for presumed sepsis; administered alongside the standard antibiotics. Another 60 babies receiving standard treatment only (without PK sampling) will be monitored in the same way to compare adverse events. In the laboratory at CGMR-C, previously archived bacterial isolates will be tested for their sensitivity to fosfomycin.

Abbreviations

AE	Adverse Event
AGISAR	WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance
AMR	Antimicrobial Resistance
BSAC	British Society of Antimicrobial Chemotherapy
BW	Birth weight
C _{max}	Peak serum concentration of a therapeutic drug
CBC	Complete blood count
CGMR-C	Centre for geographic medicine research, Coast (Kenya)
CI	Confidence Interval
CLSI	Clinical and Laboratory Standards Institute
CMP	Calcium, Magnesium and Phosphate
CNS	Central Nervous System
CR	Carbapenem resistance/resistant
CRF	Case report form
CRO	Carbapenem resistant organisms
CSF	Cerebrospinal Fluid
DSMB	Drug Safety Monitoring Board
ECCMID	European Congress of Clinical Microbiology and Infectious Diseases
EMLc	Essential Medicines List for children
ESBL	Extended Spectrum Beta-Lactamase
ESPGHAN	European Society for Paediatric Gastroenterology, Hepatology and Nutrition
EUCAST	European Committee on Antimicrobial Susceptibility Testing
FBC	Full blood count
GNB	Gram-negative bacteria
HIE	Hypoxic Ischaemic Encephalopathy
ICF	Informed consent form
IMP	Investigational Medicinal Product
IV	Intravenous
IP	Intellectual Property
LBW	Low birth weight
LMICs	Low- and middle-income countries
LC-MS	Liquid chromatography mass spectrometry
LSM	Local Safety Monitor

MDR	Multi-drug resistant
MIC	Minimum inhibitory concentration
MRSA	Multi-resistant <i>Staphylococcus Aureus</i>
OxTREC	Oxford University Tropical Research Ethics Committee
PK	Pharmacokinetic
PO	Per os (oral)
PPB	Republic of Kenya Ministry of Health Poisons and Pharmacy Board
SAE	Serious Adverse Event
SBI	Serious bacterial infection
SERU	Scientific and Ethics Review Committee (Kenya)
SIADH	Syndrome of inappropriate antidiuretic hormone secretion
SOC	Standard-of-care
SOP	Standard operating procedure
SPC	Summary of Product Characteristics
SUSAR	Suspected Unexpected Serious Adverse Reaction
UTI	Urinary tract infection
VRE	Vancomycin-resistant enterococci
WHO	World Health Organization

Introduction / Background

The purpose of this study is to support the design of an international multi-centre randomized trial of fosfomycin to treat neonates with presumed sepsis, by providing an improved understanding of fosfomycin pharmacokinetics, safety and antimicrobial susceptibility of local invasive bacterial species.

Maternal and child deaths have halved over the past two decades;¹ however neonatal mortality has remained unacceptably high, with an estimated 2.9 million deaths in newborns every year.² The proportion of deaths (in children under 5 years) occurring in the neonatal period has increased from 38% to 44% between 2000 and 2013,² and 23% of neonatal deaths are due to presumed serious bacterial infections (SBI).¹ Aside from this mortality burden, sepsis in the neonatal period is also associated with significant morbidity secondary to an increased risk of adverse neurodevelopmental outcomes.³

The WHO and Kenyan guidelines currently recommend ampicillin (or penicillin) plus gentamicin for the treatment of sepsis in neonates and infants <2 months of old, with third-generation cephalosporins listed as second-line therapy.⁴ However, two recent systematic reviews have documented increasing rates of AMR to this regimen.^{5,6} Downie *et al.* (2013) examined 19 studies from 13 LMICs across Asia and Africa, revealing non-susceptibility to penicillin/gentamicin and third-generation cephalosporins of 44% and 43% respectively.⁵ Le Doare *et al.* (2015) identified 15 studies investigating non-susceptibility among Gram-negative pathogens across SE Asia, Africa and the Middle East which revealed *Enterobacteriaceae* exhibit high rates of non-susceptibility to ampicillin (80%), gentamicin, (22%) and ceftriaxone (74%).⁶

Challenges in interpreting this literature include the limited data available being mostly from urban tertiary hospital settings (rather than district- or community-level facilities), failure to account for prior treatment, not distinguishing community- from hospital-acquired infections, and inconsistent laboratory facilities. Nevertheless a consensus is emerging that AMR to recommended first-line antibiotics in LMICs is associated with significant morbidity and mortality.^{7,8} A recent study of neonatal deaths attributable to MDR sepsis (in 5 countries accounting for half the global neonatal sepsis death rates - India, Pakistan, Nigeria, DR Congo and China) identified 214,000 neonatal deaths occurring each year due to resistant bacterial infections.⁹ Notable is the emergence and spread of extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*, which render many commonly used (and cheaply available) antimicrobials ineffective. Carbapenems are increasingly being used as second-line therapy in neonatal sepsis, but they are expensive, and their use is associated with increasing AMR due to the dissemination of infections with carbapenem-resistant organisms (CRO). There is therefore a need to clarify an empiric regimen with improved for use in LMICs.

The repurposing of older antimicrobials for current treatment regimens has recently received increasing international attention. The WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) included fosfomycin in the current revision of critically important antimicrobials for human medicine.¹⁰ Fosfomycin is a bactericidal peptidoglycan antibiotic that was first produced in the 1970s¹¹ though its marketing was largely replaced in the 1980s by oral cephalosporins. Its infrequent international use over the past 30 years has resulted in low global resistance rates.

Fosfomycin is orally absorbed, crosses the blood brain barrier and is renally excreted. It exhibits minimal toxicity, low levels of cross-resistance, and provides synergistic effects with other antibiotics (including beta-lactams, aminoglycosides and fluoroquinolones).¹² IV fosfomycin is licensed in Europe and the USA as a second-line treatment in adults and children with osteomyelitis, complicated UTI, nosocomial lower respiratory tract infections, bacterial meningitis, or bacteraemia associated with any of these causes. Oral fosfomycin is used for treating UTI caused by *Escherichia coli* and *Enterococcus faecalis*.

Fosfomycin has a broad-spectrum of activity against both Gram-negative and Gram-positive organisms, including MRSA and ESBL infections.¹³ A recent systematic review evaluated the susceptibility of contemporary bacteria to fosfomycin, revealing 84 studies which documented susceptibility to *Staphylococcus aureus* (range 33% to 100%); ESBL-producing *Escherichia coli* (range 81% to 100%); ESBL-producing *Klebsiella pneumoniae* (range 15% to 100%); and carbapenem-resistant *Klebsiella pneumoniae* (range 39% to 100%).¹⁴ Thus, fosfomycin currently exhibits high levels of antimicrobial activity against common causes of neonatal sepsis.

The Summary of Product Characteristics (SPC) gives a neonatal intravenous dosing, including for preterm and term infants by age and body weight (Table 1). However, parenteral dosing recommendations for neonates and children patients vary widely between countries in Europe (Table 2), and there are currently no PO dosing recommendations for neonates.

Age/weight	Daily dose
Premature neonates (age ^a < 40 weeks)	100 mg/kg BW in 2 divided doses
Neonates (age ^a 40-44 weeks)	200 mg/kg BW in 3 divided doses
Infants 1-12 months (up to 10 kg BW)	200-300 ^b mg/kg BW in 3 divided doses
Infants and children aged 1-12 years (10-40 kg BW)	200-400 ^b mg/kg BW in 3-4 divided doses

^a Sum of gestational and postnatal age.

^b The high-dose regimen may be considered for severe infections and/or serious infections (such as meningitis), in particular when known or suspected to be caused by organisms with moderate susceptibility.

Table 1. Parenteral Fosfomycin Neonatal Dosing Recommendations (Nordic Pharma, 2016)

Country	Neonates (pre- & full-term; 0-1 months)	Infants (1-12 months, up to 10kg)	Children (1-12 years; 10-40kg)
Austria	100-200/400* mg/day in 2-3 doses	100-200/400* mg/day in 2-3 doses	4-8g/day, in 2-3 doses
Germany	100mg/day in 2 doses	200-250mg/day in 3 doses	100-200/300*mg/day in 3 doses
United Kingdom	Premature: 100mg/kg in 2 doses Term: 200mg/kg in 3 doses	200-300mg/kg/day in 3 doses	200-400mg/kg in 3-4 doses
Spain	Not specified	Not specified	100-200/400mg/day in 2-3 doses
France	Not specified	Not specified	100-200mg/day; number of daily doses not specified

*Maximum dosage for severe infections

Table 2: Recommended total daily dosages for IV fosfomycin in paediatric patients with normal renal function across various European settings

Safety and Clinical Outcomes of Fosfomycin:

Five published papers have documented the clinical outcomes of (n=84) neonates treated with parenteral

fosfomycin therapy for a range of diagnostic situations (Table 3), with no deaths or severe adverse events attributed to this therapy.

A 2015 review of adverse events (AE) reported to the FDA and the international literature in association with fosfomycin administration (in both adult and paediatric patients) concluded that fosfomycin exhibits low toxicity and few concerns regarding its safety profile.¹⁵ This review included data assessing 254 paediatric patients across 6 trials (3 trials of parenteral and 3 of oral fosfomycin; age range: neonates – 15.5 years), 3 of which were retrospective (n=118)^{16–18} and 3 prospective randomized trials (n=134)^{19–21} investigating oral fosfomycin. In the trials of parenteral fosfomycin, the drug was administered for up to 4 weeks for the treatment of acute hematogenous osteomyelitis, bacteraemia, and lung infection; while oral fosfomycin was administered as a single dose for the treatment of UTI. Overall, no serious safety issues related to the use of fosfomycin in children were identified in this review; with the most frequently reported AEs associated with (IV and PO) administration across all age ranges identified as being rash, peripheral phlebitis and gastrointestinal symptoms. Less common AEs include hypersensitivity and abnormal liver function. These are common AEs which also occur with other antibiotics.

Combined with the 31 babies documented in the literature investigating fosfomycin PK data (discussed below), this results in a total of 367 children in whom fosfomycin has been administered in the published literature with no significant safety concerns having been reported in this cohort.

However, an important potential safety consideration for parenteral fosfomycin is the sodium (Na⁺) content (14.4mmol/330mg sodium per gram). The European Society for Paediatric Gastroenterology and Hepatology (ESPGHAN) recommends a daily (enteral) sodium intake of 69mg/kg (minimum) to 115mg/kg (maximum) for preterm infants (with enteral values for term infants not published),²² and a parenteral sodium intake of 2–3mmol/kg/day for term neonates and 3–5mmol/kg/day for premature neonates.²³ Fosfomycin's sodium content equates to a sodium load of 2.8mmol/kg/day (based on dosing of 200mg/kg/day), which is within the published guidelines for neonates. There are negligible amounts of sodium in IV ampicillin and gentamicin, the antibiotics alongside which fosfomycin will be administered; and there is no sodium in the oral fosfomycin formulation.

The ability to reabsorb sodium is inversely proportional to gestational age, and nephrogenesis is complete by 34 weeks gestation.²⁴ Hence, we aim to restrict our patient population to exclude very preterm infants. Hypermnatremia may also occur secondary to hypoxic-ischemic encephalopathy (i.e., as a consequence of asphyxiation, due to central diabetes insipidus or via acute renal injury). Therefore, any baby presenting with seizures or with admission sodium ≥ 150 mmol/L or creatinine ≥ 150 micromol/L will be excluded from the study. All poorly feeding babies will receive IV (10% dextrose) fluids (as per Kenyan Paediatric Protocols).

Of note, the oral fosfomycin suspension contains no sodium, using a calcium base at a dose equivalent to 1.4mmol/kg/day, within the published neonatal guidelines for calcium administration (of 1.3–3mmol/kg/day).²³ Monitoring of calcium, magnesium and phosphate will therefore be undertaken. Oral fosfomycin also contains fructose to the equivalent of 1600mg/kg/day. There is little published research regarding high fructose loads in neonates, with most previous trials documenting safety at lower doses (150mg as an analgesic therapy);²⁵ while a recent meta-analysis evaluating sucrose administration (in 7,049 infants) documented a “very low” incidence of minor adverse events, with no reported major adverse events.²⁶ Nonetheless, the possible adverse event of osmotic diarrhoea will therefore be closely monitored in this study.

Study	N (Total n=82)	Dose and clinical setting	Clinical Setting	Outcomes
Taylor et al. 1977 ²⁷	43 neonates	150-200mg/kg/day	Enterocolitis caused by enteropathic <i>E. coli</i>	Favourable clinical outcome in 88%
Rossignol & Regnier 1984 ²⁸	21 neonates	200mg/kg/day in two divided doses, in combination with gentamicin/tobramycin	Sepsis and UTI	Clinical recovery in 19/21 (90.5%)
Guillois et al. 1989 ²⁹	Case report (n =1)	IV fosfomycin-vancomycin, followed by oral pristinamycin	MSSA septicaemia with a liver abscess	Full recovery
Gouyon et al. 1990 ³⁰	16 neonates	IV fosfomycin-cefotaxime	<i>Staphylococcal</i> septicaemia (<i>epidermidis</i> (n=10) and <i>aureus</i> (n=6)) (including meningitis and osteomyelitis)	Full recovery in n=15 (94%)
Algubaisi et al. 2015 ³¹	Case report (n=1 term infant)	120mg/kg/day fosfomycin and meropenem	Multiple <i>Citrobacter koseri</i> intracerebral abscesses	Clinical recovery

Table 3: Clinical studies describing the use of fosfomycin in neonatal sepsis. Modified from Li et al (in publication)³²

Documented Pharmacokinetics of Fosfomycin:

A recent review of the PK profile of fosfomycin in neonates identified four small additional published studies assessing IV fosfomycin (with no oral PK data available) (Table 4). The elimination half-life ($t_{1/2}$) of fosfomycin ranged from 2.4-7 hours following an IV bolus of 25-50mg/kg administered to neonates which included LBW and premature infants.^{33,34} Fosfomycin is almost completely eliminated by glomerular filtration, with 80-95% of the dose unchanged in the urine within 24 hours.³⁵ Consequently, neonates have a prolonged fosfomycin $t_{1/2}$ compared to older children and adults due to immature glomerular filtration and a greater volume of distribution.³⁴ Serum protein binding of fosfomycin has been estimated to be below 3%, and the neonatal C_{max} (60-90mg/L) is comparable with adult populations.^{35,36}

Study	N (Total n=31)	Dose and study	Outcome
Molina et al. 1977 ³⁴	11 neonates	50mg/kg IV, comparing infants 1-3d old and 3-4 weeks old	Elimination slower at earlier corrected gestational age
Guggenbichler 1978 ³³	5 term & 5 pre-term neonates	25mg/kg IV	95-98% recovered in the urine, 1 compartment model

Study	N (Total n=31)	Dose and study	Outcome
Guibert et al. 1987 ³⁷	10 neonates	200mg/kg BD, comparing 30m or 2hr infusion schedules	No difference between schedules, serum concentrations are above MIC of common pathogens at 12h post dose
Suzuki et al. 2009 ³⁸	Not identified	Dose estimation for renally excreted drugs	Dose estimation validated with GFR, tubular secretion clearance and fraction of unbound drug in plasma

Table 4: Neonatal fosfomycin pharmacokinetic studies; modified from Li et al (2016; in publication)

Bactericidal effects correlate with time above the MIC ($t > \text{MIC}$).³⁹ Pharmacokinetic modelling suggests that the current lower recommended paediatric doses (100mg/kg/day, Table 2 & Table 3) are insufficient for achieving target $t > \text{MIC}$ for term neonates; and the corrected gestational age and body weight in neonates are the key explanatory variables for fosfomycin's PK.³⁹

Previous research investigating the oral bioavailability of fosfomycin in adults documented a range between 34 and 58%.^{40,41} Absorption is via the small intestine and is reduced by concurrent administration with food (37% when fasting versus 30% with food), thus, C_{max} that is higher under fasting conditions.⁴²

Justification for the study

Neonatal sepsis has a high risk of morbidity and mortality. The current WHO and national guidelines recommend antibiotics to which resistance is reported in neonatal populations, although the available data is limited. Research on alternative empirical regimens for neonatal sepsis which are affordable, safe and cost-effective, with a step-down oral option, is needed. AMR is an issue of global public health concern and is one of the WHO's global health priority areas.⁴³ Understanding the benefits, risks, MIC capacity and PK of fosfomycin will influence global policy on the case management of neonates with sepsis in Kenya and international settings.

State the Null Hypotheses

- The pharmacokinetics of the currently recommended various doses of IV and PO fosfomycin are unsuitable for treating neonates.
- Fosfomycin administration is not associated with altered plasma sodium in neonates.
- Fosfomycin does not inhibit growth of more than 25% of archived isolates of *Enterobacteriaceae* that express an ESBL phenotype *in vitro*.

Objectives

a) General Objectives

To improve the understanding of fosfomycin pharmacokinetics and safety amongst newborns aged ≤ 28 days hospitalized with clinical sepsis and provide detailed information regarding the antimicrobial susceptibility of local invasive bacteria to fosfomycin.

b) Specific Objectives

- To estimate the PK disposition parameters of IV and PO fosfomycin in neonates
- To assess the safety of fosfomycin, particularly with regard to possible elevation of sodium after 48 hours of IV fosfomycin administration in neonates
- To estimate the oral bioavailability of fosfomycin in neonates
- To generate preliminary data on the safety of oral fosfomycin in neonates

- With the above information, generate a recommended dosing schedule for future IV and PO fosfomycin efficacy trials
- c) Secondary Objective
 - To gain information regarding susceptibility patterns of local bacterial species to fosfomycin

Study Design

A safety and pharmacokinetic study among neonates admitted to a rural hospital in Kenya and eligible for IV antibiotics under current national guidelines. 120 patients will be randomized 1:1 to standard-of-care antibiotics *plus* a 7-day course of fosfomycin (n=60); or standard-of-care (n=60) antibiotics only (ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).

For the group receiving fosfomycin, fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged). Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (0 to 4h) and late (4 to 12h) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients. In total, four PK blood samples of 0.5ml each will be drawn from each participant, plus a fifth sample collected at 7 days to check electrolytes, and from which a PK sample will be assessed from any residual blood. Biochemistry (a commonly performed investigation for babies with sepsis) will be checked at 48 hours and 7 days for participants in both groups at the same time that the PK sample is collected. Daily observations until discharge and AEs up to a follow-up visit at day 28 will be recorded.

For the group receiving standard-of-care only, daily observations until discharge and AEs up to a follow-up visit at day 28 will be recorded.

Study site:

Kilifi County Hospital, Kilifi, Kenya

Definition of Study Population:

a) Criteria for inclusion of subjects (for pharmacokinetics):

Neonates defined as:

- Age 0 to 28 days inclusive
- Weight >1500g
- Born (an estimated) >34 weeks gestation (calculated as per the Ballard Maturational Assessment)
- Admitted to hospital and eligible to receive IV antibiotics, according to national guidelines

All neonates presenting to Kilifi County Hospital meeting the above criteria will be screened for inclusion in a systematic recruitment process.

b) Criteria for exclusion of subjects

- Baseline sodium level ≥ 150 mmol/L
- Baseline creatinine ≥ 150 micromol/L
- Presenting with severe (grade 3) Hypoxic Ischemic Encephalopathy (HIE), defined as per Sarnat and Sarnat⁴⁴ as a stuporous, flaccid infant (with or without seizure activity) with suppressed brainstem and autonomic functions and absent reflexes
- Requiring cardiopulmonary resuscitation on admission

- Jaundice requiring exchange transfusion
- Admitted as a transfer after an overnight inpatient stay at another hospital
- Known allergy or contraindication to fosfomycin
- A specific clinical indication for another class of antibiotic (other than the nationally recommended standard-of-care)
- More than 4 hours after initiating ampicillin plus gentamicin (one dose), which allows for administration of these first-line antibiotics not to be delayed by study procedures
- Concurrent participation in another clinical trial
- Attending clinician's judgement that the child is so severely ill that adequate communication about the study with the parent or legal guardian is not possible.
- Not planning to remain resident in the County for the next 28 days.
- Lack of consent

Rationale for animal use and justification for animal species chosen

Not applicable

Sampling

i. Sample size determination:

i. For Pharmacokinetics:

Sample size has been calculated to ensure that the following PK parameters can be estimated with sufficient precision such that a dose schedule can be recommended for a future efficacy trial:

- Clearance (CL)
- Central volume (V)
- Oral Bioavailability (F)

Precision limits were set to 20%, and the power to estimate parameters with 95% confidence intervals within these limits was assessed by simulation-estimation. The simulation model consisted of an adult disposition model, with age and size scaling down to neonates, with added first-order absorption and assumed bioavailability. Six sampling time points were chosen to cover the dose intervals (3 early, 3 late) and the simulated population was randomly assigned age and weight combinations across the range expected for neonates. Parallel and crossover (IV/oral) designs were considered, with a range of 2-4 samples per patient. Power for sample size was greatest for the cross-over design. For the cross-over design, a minimum of 45 subjects contributing the complete set of 4 samples each (allocated early and late sample following the first IV and PO dose) are required to provide power of >85% to estimate all parameters within 20% precision limits. We estimate that up to 25% of subjects will not provide complete sample sets (either due to missing samples or withdrawal), so plan to recruit 60 subjects to ensure 45 complete sample sets. If all 60 subjects provide complete sample sets, power would rise to 96%.

ii. For Plasma Sodium

We have reviewed the data of (n=1,785) neonates >1500g admitted to Kilifi County Hospital (2015/6), which indicate a sodium mean and standard deviation of 139mmol/L and (SD 7.6, range 106 to 198mmol/L). 7.4% of babies had an admission sodium of >150mmol/L (our exclusion criterion). Excluding these babies, the mean sodium level in (the remaining n=1,653) babies was 137mmol/L (SD 5.2). With a minimum of 45 in each group (PK versus standard-of-care), the study has >85% power to detect a difference in sodium of 5mmol/L between groups.

The sample size is not intended to be powered for antimicrobial efficacy or clinical outcomes.

iii. For MIC of stored bacterial isolates and bowel flora:

Susceptibility of fosfomycin and other antibiotics is already being tested as per protocol SSC-1433. We will test n=200 invasive isolates from paediatric patients collected within the last 5 years, calculated based on >80% power

to discriminate a non-susceptible proportion of up to 17% from a hypothetical proportion of 25% (one-sided). This is selected as a proportion which would render fosfomycin ineffective for introduction should this level of non-susceptibility be found. We shall then investigate fosfomycin susceptibility on other (ESBL-negative) Gram-negative isolates, and Gram-positive pathogens. For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs from those babies included in the study.

ii. Study Endpoints:

1. Primary Endpoint:

Estimation of the pharmacokinetic disposition and absorption parameters of IV and oral fosfomycin in neonates with clinical sepsis with sufficient precision such that a dose schedule can be recommended for a future efficacy trial

2. Secondary Endpoint(s):

- Difference between the groups in mean 48-hour plasma sodium concentrations
- Difference between the groups in mean 7-day plasma sodium concentrations
- Difference between groups in the rate of adverse events (any grade) to 28 days after enrolment in the study.

Procedures:

A) Analysis of Bacterial Isolates:

Isolates collected from nappy swabs will be subcultured and tested for fosfomycin susceptibility using disk diffusion (*E. coli*) and agar dilution (all isolates).⁴⁵ For disc diffusion, commercially available discs containing 200ug fosfomycin and 50mg of glucose-6-phosphate will be used. MICs will be determined by the agar dilution method using Mueller-Hinton agar supplemented with 25ug/m of glucose-6-phosphate and doubling concentrations of fosfomycin. The MIC will be recorded as the lowest concentration inhibiting visible growth. Plates will be incubated in ambient air at 35°C for 16 to 18 hours. Testing will be performed in duplicate, and mean MICs / zone diameters interpreted using EUCAST breakpoints (http://www.eucast.org/clinical_breakpoints/).

B) Pharmacokinetic Study - Enrolment Procedure:

All neonates presenting to Kilifi County Hospital will be systematically screened to assess their eligibility in meeting the inclusion criteria and consent requested from the parent / guardian. Sequential study numbers will be generated according to a blocked randomization from a list of random block sizes created before the study begins. Randomization cards linking allocation (to standard care plus fosfomycin or standard care alone) to study number will be placed in sealed opaque envelopes by the study sponsor. On enrolment, infants will be allocated study numbers sequentially, thus randomly allocating the two groups. Since this is an open-label study, once an envelope is opened, the randomization card will be securely attached to the patient's CRF.

a) Consent Process

Consent will be required for all data and samples taken for research purposes. Consenting will be done in a private room by study clinicians or trained field assistants, with the opportunity to ask questions and discuss concerns. Informed consent will be administered in a language that the parent/guardian best understands (English, Swahili or Giriama) after assessment of his/her literacy level. This will be done in the paediatric ward or high dependency unit once the decision to admit has been made. Whilst giving written consent parents/legal guardians will be able to agree to consent separately for participation in the study, storage of data and samples for future research, and export of samples for the PK assay that cannot currently be conducted in Kenya.

b) Data Collection

For all participants, a study-specific case report form (CRF) will be used from the time of enrolment and captured information will be entered into a database. The CRF will include a daily standardized record of clinical progress and drugs administered which will also be entered into a database. At discharge, the date, vital status and weight will be recorded.

c) Data Management and Analysis:

After the CRF has been completed and monitored by the clinical monitor, CRFs will be collected and data will be entered onto a validated password protected Openclinica database. Data will be kept confidential, with access restricted on password-protected computers, with regular secure backup. Any data transferred between Kenya and Europe will be emailed within password-protected encrypted files.

Analysis of fosfomycin and major metabolite concentration in plasma will be undertaken by Liquid Chromatography Mass Spectrometry (LC-MS) using validated methods in the GCP/GLP compliant laboratory in Analytical Services International Ltd, St George's Hospital, London, UK. Where possible, (scavenged) PK for penicillin and gentamicin will be measured using the same sample. Analysis will undertake by Dr Karin Kipper, Dr Joe Standing and Mr Martin Ongas, who will be trained on the techniques whilst running the analyses.

PK modelling and dosing simulations will be undertaken by non-linear mixed-effects modelling using NONMEM® software. The volume of distribution, half-life, clearance and trough levels of bound and unbound drug, and active metabolites will be estimated with 95% confidence intervals. Periods with concentrations above the CLSI, EUCAST and BSAC susceptibility breakpoints will be estimated. We will examine the effects of covariates including age, weight, and concurrently measured plasma sodium, potassium, and liver enzymes. Monte-Carlo simulations will be performed to determine the appropriate dosage and frequency of administration.

d) Clinical Care

Alongside protocol specific training, the study team will also conduct refresher training for clinicians on the current national guidelines for managing neonates presenting with presumed sepsis. Neonates will be reviewed every day by study clinicians, working together with the hospital team. All adverse events will be documented and reported, with any grade 4 or SAE reported within 48 hours to an independent DSMB. All other aspects of care will be provided according to national guidelines. Should a patient require second-line antimicrobials (third-generation cephalosporins), they will not be removed from the study as this will not impact the fosfomycin PK data.

e) Study Treatment:

Fosfomycin is a peptidoglycan antibiotic which has bactericidal effects. There will be two formulations of fosfomycin utilized in this study:

- Fosfomycin 40 mg/ml powder for solution for infusion
- Fosfomycin powder for reconstituted suspension (250mg/5ml)

Preparation will be in accordance with manufacturer's instructions. Further details regarding treatment dispensing, administration and accountability is documented in Appendix D. Training will be provided to all staff involved in its administration.

f) Timing of Assessments:

A schedule of events identifying the timing of required assessments and investigations is documented in Figure 2:




Figure 2: Schedule of Events

Note: If a Lumbar Puncture is clinically indicated after commencing fosfomycin, a scavenged PK sample will be obtained from the CSF

g) Pharmacokinetics Procedures:*Baseline Assessments:*

Following informed consent, study clinical officers will prescribe both routine standard-of-care antibiotics (ampicillin 50mg/kg twice daily, and gentamicin [3mg/kg for babies <2kg, 5mg/kg for babies >2kg] once daily) and, for the PK group, fosfomycin (100mg/kg every 12 hours, initially IV). Findings from history and examination, and standard admission investigations (CBC and biochemistry) will be collected at baseline. A blood culture will be performed at admission +/- lumbar puncture; from which a scavenged PK sample will be sent for analysis if sufficient CSF remains (if there is a clinical indication for this to occur following the administration of IV fosfomycin). In order to assess antimicrobial resistance that is brought into hospital and that which has been acquired on the ward, an antimicrobial susceptibility profile will be determined for rectal carriage of resistant isolates by collecting a nappy swab at admission and discharge. This will enable determination of the effect of carriage of antimicrobial resistance following treatment with fosfomycin.

Pharmacokinetic Assessments:

The first dose of fosfomycin will be followed by the collection of two PK samples at allocated times: one early (during 0 to 4 hours post-dose) and one late (during 4 to 12 hours post-dose). After a minimum of 48 hours (or 4 IV doses), when tolerating oral medications, fosfomycin will be changed to oral and prescribed at the same dose (100 mg/kg every 12 hours). Following the first oral dose, one early and one late PK sample will again be obtained. For those who remain as inpatients, a PK sample of 0.5ml will be obtained together with a day 7 biochemistry. This will involve 5 plasma PK samples in total per patient, estimated as requiring an upper limit of 0.5 mL/sample (resulting in 2.5mL total study PK sample collection).

As per usual clinical procedures, blood for plasma electrolytes will be drawn at ~48 hours (co-ordinated with the first post-oral PK sample time-point for patients who step-down to oral fosfomycin at this point) and again at 7 days (for those who remain as inpatients in each study group).

All participants will receive a structured daily review including clinical status and current treatment. Standard antibiotics may be altered in line with the results of a blood culture, which is currently done routinely for clinical care (fosfomycin will be continued). Planned follow-up for clinical review will be done at day 28. Participant fares and compensation for lost work time will be provided at standard rates for this visit. Participants may also attend the ward in case of significant illness between discharge and day 28.

Drug dose or sample	Target times
Dose: 1 st Ampicillin	After admission investigations
Dose: 1 st Gentamicin	After admission investigations
Dose: 1 st Fosfomycin IV	After admission investigations
SAMPLE 1*: ONLY ONE OF:	
5 minutes	5 minutes after 1 st fosfomycin intravenous dose
30 minutes	30 minutes after 1 st fosfomycin intravenous dose
60 minutes	60 minutes after 1 st fosfomycin intravenous dose
SAMPLE 2: ONLY ONE OF:	
2 hours	2 hours after 1 st fosfomycin intravenous dose
4 hours	4 hours after 1 st fosfomycin intravenous dose
8 hours	8 hours after 1 st fosfomycin intravenous dose
Dose: 2 nd Ampicillin	12 hours after 1 st ampicillin dose; <i>continuing 12 hourly</i>
Dose: 2 nd Fosfomycin IV	12 hours after 1 st fosfomycin dose
Dose: 2 nd Gentamicin	24 hours after 1 st Gentamicin dose; <i>continuing daily</i>
Dose: 3 rd Fosfomycin IV	24 hours after 1 st fosfomycin dose
Dose: 4 th Fosfomycin IV	36 hours after 1 st fosfomycin dose
--Change to PO fosfomycin-- 1 st dose Fosfomycin PO	48 hours after 1 st fosfomycin dose; when tolerating oral medication and without signs of sepsis (otherwise continue IV 12 hourly)
SAMPLE 3: ONLY ONE OF: (collected alongside biochemistry)	
5 minutes	5 minutes after 1 st fosfomycin oral dose
30 minutes	30 minutes after 1 st fosfomycin oral dose
60 minutes	60 minutes after 1 st fosfomycin oral dose
SAMPLE 4: ONLY ONE OF:	
2 hours	2 hours after 1 st fosfomycin intravenous dose
4 hours	4 hours after 1 st fosfomycin intravenous dose
8 hours	8 hours after 1 st fosfomycin intravenous dose
Dose: 2 nd Fosfomycin PO	12 hours after 1 st fosfomycin oral dose; <i>continuing 12 hourly for up to 7 days</i>
SAMPLE 5: (collected alongside biochemistry)	7 days after 1 st fosfomycin intravenous dose

***Note: Subjects will be allocated to only one of each sampling timeframe**

Samples will be collected into heparinised tubes, centrifuged and the separated plasma stored at minus 80°C. Biochemistry will be measured in real time, and results returned immediately to assist clinical care.

If a lumbar puncture is conducted and processed in the laboratory for clinical reasons, residual CSF will be stored at minus 80°C to assess CSF antimicrobial penetration.

Samples will be securely stored on site in the KEMRI-CGMRC in Kilifi. Following export approval by SERU, samples will be packaged and shipped according to IATA regulations by a reputable courier, such as World Courier to Analytical Services International Ltd. At St. George's Hospital, London and University College London for analysis. Pharmacokinetic assay results will be returned to Kenya. Samples may be stored for up to 5 years. Additional analyses beyond those described in this protocol: assaying antimicrobial drug levels and biochemistry/liver function will first require further approval by SERU. Remaining samples will be destroyed by incineration according to GCP after 5 years.

PROCEDURES	SCREENING	BASELINE	←-----TREATMENT PHASE-----→				FOLLOW- UP
			Daily until discharge	48 hours	Day 7	Discharge	Day 28
Informed Consent	X						
Demographics	X						
Medical History	X		X			X	X
Physical Examination	X		X			X	X
Vital Signs (incl. wt)	X		X			X	X
PK Sampling				X [#]	X [^]		
Biochemistry	X			X [#]	X [^]		
Eligibility Assessment	X						
Allocation		X					
Dispensing Trial Drugs		X		X	X		
Nappy Swab		X				X	
Adverse Event Assessment	X	X	X	X	X	X	X

*Or when tolerating oral medication

[#]Acceptable time point: within 12 hours (either side) of 48 hours since commencing IV fosfomycin

[^]Acceptable time point: within 24 hours (either side) of day 7 since commencing IV fosfomycin

h) Provisions for data verification, and validation

Clinical data will be collected prospectively, supervised by a consultant paediatrician investigator, and overseen by the coordinating team in Kilifi. Data will be monitored for integrity and completeness weekly by the data manager. The study will be monitored by the KEMRI/Wellcome Clinical Trials Facility Monitoring Team. For the PK study, a comprehensive study initiation visit will be done at which all staff will be trained in protocol specific procedure, and check that all trial logistics are in place. A site initiation visit, then routine monitoring will be conducted during PK study. The monitor's role is part of the quality system that will ensure that all participants have duly completed informed consent; entries relating to eligibility, consent and data collected on the CRF are source-verified; and that staff on the study are following standard operating procedures (SOPs) which are in accordance with the protocol.

Clinical Trial Governance:

An independent DSMB will have an advisory role to safeguard the interests of trial's participants, investigators and sponsor; to assess the safety and efficacy of the trial's intervention, and to monitor the trial's overall conduct, and protect its validity and credibility. Its recommendations will be addressed by the TSC. The DSMB operations will be facilitated by the PI and TSC. The DSMB will usually be convened annually, by teleconference, at the chair's discretion. The chair may also call for *ad hoc* or emergency meetings. The DSMB will report to the TSC, usually within 2 weeks of a meeting, copied to the trial statistician. Unless the DSMB is recommending that the trial protocol be changed, the letter to the TSC should not usually reveal any confidential information. If the DSMB has serious concerns about a TSC decision, a meeting of these groups should be held, chaired by an external expert not directly involved with the trial.

Safety reporting

i) Assessment of Safety:

Neonates will be reviewed every day by study clinicians, working together with the hospital team. All adverse events will be documented and reported, with any grade 4 AE or Serious AE (SAE) that are not 'Anticipated SAEs' (see below) will be reported immediately (no later than within 24h of knowledge by the investigator) to

the Sponsor, within 48 hours of knowledge by the Sponsor (DNDi) to an independent DSMB, and within 72 hours of knowledge by the Sponsor to the Ethics Committee and PPB.

Safety will be assessed through routine monitoring of adverse events. In addition, evaluation of haematology and blood chemistry parameters, regular measurement of vital signs and physical examinations will be conducted as per the protocol and clinical indication. The frequency, severity, seriousness and causality assessments of AEs will be described, as well as frequency of SAEs or AEs that lead to treatment discontinuation. AEs will be collated for both patient groups in the CRF. The AE reporting period begins upon issuance of a clinical trial participant number and ends at the day 28 follow-up visit.

ii) Protocol Violations:

Any protocol violations will be reported to the Sponsor (DNDi), to an independent DSMB, and to the Ethics Committee and PPB.

iii) Laboratory examinations

Haematology parameters (CBC, WBC with differential and platelets) will be analysed at screening, on days 2 and day 7 as is normally clinically indicated (plus any additional investigations as clinically indicated). Biochemistry parameters will be analysed at screening, on day 2 and day 7 (plus additional frequency if clinically indicated). Samples will be analysed at the adjacent KWTRP Clinical Trials Laboratory using standardized equipment. Approximately 0.5ml of blood will be collected for each study investigation. Abnormal Lab parameters will be assessed for clinical significance.

iv) Adverse event definitions and reporting

The definition of adverse drug reactions, events or suspected unexpected serious adverse reactions is outlined below:

TERM	DEFINITION
Adverse Event (AE)	Any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment ^A
Adverse Drug Reaction (ADR)	All untoward and unintended responses to an investigational medicinal product related to any dose administered ^B
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)	Any untoward medical occurrence or effect that at any dose which: • Results in death • Is life-threatening • Requires hospitalization or prolongation of existing hospitalization • Results in persistent or significant disability or incapacity • Is a congenital anomaly or birth defect

TERM	DEFINITION
	Is considered medically important/clinically significant^C
Non-Serious Adverse Event / Non-Serious Adverse Drug Reaction	An adverse event or adverse drug reaction that does not meet the criteria listed above for a serious adverse event/serious adverse drug reaction
Expected Adverse Reaction (EAR)	An adverse reaction, the nature or severity of which is consistent with the SPC for Fosfocina, 500 mg capsules and suspension (250mg/5ml) Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, Nordic Pharma
Unexpected Adverse Reaction (UAR)	An adverse reaction, the nature or severity of which is <u>not</u> consistent with the SPC for Fosfocina, 500 mg capsules and suspension (250mg/5ml) Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, Nordic Pharma
Suspected Unexpected Serious Adverse Reaction (SUSAR)	An adverse reaction that is <u>unexpected</u> (not consistent with the SPC for Fosfocina, 500 mg capsules and suspension [250mg/5ml] Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, Nordic Pharma) <u>and</u> meets the definition of a serious adverse event/reaction

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether considered related to the IMP.

What is not an AE?

- Medical conditions present at the initial study visit, that do not worsen in severity or frequency during the study, are not considered as AE.
- Lack of efficacy of the IMP is not considered as AE.

Laboratory/procedures abnormalities considered as an AE:

Laboratory/procedures abnormalities (or worsening in severity or frequency of pre-existing abnormalities) should be assessed as “clinically significant” if they meet AT LEAST ONE of the following conditions:

- The abnormality suggests a disease and/or organ toxicity AND this abnormality was not present at the screening visit or is assessed as having evolved since the screening visit
- The abnormality results in discontinuation of the study drug
- The abnormality requires medical intervention or concomitant therapy

When reporting an abnormal laboratory/procedure result, a clinical diagnosis should be recorded rather than the abnormal value itself, if available (for example, “anaemia” rather than “low haemoglobin”). For every laboratory assessment, the investigator will evaluate if the lab test is normal or abnormal. If abnormal, the investigator will

assess if this finding is clinically significant or not. If a lab parameter is abnormal and clinically significant, it should be reported as an adverse event, after comparison with the previous value (AE).

v) Eliciting Adverse Event information

The investigator will report all directly observed AEs and all AE spontaneously reported by the parents/guardians using concise medical terminology. In addition, at follow-up visit the parents/guardians will be asked a generic question such as *“Since you were discharged from hospital, has your child had any health problems?”* Information on AEs will be evaluated by a physician.

vi) Adverse Event reporting period

The adverse events reporting period begins upon subject enrolment in the trial (after signature of informed consent) and ends 28 days (4 weeks) after the first dose was administered.

vii) Anticipated Serious Adverse Events:

Adverse events are relatively common in this patient group due to low birth weight, possible birth asphyxia and concomitant disease processes.⁴⁶ Anticipated serious adverse events defined in the table below will be recorded and reported in the CRF, but will be exempt from expedited reporting to the Sponsor and regulatory bodies as they are anticipated in this high-risk population. If an Investigator believes that one of these events is causally related to fosfomycin, this would be classified as a SUSAR and requires expedited reporting.

ANTICIPATED SERIOUS ADVERSE EVENTS
Necrotising enterocolitis (diagnostic radiological/surgical changes)
Intracranial abnormality on cranial ultrasound scan (parenchymal haemorrhage or focal white matter injury)
Patent ductus arteriosus
Pulmonary haemorrhage
Severe anaemia requiring transfusion (due to ABO incompatibility, prematurity or haemorrhage)
Jaundice requiring phototherapy or exchange transfusion
Congenital birth defect diagnosed during admission
Fracture secondary to birth trauma
Apnoea
Infection (positive blood culture with clinical signs)*
Persistent derangement of liver function tests (beyond 36 weeks CGA)
Abnormal muscle tone, posturing or convulsions (secondary to suspected birth asphyxia)
An episode of Hypoglycaemia (defined as per the World Health Organization, ≤ 2.6mmol/L)⁴⁷

* Both infections other than condition for inclusion in trial and, in case of infections linked to the sepsis episode that is the reason of the participant's inclusion in the trial, worsening (e.g. septic shock) and relapse.

viii) Adverse Event Recording:

All AEs will be recorded on the AE CRF and reported as a listing at the end of the study. In the CRF, a given AE will be recorded one time per subject, and the severity will be assessed and recorded as the maximum level reached. If several distinct episodes of the same condition occur, their number will be recorded in the CRF. In addition, the causal relationship between the onset of each AE and the IMP (for those not already identified as anticipated SAEs) will be assessed.

Information on adverse events will be evaluated by a physician. Each adverse event will be classified by the investigator as serious or non-serious. This classification will determine the reporting procedure for the event.

All unexpected serious adverse events (SAE) will be reported immediately to DNDi and SERU (the Sponsor) within 24 hours of awareness by the investigator, and within 48 hours of awareness of SUSAR by the investigator to OxtREC, PPB and the DSMB (whether or not the event is considered study drug-related), using the SAE report form. This includes a description of the event, onset date and type, duration, severity, relationship to study drug, outcome, measures taken and all other relevant clinical and laboratory data. The initial report will be followed by submission of additional information (follow-up SAE form) as it becomes available.

Any follow-up reports will be submitted within 5 working days. In addition to documenting the SAE on the SAE report form, the SAE will also be documented on the CRF and all medications used to treat the SAE will be documented on the concomitant treatments CRF.

ix) Grading of Adverse Event severity

Toxicities and adverse events will be graded for severity to describe the maximum severity of the adverse event according to the DAIDS grading scales (version 2.1, March 2017; Available at: <https://rsc.tech-res.com/docs/default-source/safety/daids-ae-grading-table-mar2017.pdf?sfvrsn=6>).

In case of AEs that are not described in the DAIDS AE grading system, the investigator will use the terminology “mild”, “moderate”, “severe” or “life-threatening” to describe the maximum severity of the adverse event. These severity grades are defined as follows:

MILD	Does not interfere with subject's usual functions
MODERATE	Interferes to some extent with subject's usual functions
SEVERE	Interferes significantly with subject's usual functions
LIFE-THREATENING:	The subject is at risk of death at the time of the AE it does not refer to an AE that hypothetically might have caused death if more severe.

It is to be noted there exists a distinction between severity and seriousness of adverse events. *A severe adverse event is not necessarily a serious event.*

x) Adverse Event causality assessment

For both serious and non-serious AEs, the investigator is required to assess the causal relationship between the AE and the study drug, i.e. to determine whether there exists a reasonable possibility that the study drug caused or contributed to the adverse event, or evidence to suggest a causal relationship.

To help investigators with the decision binary tree in the evaluation of causality, as per the CIOMS VI group recommendation, the investigators will consider the following before reaching a decision:

- Medical history
- Lack of efficacy/worsening of existing condition
- Study medications
- Other medications (concomitant or previous)
- Withdrawal of study medication, especially following trial discontinuation / end of study medication
- Erroneous treatment with study medication (or concomitant)
- Protocol related procedure

The terms for reporting are:

Definite	The adverse event and administration of IMP are related in time, and a direct association can be demonstrated.
Probable	The adverse event and administration of IMP are reasonably related in time, and the adverse event is more likely explained by study agent than other causes
Possibly related	The adverse event and administration of IMP are reasonably related in time, and the adverse event can be explained equally well by causes other than IMP
Unlikely	A potential relationship between IMP and the adverse event could exist (i.e. the possibility cannot be excluded), but the adverse event is most likely explained by causes other than the IMP
Not related	The adverse event is clearly explained by another cause not related to the IMP

xi) Adverse event follow up

All participants with AEs will receive treatment for those events and be followed up until they are resolved, or the investigator assesses them as chronic or stable, or the subject participation in the study ends (i.e., until a final report is completed for that subject) and care is ongoing.

In addition, all SAEs and those non-serious AEs assessed by the investigator as related (related/probably related/possibly related) to the investigational medication will continue to be followed even after the subject participation in the study is over. Such events will be followed until they resolve or until the investigator assesses them as chronic or stable. Resolution of such events will be documented on the CRF.

Withdrawal criteria:

A subject should be withdrawn from the study treatment if, in the opinion of the investigator, it is medically necessary, or if it is the wish of the parent/guardian. If a patient is withdrawn from the study before the full course of the treatment is completed, the physician will make all necessary arrangements to ensure that the subject receives the appropriate treatment for the relevant medical condition (ie with medication/s currently recommended by national guidelines). Should a patient require second-line or alternative antimicrobials, they will not be removed from the study as this will not impact the fosfomycin PK data.

If a subject does not return for the follow-up assessments, every effort will be made to contact their parents/guardian. In any circumstance, every effort should be made to document subject outcome, if possible. If the subject withdraws consent, no further evaluations should be performed and no attempts should be made to collect additional data, except for safety data, which should be collected if possible and in accordance with consent.

If a subject is withdrawn from the study, the reason will be noted on the CRF. If a subject is withdrawn from the study because of a treatment limiting adverse event, thorough efforts will be made to clearly document the outcome of AE.

Data Safety Monitoring Board:

A Data Safety Monitoring Board (DSMB), composed of 3 members independent of the investigator and sponsor, will be set up prior to study initiation. The DSMB monitors the study in order to ensure that harm is minimized, and benefits maximized for the study subjects. They will review the study data at pre-determined intervals and issue recommendations about the study. The data and intervals will be agreed prior to, or soon after, the study initiation and documented in the DSMB Charter.

Quality Assurance and Quality Control Procedures

A) Investigator's file:

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents include:

- Investigator's Site File
- Subject clinical source documents
- Screening / enrolment logs.

The Investigator's Site File will contain the protocol/protocol amendments, CRF and query forms, REC and regulatory approval with correspondence, sample informed consent, drug accountability records, staff curriculum vitae, authorization forms and other appropriate documents and correspondence.

B) Case report forms (CRFs):

For all participants, a study-specific standardized daily record (which will constitute part of the CRF) will be used from admission (enrolment), with data entered directly into the CRF, and subsequently into the trial database. At discharge, the date, vitals status and weight will be recorded. Clinical data will be collected prospectively, supervised by a consultant paediatrician investigator to ensure data completeness and accuracy. Data that are derived should be consistent with the source documents or the discrepancies will be explained. All CRF data will be anonymized (identified by study patient number only). The study will be reviewed by the KEMRI/Wellcome Clinical Trials Facility Monitoring Team. Study monitors will raise queries on data discrepancies, and these will be corrected by the study investigator against verified source information.

The investigators will ensure the accuracy, completeness, legibility, and timelines of all data reported to the sponsor in the CRFs and any other additional information that is required. The investigator is responsible for keeping all consent forms, screening forms, CRF and the completed subject identification code list in a secure location.

C) Source documents:

The verification of the CRF data will be by direct inspection of source documents. Source documents include subject hospital/clinic records, physician's and nurse's notes, appointment book, original laboratory reports, letters, and subject screening and enrolment logs. The Investigator / designee will record the date of each subject's visit together with a summary of their status and progress in the study. The investigator will maintain source documents for possible review and/or audit by DNDi, Ethics Committees and/or Regulatory Authorities.

D) Record Retention:

The sponsor will keep all study documents on file for at least 25 years after completion or discontinuation of the study, at a secure facility contracted by the DNDi Nairobi offices, within Kenya. After that period of time the documents may be destroyed with prior permission from DNDi, subject to local regulations. Should the investigator wish to assign the study records to another party or move them to another location, DNDi will be notified in advance.

E) Monitoring, audits and inspections:

The investigators will permit representatives of DNDi, designated clinical monitors and representatives of Ethics Committees or Regulatory Authorities to review all CRFs, medical records, laboratory work sheets and to assess the status of drug storage, dispensing and retrieval at any time during the study. The Investigator's File and

corresponding source documents for each subject will be made available provided that subject confidentiality is maintained in accordance with local regulations. The monitoring, audits or inspections are for the purpose of verifying the adherence to the protocol and to ensure the study is conducted according to GCP. It is important that the investigators and other trial site staff are available at these visits.

F) Protocol Amendments:

The principal investigator will ensure that the study protocol is strictly adhered to throughout, and that all data are collected and recorded correctly on the CRF. All protocol modifications must be documented in writing. Any protocol amendment must be approved and signed by the sponsor and the Principal investigator and is to be submitted to the appropriate IEC for information and approval in accordance with local requirements, and to regulatory agencies if required. Approval by IEC (and Regulatory Authority, if applicable) must be awaited before any changes can be implemented, except for changes necessary to eliminate an immediate hazard to trial subjects, or when the change involves only logistical or administrative aspects of the trial [e.g. change in clinical monitor[s], change of telephone number[s].

The protocol amendment can be initiated by either sponsor or by any Principal investigator. The investigator will provide in writing the reasons for the proposed amendment and will discuss with the medical coordinator and sponsor.

Data Sharing

The results of this work will be accessible with no financial barriers, by contributing to open source initiatives such as public databases and open access journals in a timely fashion. Permission to utilize anonymized data will be by application to the Data Governance Committee at CGMR-C who will ensure that appropriate ethical approval is in place for any new analysis. Explanation of this eventuality will be included in the participant Information and Consent Form (ICF).

Intellectual property

Any intellectual property rights that arise from the work will be safeguarded according to DNDi's IP policy and current KEMRI guidelines and the Industrial Property Act of 2001, sections 32, 58 and 80. The scientific and intellectual contributions of all persons involved in the research will be appropriately acknowledged in all publications and presentations arising from the work.

Time Frame/Duration of the Project

May 2017 – December 2017: MIC analysis (once approval is granted)

October 2017 – February 2018: PK study (once approval is granted)

February 2018 – June 2018: Analysis and write-up / publication

Activity	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018
Scientific & ethical approval	X	X				
Database set up		X				
Training		X	X			
PK recruitment & sampling			X	X	X	
PK analysis				X	X	

PK dissemination				X	X	
MIC analysis			X	X	X	
Write-up				X	X	X
Publication						X

Table 7: GANTT Chart of Work Package

Ethical Considerations

The experimental protocol for this study has been designed in accordance with the general ethical principles outlined in the Declaration of Helsinki and ICH guidelines for Good Clinical Practice (International Committee for Harmonization). DNDi assures that it will comply with all applicable state, local and foreign laws for protecting the rights and welfare of human subjects. This protocol and any protocol amendments will be reviewed / approved by the KEMRI Scientific and Ethical Review Unit, Nairobi and the Oxford Tropical Research Ethics Committee, Oxford, UK. The study will be registered on www.clinicaltrials.gov.

Participation in research is voluntary and consent must be given with free will of choice, and without undue inducement. The parent/legal guardian must have sufficient knowledge and understanding of the nature of the proposed research, the anticipated risks and potential benefits, and the requirements of the research to be able to make an informed decision.

b) Human Subjects
First do no harm

(i) Risks

The study will be performed in a patient group who may potentially benefit from the treatment. Fosfomycin is licensed for use in neonates throughout Europe and is used to treat resistant UTIs among adults in Europe and the USA. Adverse events are reported to be rare, and monitoring of renal function, sodium and potassium levels should pre-empt major adverse clinical outcomes from occurring.

The risks of blood drawing include pain and thrombophlebitis. These will be minimized by careful aseptic technique according to a standard SOP. No more than 1ml/kg of blood will be drawn for research at any one time, and no more than a total of 2.5ml will be drawn for research during the entire study. DNDi has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the performance of the study.

(ii) Benefits to the Patients and Community as a whole

Additional clinical staff will be recruited and will undertake study duties and assist in care, adding to the staff available for clinical care on the wards. For babies who do not improve on the currently recommended standard-of-care, we will provide second-line antibiotics free of charge if they are required. This study contributes to knowledge informing the appropriate use of antimicrobials, thus benefiting the whole community both at a local and international level.

(iii) Confidentiality

On enrolment, participants will be issued with a unique identifying number and names recorded on CRFs and in the database as initials only. All clinical data will be held confidentially, and the investigator will ensure that

subjects' anonymity will be maintained, and their identities protected from unauthorized parties. No documents containing patient identity will be submitted to the sponsor. The investigator will maintain documents for submission to sponsor authorized representatives, and the subject's signed written consent forms, in strict confidence.

(iv) Community Engagement Strategy

Community engagement will commence prior to the study with a stakeholders meeting involving Ministry of Health County staff and relevant national Government authorities and policy makers. This will be facilitated by the study sponsor, with attendance by investigators. Ongoing community engagement will be through regular meetings with the community involving KEMRI-Community Representatives and County Government Health and hospital management teams. At these meetings, information and feedback will be given and received.

(v) Stakeholder information giving

We will engage key individuals whom patients may receive information from, including nurses and all ward staff. We will expand ongoing communication activities about research to include this study in order to support parents and guardians receiving information on the study, before being asked for consent.

(vi) Individual informed consent process

Written consent will be required for all data and samples taken for research purposes. Consenting will be done in a separate area to ensure privacy and the opportunity to ask questions and discuss concerns in the paediatric ward, high dependency unit or in casualty once the decision to admit has been made. It is the responsibility of the investigator / designee to obtain written informed consent for each individual participating in this study, after adequate presentation of the aims, methods, anticipated benefits, and potential hazards of the study. The written informed consent document will be translated into the local language (Swahili and Giriama). If needed, the person will be given time to discuss the information received with other members of the family before deciding to consent, providing this does not extend beyond the time identified for inclusion in the study as per the inclusion criteria. The subject or parent/guardian will be asked to provide written and signed consent. Parents or legal guardians will be able to consent separately for participation in the study, storage of data and samples for future research, and export of samples for investigations that cannot currently be conducted in Kenya. Where the attending clinician judges that the child is so severely ill that adequate communication with the parent or legal guardian is not possible, the child will be excluded from participation. If the parent /guardian is illiterate, a literate witness must sign (this person should have no connection to the research team and the sponsor, and, if possible, should be selected by the participant). The witness shall attest that they have provided information accurately to the parent/guardian and this was understood; a thumbprint of the parent/guardian must be provided to attest to this. If new safety information results in significant changes in the risk/benefit assessment, the consent form should be reviewed and updated if necessary. All subjects (including those already being treated) should be informed of the new information, given a copy of the revised form and give their consent to continue in the study.

(vii) Training / support for those involved in community engagement and administering consent

Clinical officers, nurses and field workers will be trained in providing information and administering the consent procedure, following a standard operating procedure in the local language of participants, using didactic learning and role plays. In addition, all investigators will complete relevant courses in Good Clinical Practice ethical training specifically addressing research involving human subjects.

(viii) Feedback of information

This study will be undertaken with the medical and nursing unit staff and the hospital consultants, who have been involved in its design and will be essential in its implementation. Information arising from the study will be fed back through hospital-wide meetings. Study results will be disseminated to study staff, hospital staff and local communities through meetings targeting respective groups. Results will also be published in peer-reviewed journals and presented at local and international meetings or conferences.

(ix) *Animal Subjects*

N/A

Expected Application of the Results

The results will contribute to both local and international knowledge regarding the appropriate use of antimicrobials in neonates with presumed sepsis, and help in the design of a subsequent multi-centre, large-scale randomized clinical trial to determine the risks and benefits (in terms of mortality and antimicrobial resistance) of an updated antibiotic schedule, particularly where multidrug resistant bacteria are prevalent.

References

- 1 Lawn J, Blencowe H, Oza S, You D, Lee A. Every Newborn: Progress, Priorities, and Potential beyond Survival. *Lancet* 2014; **384**: 189–205.
- 2 Liu L, Oza S, Hogan D, *et al.* Global, regional, and national causes of child mortality in 2000–2013; with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet* 2014; **385**: 430–40.
- 3 Shah D, Doyle L, Anderson P, *et al.* Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. *J Pediatr* 2008; **153**: 170–5.
- 4 The World Health Organization. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources. 2013. <http://apps.who.int/iris/bitstream/10665/43206/1/9241546700.pdf>.
- 5 Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics- systematic review and meta-analysis. *Arch Dis Childhood* 2013; **98**: 146–54.
- 6 Le Doare J, Heath, P. and Sharland, M. KB. Systematic review of antibiotic resistance rates among gram-negative bacteria in children with sepsis in resource-limited countries. *J Paediatr Infect Dis Soc* 2014; **4**: 11–20.
- 7 Folgori L, Livadiotti S, Carletti M, *et al.* Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary paediatric hospital during a 12-month period. *Pediatr Infect Dis J* 2014; **33**: 929–32.
- 8 Delhi Neonatal Infection Study (DeNIS). Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. *Lancet Glob Heal* 2016; **4**: e752–60.
- 9 Laxminarayan R, Matsoso P, Pant S, *et al.* Access to effective antimicrobials: A worldwide challenge. *Lancet* 2016; **387**: 168–75.
- 10 The World Health Organization. Critically important antimicrobials for human medicine. 3rd Revis. 2011.
- 11 Hendlin D, Stapley M, Jackson H, Wallick A, Miller A, Wolf F. Phosphonomycin. A new antibiotic produced by strains of *Streptomyces*. *Science* (80-) 1969; **166**: 122–3.
- 12 Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. *Int J Infect Dis* 2011; **15**: e732–9.
- 13 Falagas M, Vouloumanou E, Samonis G, Vardakas K. Fosfomycin. *Clin Microbiol Rev* 2016; **29**: 321–47.
- 14 Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. *Int J Antimicrob Agents* 2016; **47**: 269–85.
- 15 Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. *Infect Dis Ther* 2015; **4**: 433–58.
- 16 Baquero F, Hortelano JG, Navarro M, *et al.* Antibiotherapy of *Serratia marcescens* septicemia in children. *Chemotherapy* 1977; **23 Suppl 1**: 416–22.
- 17 Corti N, Sennhauser FH, Stauffer UG, Nadal D. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. *Arch Dis Child* 2003; **88**: 512–6.
- 18 Llorens J, Lobato A, Olay T. The passage of fosfomycin into the cerebrospinal fluid in children's meningitis. *Chemotherapy* 1977; **23 Suppl 1**: 189–95.

- 19 Careddu P, Borzani M, Scotti L, Varotto F, Garlaschi L, Fontana P. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus piperimide acid. *Chemioterapia* 1987; **6**: 290–4.
- 20 Principi N, Corda R, Bassetti D, Varese LA, Peratoner L. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. *Chemotherapy* 1990; **36 Suppl 1**: 41–5.
- 21 Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children's lower urinary tract infections. *Eur Urol* 1987; **13 Suppl 1**: 119–21.
- 22 Nutrition A et al. for the EC on. Enteral Nutrient Supply for Preterm Infants: Commentary From the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Committee on Nutrition. *Hepatol Nutr* 2010; **50**: 85–91.
- 23 Group K et al. for the PNGW. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric. *J Pediatr Gastroenterol Nutr* 2005; **41**: S1–S4.
- 24 Nash P. Potassium and Sodium Homeostasis in the Neonate. *Neonatal Netw* 2007; **26**: 125–8.
- 25 Akçam M. Oral fructose solution as an analgesic in the newborn: A randomized, placebo-controlled and masked study. *Pediatr Int* 2004; **46**: 459–62.
- 26 Bueno M, Yamada J, Harrison D, et al. A systematic review and meta-analyses of nonsucrose sweet solutions for pain relief in neonates. *Pain Res Manag* 2013; **18**: 153–61.
- 27 Taylor CG, Mascaro E, Roman J, et al. Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. *Chemotherapy* 1977; **23 Suppl 1**: 310–4.
- 28 Rossignol S, Regnier C. [Fosfomycin in severe infection in neonatology]. *Ann Pediatr (Paris)* 1984; **31**: 437–44.
- 29 Guillois B, Guillemin MG, Thoma M, Sizun J, Monnery JL, Alix D. [Neonatal pleuropulmonary staphylococcal infection with multiple abscesses of the liver]. *Ann Pediatr (Paris)* 1989; **36**: 681–4.
- 30 Gouyon JB, Francois C, Semama D, Sandre D, Duez JM, Portier H. [Nosocomial Staphylococcus epidermidis and Staphylococcus aureus septicemias in neonates]. *Ann Pediatr (Paris)* 1990; **37**: 21–5.
- 31 Aljubaisi S, Buhner C, Thomale U-W, Spors B. Favorable outcome in cerebral abscesses caused by *Citrobacter koseri* in a newborn infant. *IDCases* 2015; **2**: 22–4.
- 32 Li G, Standing J, Bielicki J, et al. The potential role of fosfomycin in neonatal sepsis caused by multidrug resistant bacteria. *Publ* 2016.
- 33 Guggenbichler JP, Kienel G, Frisch H. [Fosfomycin, a new antibiotic drug (author's transl)]. *Padiatr Padol* 1978; **13**: 429–36.
- 34 Molina MA, Olay T, Quero J. Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period. *Chemotherapy* 1977; **23 Suppl 1**: 217–22.
- 35 Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. *Infection* 1990; **18 Suppl 2**: S65–9.
- 36 Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin trometamol. *Chemotherapy* 1993; **39**: 297–301.
- 37 Guibert M, Magny JF, Poudenx F, Lebrun L, Dehan M. [Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration]. *Pathol Biol (Paris)* 1987; **35**: 750–2.
- 38 Suzuki S, Murayama Y, Sugiyama E, Sekiyama M, Sato H. [Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function]. *Yakugaku Zasshi* 2009; **129**: 829–42.

- 39 Traunmuller F, Popovic M, Konz K-H, Vavken P, Leithner A, Joukhadar C. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. *Clin Pharmacokinet* 2011; **50**: 493–503.
- 40 Patel S, Balfour J, Bryson H. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. *Drugs* 1997; **53**: 637–56.
- 41 Duez J, Mousson C, Siebor E, *et al.* Fosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infections. *Clin Med Rev Ther* 2011; **3**: 123–42.
- 42 Borgia M, Longo A, Lodola E. Relative bioavailability of fosfomycin and of trometamol after administration of single dose by oral route of fosfomycin trometamol in fasting conditions and after a meal. *Int J Clin Pharmacol Ther Toxicol* 1989; **27**: 411–17.
- 43 WHO | Antimicrobial resistance: a priority for global health action. *Bull World Heal Organ* 2015; **93**: 437–512.
- 44 Sarnat H, Sarnat M. Neonatal encephalopathy following fetal distress: A clinical and electroencephalographic study. *Arch Neurol* 1976; **33**: 696–705.
- 45 Lu C, Liu C, Huang Y, *et al.* Antimicrobial Susceptibilities of Commonly Encountered Bacterial Isolates to Fosfomycin Determined by Agar Dilution and Disk Diffusion Methods. *Antimicrob Agents Chemother* 2011; **55**: 4295–4301.
- 46 Morgan C, Herwitker S, Badhawi I, *et al.* SCAMP: standardised, concentrated, additional macronutrients, parenteral nutrition in very preterm infants: a phase IV randomised, controlled exploratory study of macronutrient intake, growth and other aspects of neonatal care. *BMC Pediatr* 2011; **11**.
- 47 The World Health Organization. Hypoglycaemia of the Newborn: Review of the Literature. 1997 DOI:WHO/CHD/97.1 / WHO/MSM/97.1.



Drugs for Neglected Diseases initiative



**Intravenous and Oral Fosfomycin in Hospitalized Neonates with Clinical Sepsis:
an open-label safety and pharmacokinetics study
(neoFosfo)**

Short title	Neo-Fosfo
Name of product(s)	Fosfomycin oral and IV formulations
Drug Class	Antibiotic
Indication	
Protocol Number	Neo-Fos-001
EudraCT	Not applicable
Study Sponsor	DNDi Tetezi Towers, 3 rd Floor George Padmore Rd Kilimani PO BOX 21936-00505 Nairobi KENYA +254 20 3995 000 Head Office: Chemin Louis Dunant, 15, 1202 GENEVA Switzerland Phone: +41 22 906 9230
Principal Investigator	Professor James A. Berkley
Coordinating Institutions	KEMRI/Wellcome Trust Research Programme PO Box 230, Kilifi, 80108, Kenya University of Oxford, University Offices, Wellington Square, Oxford, OX1 2JD, UK
Clinical Trial Protocol Version / Date	Version 1.1 dated 23 rd August 2017
Protocol Amendment Number / Date	Version 2.0 dated 13th April 2018

The information contained in this document is confidential. It is to be used by investigators, potential investigators, consultants, or applicable independent ethics committees. It is understood that this information will not be disclosed to others without written authorisation from DNDi, except where required by applicable local laws

CLINICAL TRIAL PROTOCOL SIGNATURE PAGE

Statistician

Signature		Date of Signature (DD/MM/YY)
Name	Sarah Walker	
Title	Professor	
Institution	MRC Clinical Trials Unit	
Address	University College London, London, UK	

Principal Investigator

Investigator Signature		Date of Signature (DD/MM/YY)
Name	Prof James A Berkely	
Title	Professor	
Institution	KEMRI/Wellcome Trust Research Programme	
Address	PO Box 230, Kilifi, 80108, Kenya	

Investigators Signature Page

I have read this protocol and agree that it contains all necessary details for carrying out this trial. I will conduct the trial as outlined herein and will complete the trial within the time designated.

I will provide copies of the protocol and all pertinent information to all individuals responsible to me who assist in the conduct of this trial. I will discuss this material with them to ensure they are fully informed regarding the drug and the conduct of the trial.

I will use only the informed consent form approved by the sponsor or its representative and will fulfil all responsibilities for submitting pertinent information to the Institutional Review Board/Independent Ethics Committee (IRB/IEC) responsible for this trial if required by national law.

I agree that the sponsor or its representatives shall have access to any source documents from which case report form information may have been generated.

Table of Contents

Supplementary Methods	Error! Bookmark not defined.
Study Site and Population	Error! Bookmark not defined.
Screening and Enrolment of Study Participants	Error! Bookmark not defined.
Procedures	Error! Bookmark not defined.
Study Treatment	Error! Bookmark not defined.
Clinical Definitions	Error! Bookmark not defined.
Safety Assessment	Error! Bookmark not defined.
PK Modelling and Simulations	Error! Bookmark not defined.
Supplementary Tables	Error! Bookmark not defined.
Table S1: Baseline laboratory test parameters by treatment arm	Error! Bookmark not defined.
Table S2: Serious and non-serious AEs by treatment arm, severity and MedDRA coding classification	Error! Bookmark not defined.
Table S3: Anticipated adverse events by treatment arm	Error! Bookmark not defined.
Table S4: AE outcome at study termination excluding events that either resolved or occurred in neonates who died	Error! Bookmark not defined.
Table S5 Blood and CSF culture results by treatment arm	Error! Bookmark not defined.
Supplementary Figures	Error! Bookmark not defined.
Figure S1: Outline of study procedures	Error! Bookmark not defined.
References for Supplementary Appendix	Error! Bookmark not defined.
Trial Protocol	Error! Bookmark not defined.
Investigators and Institutional Affiliations	43
Lay summary	44
Abstract	46
Abbreviations	47
Introduction / Background	49
Justification for the study	52
State the Null Hypotheses	52
Objectives	53
General Objectives	53
Specific Objectives	53
Secondary Objective	53
Study Design	53
Study site	53
Definition of Study Population	53
Rationale for animal use and justification for animal species chosen	54
Sampling	54
i. Sample size determination	54
i. For Pharmacokinetics	54
ii. For Plasma Sodium	54
iii. For MIC of stored bacterial isolates and bowel flora	55
Procedures	55
Clinical Trial Governance	60
Safety reporting	61
i) Assessment of Safety	61
ii) Protocol Violations	61
iii) Laboratory examinations	61

iv)	Adverse event definitions and reporting	61
v)	Eliciting Adverse Event information	62
vi)	Adverse Event reporting period	62
vii)	Anticipated Events in neonatal setting:	62
viii)	Adverse Event Recording:	63
ix)	Grading of Adverse Event severity	63
x)	Adverse Event causality assessment	64
xi)	Grading of Adverse Event seriousness	64
xii)	Serious Adverse Event Reporting:	65
xiii)	Adverse event follow-up	66
	Withdrawal criteria:	66
	Data Safety Monitoring Board:	66
	Quality Assurance and Quality Control Procedures	66
	A) Investigator's file:	66
	B) Case report forms (CRFs):	66
	C) Source documents:	67
	D) Record Retention:	67
	E) Monitoring, audits and inspections:	67
	F) Protocol Amendments:	67
	Data Sharing	67
	Intellectual property	67
	Expected Application of the Results	69
	References	70

Title of the Project

Intravenous and oral fosfomycin in hospitalized neonates with clinical sepsis: An open-label safety and pharmacokinetics study.

*Investigators and Institutional Affiliations***KEMRI CGMR-C**

James Berkley (PI)

Phoebe Williams

Christina Obiero

Alexander Balo Makazi

Joseph Waichungo

Johnstone Thitiri

Mwanamvua Boga

Sheila Murunga

KEMRI CCR

Martin Ongas

Non-KEMRI*:

Mike Sharland: St George's Hospital, University of London, UK

Julia Anna Bielicki: St George's Hospital, University of London, UK

Karin Kipper: St George's Hospital, University of London, UK

Joseph Standing: University College, London, UK

Sarah Walker: Medical Research Council Clinical Trials Unit at University College London, UK

*Curriculum Vitae of non-KEMRI investigators attached, see appendix E.

Lay summary

A study measuring the levels of an additional antibiotic (fosfomycin) to treat severe infections in newborns.

What is the problem?

Among babies presenting with signs of serious infection, or who develop these signs whilst in hospital, bacterial resistance to the antibiotics that are normally used is increasing. This means that babies with infections may be at a higher risk of dying. In Africa, alternative antibiotics are often expensive and may themselves cause the bacteria to become resistant. Therefore, new treatment strategies are needed. Fosfomycin is a potentially inexpensive antibiotic that is licensed for use in children in Europe and may be useful to resource-poor countries. It has a good safety profile in children and is expected to be effective against infections that do not respond to the currently used antibiotics. However, more information is needed to inform how fosfomycin should be used in babies in Kenya.

What questions are we trying to answer?

We want to find out what doses of fosfomycin would be most suitable for sick newborns in Kenya in order to optimize its use in an effective and safe way. We also want to find out how well local bacteria that have been previously found (and stored) from patients at Kilifi County Hospital are able to be killed by fosfomycin.

Where is the study taking place?

The study will take place in Kilifi County Hospital, Kilifi, Kenya.

How many people does it involve?

For the study measuring the levels of antibiotics in newborn babies, we will include approximately 120 babies admitted to the hospital with presumed infection. Approximately 60 of these babies will be given fosfomycin in addition to standard treatment and drug levels measured; the other 60 will receive standard treatment.

How are these people selected?

We will ask parents and guardians of all babies aged 28 days or less who are admitted to Kilifi County Hospital with signs of infection to participate, unless they are being transferred from another hospital, already received other antibiotics by injection, are very sick or premature, or have abnormally high salt (sodium) levels in their blood.

What does the study involve for those who are in it?

After providing information and answering any questions, informed consent will be requested from the child's parent or guardian. A doctor or study clinical officer will examine the baby and take the usual admission investigations, then prescribe the two antibiotics that are currently recommended by the WHO for the treatment of presumed infection in babies (ampicillin and gentamicin).

Half of the babies will be selected randomly to receive intravenous fosfomycin *as well as* the standard antibiotics. The nurse or clinical officer will then take two blood samples to check fosfomycin levels. After a minimum of four doses of intravenous (IV) fosfomycin (over 48 hours), when their condition is improved and they are tolerating feeds by mouth, the baby will then be changed on to oral fosfomycin. A further two blood samples will be collected after the first oral dose of fosfomycin, including one to check the kidney and liver function and level of salts in the blood (which is currently a routine investigation). Each of these blood samples is 0.5ml, giving a total for this research of 2.5ml (half a teaspoon) for checking the drug levels, and a further 1ml (a quarter of a teaspoon) for checking the level of salts in their blood.

For all babies, a blood test will be taken (which is normally part of routine care) at around 48 hours to check the blood count, kidney and liver function and level of salts in the blood. If a baby has a lumbar puncture as part of their normal treatment (if their doctor is concerned about an infection in their brain), the fosfomycin level in the fluid surrounding their brain will also be checked.

The babies will be closely followed by the study team, working together with the hospital staff to provide the best care available in the hospital. On day 7, any babies who remain as inpatients will have a blood test to check blood count, kidney and liver function and level of salts in the blood (and 0.5ml drawn for fosfomycin levels in the group receiving this antibiotic). Breastfeeding and health counselling will be given according to national guidelines. All babies will be followed up in our outpatients' clinic 28 days after their presentation to hospital.

and parents/guardians may also phone the study team directly on a study-specific mobile phone or bring the baby to the ward prior to that review, in case of health concerns.

What are the benefits and risks/costs of the study for those who are involved?

Additional staff (clinical officers and nurses) will be recruited to undertake study duties and assist in general care on the ward, adding to the staff available. Training will be enhanced for all paediatric ward staff on the treatment of babies presenting with infections, and on the prevention of infections within the hospitals. We will also make available additional antibiotics as needed, should a baby continue to have signs of infection despite treatment or remain unwell. Drawing a blood sample carries the potential risks of bruising to the vein or infection, and careful training on procedures will help to prevent these. There may be a small risk of the baby having high levels of salt (sodium) in their blood due to the salt content of the fosfomycin injection. Improved monitoring of kidney function and blood salt levels will offset these risks.

How will the study benefit society?

This study is leading up to a large clinical trial assessing how effective fosfomycin is to treat babies with infections, and if it is effective, will support efforts to make fosfomycin available at low cost for Kenya and other countries. This will help babies to be more effectively treated when bacteria are resistant to the currently used antibiotics.

When does the study start and finish?

The study aims to start as soon as scientific and ethical approval is granted and is expected to continue for 18 months (including analysis and write-up).

Abstract

Antimicrobial resistance (AMR) has become a major issue in global health. Despite progress in the reduction of under 5 mortality rates in recent decades, the proportion of neonatal deaths occurring within this age group has increased, with almost one quarter of all neonatal deaths occurring due to serious bacterial infection. Common bacteria causing neonatal sepsis are now exhibiting widespread resistance to several classes of antibiotics. There is an urgent need to discover new, effective treatments and re-evaluate existing therapeutic agents to treat infections potentially caused by multi-drug resistant (MDR) pathogens. Gram-negative bacteria (GNB) predominate as the cause of neonatal sepsis and are increasingly associated with high rates of resistance to the currently recommended WHO empirical therapy regimen of ampicillin/penicillin and gentamicin. There is therefore a need to develop an updated empiric regimen with improved efficacy in the context of increasing MDR sepsis in neonates. New antimicrobials under development will be expensive once licensed, and there are currently virtually no planned trials to assess their efficacy in neonates in low- and middle-income countries (LMICs).

One potential strategy is utilizing an existing off-patent (and therefore affordable) antibiotic available in intravenous and oral formulations – fosfomycin. Fosfomycin has a wide spectrum of activity against Gram-positive and Gram-negative bacteria causing neonatal sepsis. It is mainly used for resistant urinary tract infections in adults but has licensed neonatal and paediatric doses in Europe (though dosing regimens vary between countries). Both oral and IV formulations are available. A large clinical trial to assess the efficacy of a fosfomycin plus an aminoglycoside combination (compared to the current WHO recommended ampicillin and gentamicin) is anticipated, including sites in Kenya. The ultimate aim is for fosfomycin to be included in the WHO Essential Medicines List for children (EMLc) and be available for use in developing countries, where rates of resistance to ampicillin and gentamicin have been estimated at over 40%. The first steps before this trial are to clarify the pharmacokinetics (PK) and safety profile of fosfomycin in neonates, as well as generating further information regarding local patterns of bacterial susceptibility to fosfomycin. The aim of this study is to fulfil both these steps. Fosfomycin (IV and oral) PK will be investigated among 60 babies admitted to hospital and being treated for presumed sepsis; administered alongside the standard antibiotics. Another 60 babies receiving standard treatment only (without PK sampling) will be monitored in the same way to compare adverse events. In the laboratory at CGMR-C, previously archived bacterial isolates will be tested for their sensitivity to fosfomycin.

Abbreviations

AE	Adverse Event
AGISAR	WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance
AMR	Antimicrobial Resistance
BSAC	British Society of Antimicrobial Chemotherapy
BW	Birth weight
C _{max}	Peak serum concentration of a therapeutic drug
CBC	Complete blood count
CGMR-C	Centre for geographic medicine research, Coast (Kenya)
CI	Confidence Interval
CLSI	Clinical and Laboratory Standards Institute
CMP	Calcium, Magnesium and Phosphate
CNS	Central Nervous System
CR	Carbapenem resistance/resistant
CRF	Case report form
CRO	Carbapenem resistant organisms
CSF	Cerebrospinal Fluid
DSMB	Drug Safety Monitoring Board
ECCMID	European Congress of Clinical Microbiology and Infectious Diseases
EMLc	Essential Medicines List for children
ESBL	Extended Spectrum Beta-Lactamase
ESPGHAN	European Society for Paediatric Gastroenterology, Hepatology and Nutrition
EUCAST	European Committee on Antimicrobial Susceptibility Testing
FBC	Full blood count
GNB	Gram-negative bacteria
HIE	Hypoxic Ischaemic Encephalopathy
ICF	Informed consent form
IMP	Investigational Medicinal Product
IV	Intravenous
IP	Intellectual Property
LBW	Low birth weight
LMICs	Low- and middle-income countries
LC-MS	Liquid chromatography mass spectrometry
LSM	Local Safety Monitor
MDR	Multi-drug resistant

MIC	Minimum inhibitory concentration
MRSA	Multi-resistant Staphylococcus Aureus
OxTREC	Oxford University Tropical Research Ethics Committee
PK	Pharmacokinetic
PO	Per os (oral)
PPB	Republic of Kenya Ministry of Health Poisons and Pharmacy Board
SAE	Serious Adverse Event
SBI	Serious bacterial infection
SERU	Scientific and Ethics Review Committee (Kenya)
SIADH	Syndrome of inappropriate antidiuretic hormone secretion
SOC	Standard-of-care
SOP	Standard operating procedure
SPC	Summary of Product Characteristics
SUSAR	Suspected Unexpected Serious Adverse Reaction
UTI	Urinary tract infection
VRE	Vancomycin-resistant enterococci
WHO	World Health Organization

Introduction / Background

The purpose of this study is to support the design of an international multi-centre randomized trial of fosfomycin to treat neonates with presumed sepsis, by providing an improved understanding of fosfomycin pharmacokinetics, safety and antimicrobial susceptibility of local invasive bacterial species.

Maternal and child deaths have halved over the past two decades;¹ however neonatal mortality has remained unacceptably high, with an estimated 2.9 million deaths in newborns every year.² The proportion of deaths (in children under 5 years) occurring in the neonatal period has increased from 38% to 44% between 2000 and 2013,² and 23% of neonatal deaths are due to presumed serious bacterial infections (SBI).¹ Aside from this mortality burden, sepsis in the neonatal period is also associated with significant morbidity secondary to an increased risk of adverse neurodevelopmental outcomes.³

The WHO and Kenyan guidelines currently recommend ampicillin (or penicillin) plus gentamicin for the treatment of sepsis in neonates and infants <2 months of old, with third-generation cephalosporins listed as second-line therapy.⁴ However, two recent systematic reviews have documented increasing rates of AMR to this regimen.^{5,6} Downie et al. (2013) examined 19 studies from 13 LMICs across Asia and Africa, revealing non-susceptibility to penicillin/gentamicin and third-generation cephalosporins of 44% and 43% respectively.⁵ Le Doare et al. (2015) identified 15 studies investigating non-susceptibility among Gram-negative pathogens across SE Asia, Africa and the Middle East which revealed Enterobacteriaceae exhibit high rates of non-susceptibility to ampicillin (80%), gentamicin, (22%) and ceftriaxone (74%).⁶

Challenges in interpreting this literature include the limited data available being mostly from urban tertiary hospital settings (rather than district- or community-level facilities), failure to account for prior treatment, not distinguishing community- from hospital-acquired infections, and inconsistent laboratory facilities. Nevertheless a consensus is emerging that AMR to recommended first-line antibiotics in LMICs is associated with significant morbidity and mortality.^{7,8} A recent study of neonatal deaths attributable to MDR sepsis (in 5 countries accounting for half the global neonatal sepsis death rates - India, Pakistan, Nigeria, DR Congo and China) identified 214,000 neonatal deaths occurring each year due to resistant bacterial infections.⁹ Notable is the emergence and spread of extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, which render many commonly used (and cheaply available) antimicrobials ineffective. Carbapenems are increasingly being used as second-line therapy in neonatal sepsis, but they are expensive, and their use is associated with increasing AMR due to the dissemination of infections with carbapenem-resistant organisms (CRO). There is therefore a need to clarify an empiric regimen with improved for use in LMICs.

The repurposing of older antimicrobials for current treatment regimens has recently received increasing international attention. The WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) included fosfomycin in the current revision of critically important antimicrobials for human medicine.¹⁰ Fosfomycin is a bactericidal peptidoglycan antibiotic that was first produced in the 1970s¹¹ though its marketing was largely replaced in the 1980s by oral cephalosporins. Its infrequent international use over the past 30 years has resulted in low global resistance rates.

Fosfomycin is orally absorbed, crosses the blood brain barrier and is renally excreted. It exhibits minimal toxicity, low levels of cross-resistance, and provides synergistic effects with other antibiotics (including beta-lactams, aminoglycosides and fluoroquinolones).¹² IV fosfomycin is licensed in Europe and the USA as a second-line treatment in adults and children with osteomyelitis, complicated UTI, nosocomial lower respiratory tract infections, bacterial meningitis, or bacteraemia associated with any of these causes. Oral fosfomycin is used for treating UTI caused by *Escherichia coli* and *Enterococcus faecalis*.

Fosfomycin has a broad-spectrum of activity against both Gram-negative and Gram-positive organisms, including MRSA and ESBL infections.¹³ A recent systematic review evaluated the susceptibility of contemporary bacteria to fosfomycin, revealing 84 studies which documented susceptibility to *Staphylococcus aureus* (range 33% to 100%); ESBL-producing *Escherichia coli* (range 81% to 100%); ESBL-producing *Klebsiella pneumoniae* (range 15% to 100%); and carbapenem-resistant *Klebsiella pneumoniae* (range 39% to 100%).¹⁴ Thus, fosfomycin currently exhibits high levels of antimicrobial activity against common causes of neonatal sepsis.

The Summary of Product Characteristics (SPC) gives a neonatal intravenous dosing, including for preterm and term infants by age and body weight (Table 1). However, parenteral dosing recommendations for neonates and children patients vary widely between countries in Europe (Table 2), and there are currently no PO dosing recommendations for neonates.

Age/weight	Daily dose
Premature neonates (age ^a < 40 weeks)	100 mg/kg BW in 2 divided doses
Neonates (age ^a 40-44 weeks)	200 mg/kg BW in 3 divided doses
Infants 1-12 months (up to 10 kg BW)	200-300 ^b mg/kg BW in 3 divided doses
Infants and children aged 1-12 years (10-40 kg BW)	200-400 ^b mg/kg BW in 3-4 divided doses

^a Sum of gestational and postnatal age.

^b The high-dose regimen may be considered for severe infections and/or serious infections (such as meningitis), in particular when known or suspected to be caused by organisms with moderate susceptibility.

Table 1. Parenteral Fosfomycin Neonatal Dosing Recommendations (Nordic Pharma, 2016)

Country	Neonates (pre- & full-term; 0-1 months)	Infants (1-12 months, up to 10kg)	Children (1-12 years; 10-40kg)
Austria	100-200/400* mg/day in 2-3 doses	100-200/400* mg/day in 2-3 doses	4-8g/day, in 2-3 doses
Germany	100mg/day in 2 doses	200-250mg/day in 3 doses	100-200/300*mg/day in 3 doses
United Kingdom	Premature: 100mg/kg in 2 doses Term: 200mg/kg in 3 doses	200-300mg/kg/day in 3 doses	200-400mg/kg in 3-4 doses
Spain	Not specified	Not specified	100-200/400mg/day in 2-3 doses
France	Not specified	Not specified	100-200mg/day; number of daily doses not specified

*Maximum dosage for severe infections

Table 2: Recommended total daily dosages for IV fosfomycin in paediatric patients with normal renal function across various European settings

Safety and Clinical Outcomes of Fosfomycin:

Five published papers have documented the clinical outcomes of (n=84) neonates treated with parenteral fosfomycin therapy for a range of diagnostic situations (Table 3), with no deaths or severe adverse events attributed to this therapy.

A 2015 review of adverse events (AE) reported to the FDA and the international literature in association with fosfomycin administration (in both adult and paediatric patients) concluded that fosfomycin exhibits low toxicity and few concerns regarding its safety profile.¹⁵ This review included data assessing 254 paediatric patients across 6 trials (3 trials of parenteral and 3 of oral fosfomycin; age range: neonates – 15.5 years), 3 of which were retrospective (n=118)¹⁶⁻¹⁸ and 3 prospective randomized trials (n=134)¹⁹⁻²¹ investigating oral fosfomycin. In the trials of parenteral fosfomycin, the drug was administered for up to 4 weeks for the treatment of acute haematogenous osteomyelitis, bacteraemia, and lung infection; while oral fosfomycin was administered as a single dose for the treatment of UTI. Overall, no serious safety issues related to the use of fosfomycin in children were identified in this review; with the most frequently reported AEs associated with (IV and PO) administration across all age ranges identified as being rash, peripheral phlebitis and gastrointestinal symptoms. Less common AEs include hypersensitivity and abnormal liver function. These are common AEs which also occur with other antibiotics.

Combined with the 31 babies documented in the literature investigating fosfomycin PK data (discussed below), this results in a total of 367 children in whom fosfomycin has been administered in the published literature with no significant safety concerns having been reported in this cohort.

However, an important potential safety consideration for parenteral fosfomycin is the sodium (Na⁺) content (14.4mmol/330mg sodium per gram). The European Society for Paediatric Gastroenterology and Hepatology (ESPGHAN) recommends a daily (enteral) sodium intake of 69mg/kg (minimum) to 115mg/kg (maximum) for preterm infants (with enteral values for term infants not published),²² and a parenteral sodium intake of 2-3mmol/kg/day for term neonates and 3-5mmol/kg/day for premature neonates.²³ Fosfomycin's sodium content equates to a sodium load of 2.8mmol/kg/day (based on dosing of 200mg/kg/day), which is within the published guidelines for neonates. There are negligible amounts of sodium in IV ampicillin and gentamicin, the antibiotics alongside which fosfomycin will be administered; and there is no sodium in the oral fosfomycin formulation.

The ability to reabsorb sodium is inversely proportional to gestational age, and nephrogenesis is complete by 34 weeks gestation.²⁴ Hence, we aim to restrict our patient population to exclude very preterm infants. Hyponatremia may also occur secondary to hypoxic-ischemic encephalopathy (ie, as a consequence of asphyxiation, due to central diabetes insipidus or via acute renal injury). Therefore, any baby presenting with seizures or with admission sodium ≥ 150 mmol/L or creatinine ≥ 150 micromol/L will be excluded from the study. All poorly feeding babies will receive IV (10% dextrose) fluids (as per Kenyan Paediatric Protocols).

Of note, the oral fosfomycin suspension contains no sodium, using a calcium base at a dose equivalent to 1.4mmol/kg/day, within the published neonatal guidelines for calcium administration (of 1.3-3mmol/kg/day).²³ Monitoring of calcium, magnesium and phosphate will therefore be undertaken. Oral fosfomycin also contains fructose to the equivalent of 1600mg/kg/day. There is little published research regarding high fructose loads in neonates, with most previous trials documenting safety at lower doses (150mg as an analgesic therapy);²⁵ while a recent meta-analysis evaluating sucrose administration (in 7,049 infants) documented a "very low" incidence of minor adverse events, with no reported major adverse events.²⁶ Nonetheless, the possible adverse event of osmotic diarrhea will therefore be closely monitored in this study.

Study	N (Total n=82)	Dose and clinical setting	Clinical Setting	Outcomes
Taylor et al. 1977 ²⁷	43 neonates	150-200mg/kg/day	Enterocolitis caused by enteropathic E. coli	Favourable clinical outcome in 88%
Rossignol & Regnier 1984 ²⁸	21 neonates	200mg/kg/day in two divided doses, in combination with gentamicin/tobramycin	Sepsis and UTI	Clinical recovery in 19/21 (90.5%)
Guillois et al. 1989 ²⁹	Case report (n=1)	IV fosfomycin-vancomycin, followed by oral pristinamycin	MSSA septicaemia with a liver abscess	Full recovery
Gouyon et al. 1990 ³⁰	16 neonates	IV fosfomycin-cefotaxime	Staphylococcal septicaemia (epidermidis (n=10) and aureus (n=6)) (including meningitis and osteomyelitis)	Full recovery in n=15 (94%)
Aljubaisi et al. 2015 ³¹	Case report (n=1 term infant)	120mg/kg/day fosfomycin and meropenem	Multiple Citrobacter koseri intracerebral abscesses	Clinical recovery

Table 3: Clinical studies describing the use of fosfomycin in neonatal sepsis. Modified from Li et al (in publication)³²

Documented Pharmacokinetics of Fosfomycin:

A recent review of the PK profile of fosfomycin in neonates identified four small additional published studies assessing IV fosfomycin (with no oral PK data available) (Table 4). The elimination half-life ($t_{1/2}$) of fosfomycin ranged from 2.4-7 hours following an IV bolus of 25-50mg/kg administered to neonates which included LBW and premature infants.^{33,34} Fosfomycin is almost completely eliminated by glomerular filtration, with 80-95% of the dose unchanged in the urine within 24 hours.³⁵ Consequently, neonates have a prolonged fosfomycin $t_{1/2}$ compared to older children and adults due to immature glomerular filtration and a greater volume of distribution.³⁴ Serum protein binding of fosfomycin has been estimated to be below 3%, and the neonatal C_{max} (60-90mg/L) is comparable with adult populations.^{35,36}

Study	N (Total n=31)	Dose and study	Outcome
Molina et al. 1977 ³⁴	11 neonates	50mg/kg IV, comparing infants 1-3d old and 3-4 weeks old	Elimination slower at earlier corrected gestational age
Guggenbichler 1978 ³³	5 term & 5 pre-term neonates	25mg/kg IV	95-98% recovered in the urine, 1 compartment model
Guibert et al. 1987 ³⁷	10 neonates	200mg/kg BD, comparing 30m or 2hr infusion schedules	No difference between schedules, serum concentrations are above MIC of common pathogens at 12h post dose
Suzuki et al. 2009 ³⁸	Not identified	Dose estimation for renally excreted drugs	Dose estimation validated with GFR, tubular secretion clearance and fraction of unbound drug in plasma

Table 4: Neonatal fosfomycin pharmacokinetic studies; modified from Li et al (2016; in publication)

Bactericidal effects correlate with time above the MIC ($t > MIC$).³⁹ Pharmacokinetic modelling suggests that the current lower recommended paediatric doses (100mg/kg/day, Table 2 & Table 3) are insufficient for achieving target $t > MIC$ for term neonates; and the corrected gestational age and body weight in neonates are the key explanatory variables for fosfomycin's PK.³⁹

Previous research investigating the oral bioavailability of fosfomycin in adults documented a range between 34 and 58%.^{40,41} Absorption is via the small intestine and is reduced by concurrent administration with food (37% when fasting versus 30% with food), thus, C_{max} that is higher under fasting conditions.⁴²

Justification for the study

Neonatal sepsis has a high risk of morbidity and mortality. The current WHO and national guidelines recommend antibiotics to which resistance is reported in neonatal populations, although the available data is limited. Research on alternative empirical regimens for neonatal sepsis which are affordable, safe and cost-effective, with a step-down oral option, is needed. AMR is an issue of global public health concern and is one of the WHO's global health priority areas.⁴³ Understanding the benefits, risks, MIC capacity and PK of fosfomycin will influence global policy on the case management of neonates with sepsis in Kenya and international settings.

State the Null Hypotheses

- The pharmacokinetics of the currently recommended various doses of IV and PO fosfomycin are unsuitable for treating neonates.
- Fosfomycin administration is not associated with altered plasma sodium in neonates.
- Fosfomycin does not inhibit growth of more than 25% of archived isolates of Enterobacteriaceae that express an ESBL phenotype in vitro.

Objectives

i. General Objectives

To improve the understanding of fosfomycin pharmacokinetics and safety amongst newborns aged ≤ 28 days hospitalized with clinical sepsis and provide detailed information regarding the antimicrobial susceptibility of local invasive bacteria to fosfomycin.

ii. Specific Objectives

- To estimate the PK disposition parameters of IV and PO fosfomycin in neonates
- To assess the safety of fosfomycin, particularly with regard to possible elevation of sodium after 48 hours of IV fosfomycin administration in neonates
- To estimate the oral bioavailability of fosfomycin in neonates
- To generate preliminary data on the safety of oral fosfomycin in neonates
- With the above information, generate a recommended dosing schedule for future IV and PO fosfomycin efficacy trials
- To collect information of the tolerability of oral fosfomycin

iii. Secondary Objective

- To gain information regarding susceptibility patterns of local bacterial species to fosfomycin

Study Design

A safety and pharmacokinetic study among neonates admitted to a rural hospital in Kenya and eligible for IV antibiotics under current national guidelines. Approximately 120 patients will be randomized 1:1 to standard-of-care antibiotics plus a 7-day course of fosfomycin (n=60); or standard-of-care (n=60) antibiotics only (ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).

For the group receiving fosfomycin, fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged). Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; for the babies who remains inpatient at D7, a 5th PK sample will be collected to check for long term accumulation together with a laboratory safety sample. PK sampling timepoints may be subject to change based on emerging data. In total, four PK blood samples of 0.5ml each will be drawn from each participant, plus a fifth sample collected at 7 days. Haematology, biochemistry and electrolytes (a commonly performed investigation for babies with sepsis) will be checked at 48 hours and 7 days (if the baby is still inpatient) in both groups at the same time that the PK sample is collected. Daily observations until discharge and AEs up to a follow-up visit at day 28 will be recorded.

For the group receiving standard-of-care only, daily observations until discharge and AEs up to a follow-up visit at day 28 will be recorded.

The Day 28 visit will ideally be conducted within 7 days of the target date but if this is not practical the visit may be later than this. The visit date will be recorded.

Study site:

Kilifi County Hospital, Kilifi, Kenya

Definition of Study Population:

Criteria for inclusion of subjects (for pharmacokinetics):

- Neonates defined as:
 - Age 0 to 28 days inclusive
 - Weight >1500g

- Born (an estimated) >34 weeks gestation (calculated as per the Ballard Maturation Assessment)
- Admitted to hospital and eligible to receive IV antibiotics, according to national guidelines

All neonates presenting to Kilifi County Hospital meeting the above criteria will be screened for inclusion in a systematic recruitment process.

ii. Criteria for exclusion of subjects

- Baseline sodium level ≥ 150 mmol/L
- Baseline creatinine ≥ 150 micromol/L
- Presenting with severe (grade 3) Hypoxic Ischaemic Encephalopathy (HIE), defined as per Sarnat and Sarnat⁴⁴ as a stuporous, flaccid infant (with or without seizure activity) with suppressed brainstem and autonomic functions and absent reflexes
- Requiring cardiopulmonary resuscitation on admission
- Jaundice requiring exchange transfusion
- Admitted as a transfer after an overnight inpatient stay at another hospital
- Known allergy or contraindication to fosfomycin
- A specific clinical indication for another class of antibiotic (other than the nationally recommended standard-of-care)
- More than 24 hours after initiating ampicillin plus gentamicin (one dose), which allows for administration of these first-line antibiotics not to be delayed by study procedures
- Concurrent participation in another clinical trial
- Attending clinician's judgement that the child is so severely ill that adequate communication about the study with the parent or legal guardian is not possible.
- Not planning to remain resident in the County for the next 28 days.
- Lack of consent

iii. Rationale for animal use and justification for animal species chosen

- Not applicable

Sampling

i. Sample size determination:

a. For Pharmacokinetics:

Sample size has been calculated to ensure that the following PK parameters can be estimated with sufficient precision such that a dose schedule can be recommended for a future efficacy trial:

- Clearance (CL)
- Central volume (V)
- Oral Bioavailability (F)

Precision limits were set to 20%, and the power to estimate parameters with 95% confidence intervals within these limits was assessed by simulation-estimation. The simulation model consisted of an adult disposition model, with age and size scaling down to neonates, with added first-order absorption and assumed bioavailability. Six sampling time points were chosen to cover the dose intervals (3 early, 3 late) and the simulated population was randomly assigned age and weight combinations across the range expected for neonates. Parallel and crossover (IV/oral) designs were considered, with a range of 2-4 samples per patient. Power for sample size was greatest for the cross-over design. For the cross-over design, a minimum of 45 subjects contributing the complete set of 4 samples each (allocated early and late sample following the first IV and PO dose) are required to provide power of >85% to estimate all parameters within 20% precision limits. We estimate that up to 25% of subjects will not provide complete sample sets (either due to missing samples or withdrawal), so plan to recruit approximately 60 subjects to ensure 45 complete sample sets. If all 60 subjects provide complete sample sets, power would rise to 96%. Recruitment will continue until 45 patients in fosfomycin arm have a complete set of PK samples.

b. For Plasma Sodium

We have reviewed the data of (n=1,785) neonates >1500g admitted to Kilifi County Hospital (2015/6), which indicate a sodium mean and standard deviation of 139mmol/L and (SD 7.6, range 106 to 198mmol/L). 7.4% of babies had an admission sodium of >150mmol/L (our exclusion criterion). Excluding these babies, the mean sodium level in (the remaining n=1,653) babies was 137mmol/L (SD 5.2). With a minimum of 45 in each group

(PK versus standard-of-care), the study has >85% power to detect a difference in sodium of 5mmol/L between groups.

The sample size is not intended to be powered for antimicrobial efficacy or clinical outcomes.

c. For MIC of stored bacterial isolates and bowel flora:

Susceptibility of fosfomycin and other antibiotics is already being tested as per protocol SSC-1433. We will test n=200 invasive isolates from paediatric patients collected within the last 5 years, calculated based on >80% power to discriminate a non-susceptible proportion of up to 17% from a hypothetical proportion of 25% (one-sided). This is selected as a proportion which would render fosfomycin ineffective for introduction should this level of non-susceptibility be found. We shall then investigate fosfomycin susceptibility on other (ESBL-negative) Gram-negative isolates, and Gram-positive pathogens. For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs from those babies included in the study.

ii. Study Endpoints:

a. Primary Endpoint:

Estimation of the pharmacokinetic disposition and absorption parameters of IV and oral fosfomycin in neonates with clinical sepsis with sufficient precision such that a dose schedule can be recommended for a future efficacy trial

b. Secondary Endpoint(s):

Difference between the groups in mean 48-hour plasma sodium concentrations

Difference between the groups in mean 7-day plasma sodium concentrations

Difference between groups in the rate of adverse events (any grade) to 28 days after enrolment in the study.

Procedures:

i. Analysis of Bacterial Isolates:

Isolates collected from nappy swabs will be subcultured and tested for fosfomycin susceptibility using disk diffusion (*E. coli*) and agar dilution (all isolates).⁴⁵ For disc diffusion, commercially available discs containing 200ug fosfomycin and 50mg of glucose-6-phosphate will be used. MICs will be determined by the agar dilution method using Mueller-Hinton agar supplemented with 25ug/m of glucose-6-phosphate and doubling concentrations of fosfomycin. The MIC will be recorded as the lowest concentration inhibiting visible growth. Plates will be incubated in ambient air at 35°C for 16 to 18 hours. Testing will be performed in duplicate, and mean MICs / zone diameters interpreted using EUCAST breakpoints (http://www.eucast.org/clinical_breakpoints/).

ii. Pharmacokinetic Study - Enrolment Procedure:

All neonates presenting to Kilifi County Hospital will be systematically screened to assess their eligibility in meeting the inclusion criteria and consent requested from the parent / guardian. Sequential study numbers will be generated according to a blocked randomization from a list of random block sizes created before the study begins. Randomization cards linking allocation (to standard care plus fosfomycin or standard care alone) to study number will be placed in sealed opaque envelopes by the study sponsor. On enrolment, infants will be allocated study numbers sequentially, thus randomly allocating the two groups. Since this is an open-label study, once an envelope is opened, the randomization card will be securely attached to the patient's CRF.

iii. Consent Process

Consent will be required for all data and samples taken for research purposes. Consenting will be done in a private room by study clinicians or trained field assistants, with the opportunity to ask questions and discuss concerns. Informed consent will be administered in a language that the parent/guardian best understands (English, Swahili or Giriama) after assessment of his/her literacy level. This will be done in the paediatric ward or high dependency unit once the decision to admit has been made. Whilst giving written consent parents/legal guardians will be able to agree to consent separately for participation in the study, storage of data and samples for future research, and export of samples for the PK assay that cannot currently be conducted in Kenya.

iv. Data Collection

For all participants, a study-specific case report form (CRF) will be used from the time of enrolment and captured information will be entered into a database. The CRF will include a daily standardized record of

clinical progress and drugs administered which will also be entered into a database. At discharge, the date, vital status and weight will be recorded.

v. Data Management and Analysis:

After the CRF has been completed and monitored by the clinical monitor, CRFs will be collected and data will be entered onto a validated password protected Openclinica database. Data will be kept confidential, with access restricted on password-protected computers, with regular secure backup. Any data transferred between Kenya and Europe will be emailed within password-protected encrypted files.

Analysis of fosfomycin and major metabolite concentration in plasma will be undertaken by Liquid Chromatography Mass Spectrometry (LC-MS) using validated methods in the GCP/GLP compliant laboratory in Analytical Services International Ltd, St George's Hospital, London, UK. Where possible, (scavenged) PK for penicillin and gentamicin will be measured using the same sample. Analysis will undertake by Dr Karin Kipper, Dr Joe Standing and Mr Martin Ongas, who will be trained on the techniques whilst running the analyses.

PK modelling and dosing simulations will be undertaken by non-linear mixed-effects modelling using NONMEM® software. The volume of distribution, half-life, clearance and trough levels of bound and unbound drug, and active metabolites will be estimated with 95% confidence intervals. Periods with concentrations above the CLSI, EUCAST and BSAC susceptibility breakpoints will be estimated. We will examine the effects of covariates including age, weight, and concurrently measured plasma sodium, potassium, and liver enzymes. Monte-Carlo simulations will be performed to determine the appropriate dosage and frequency of administration.

vi. Clinical Care

Alongside protocol specific training, the study team will also conduct refresher training for clinicians on the current national guidelines for managing neonates presenting with presumed sepsis. Neonates will be reviewed every day by study clinicians, working together with the hospital team. All adverse events will be documented and reported. All SAEs (whether or not the event is considered related to medication) are to be reported as described in section on safety reporting.

All other aspects of care will be provided according to national guidelines. Should a patient require second-line antimicrobials (third-generation cephalosporins), they will not be removed from the study as this will not impact the fosfomycin PK data.

vii. Study Treatment:

Fosfomycin is a peptidoglycan antibiotic which has bactericidal effects. There will be two formulations of fosfomycin utilized in this study:

- Fosfomycin 40 mg/ml powder for solution for infusion
- Fosfomycin powder for reconstituted suspension (250mg/5ml)


Preparation will be in accordance with manufacturer's instructions. Further details regarding treatment dispensing, administration and accountability is documented in Appendix D. Training will be provided to all staff involved in its administration.

viii. Timing of Assessments:

A schedule of events identifying the timing of required assessments and investigations is documented in Figure 2:

Figure 2: Schedule of Events

Note: If a Lumbar Puncture is clinically indicated after commencing fosfomycin, a scavenged PK sample will be obtained from the CSF



ix. Pharmacokinetics Procedures:

a. Baseline Assessments:

Following informed consent, study clinical officers will prescribe both routine standard-of-care antibiotics (ampicillin 50mg/kg twice daily, and gentamicin [3mg/kg for babies <2kg, 5mg/kg for babies >2kg] once daily) and, for the PK group, fosfomycin (100mg/kg every 12 hours, initially IV). Findings from history and examination, and standard admission investigations (CBC, biochemistry and electrolytes) will be collected at baseline, D2 and D7 (if baby remains inpatient). A blood culture will be performed at admission +/- lumbar puncture; from which a scavenged PK sample will be sent for analysis if sufficient CSF remains (if there is a clinical indication for this to occur following the administration of IV fosfomycin). In order to assess antimicrobial resistance that is brought into hospital and that which has been acquired on the ward, an antimicrobial susceptibility profile will be determined for rectal carriage of resistant isolates by collecting a nappy swab at admission and discharge. This will enable determination of the effect of carriage of antimicrobial resistance following treatment with fosfomycin.

b. Pharmacokinetic Assessments:

The first dose of fosfomycin will be followed by the collection of two PK samples at allocated times: one early (during 5, 10- or 60-minutes post-dose) and one late (during 2, 4- or 8-hours post-dose). After a minimum of 48 hours (or 4 IV doses), when tolerating oral medications, fosfomycin will be changed to oral and prescribed at the same dose (100 mg/kg every 12 hours). Following the first oral dose, one early and one late PK sample will again be obtained. For those who remain as inpatients, a PK sample of 0.5ml will be obtained together with a day 7 safety assessment. This will involve 5 plasma PK samples in total per patient, estimated as requiring an upper limit of 0.5 mL/sample (resulting in 2.5mL total study PK sample collection).

As per usual clinical procedures, blood for haematology, biochemistry and electrolytes will be drawn at ~48 hours (co-ordinated with the first post-oral PK sample time-point for patients who step-down to oral fosfomycin at this point) and again at 7 days (for those who remain as inpatients in each study group).

All participants will receive a structured daily review including clinical status and current treatment. Standard antibiotics may be altered in line with the results of a blood culture, which is currently done routinely for clinical care (fosfomycin will be continued). Planned follow-up for clinical review will be done at 28 days and will be conducted within 7 days of the target date but if this is not practical the visit may be later than this. Participant fares and compensation for lost work time will be provided at standard rates for this visit. Participants may also attend the ward in case of significant illness between discharge and day 28.

Drug dose or sample	Target times ⁺
Dose: 1 st Ampicillin	After admission investigations
Dose: 1 st Gentamicin	After admission investigations
Dose: 1 st Fosfomycin IV	After admission investigations
SAMPLE 1*: ONLY ONE OF:	
5 minutes	5 minutes after 1 st fosfomycin intravenous dose
30 minutes	30 minutes after 1 st fosfomycin intravenous dose
60 minutes	60 minutes after 1 st fosfomycin intravenous dose
SAMPLE 2: ONLY ONE OF:	
2 hours	2 hours after 1 st fosfomycin intravenous dose
4 hours	4 hours after 1 st fosfomycin intravenous dose
8 hours	8 hours after 1 st fosfomycin intravenous dose
Dose: 2 nd Ampicillin	12 hours after 1 st ampicillin dose; continuing 12 hourly
Dose: 2 nd Fosfomycin IV	12 hours after 1 st fosfomycin dose
Dose: 2 nd Gentamicin	24 hours after 1 st Gentamicin dose; continuing daily
Dose: 3 rd Fosfomycin IV	24 hours after 1 st fosfomycin dose
Dose: 4 th Fosfomycin IV	36 hours after 1 st fosfomycin dose
--Change to PO fosfomycin-- 1 st dose Fosfomycin PO	48 hours after 1 st fosfomycin dose; when tolerating oral medication and without signs of sepsis (otherwise continue IV 12 hourly)
SAMPLE 3: ONLY ONE OF: (collected alongside biochemistry)	
5 minutes	5 minutes after 1 st fosfomycin oral dose
30 minutes	30 minutes after 1 st fosfomycin oral dose
60 minutes	60 minutes after 1 st fosfomycin oral dose
SAMPLE 4: ONLY ONE OF:	
2 hours	2 hours after 1 st fosfomycin oral dose
4 hours	4 hours after 1 st fosfomycin oral dose
8 hours	8 hours after 1 st fosfomycin oral dose
Dose: 2 nd Fosfomycin PO	12 hours after 1 st fosfomycin oral dose; continuing 12 hourly for up to 7 days
SAMPLE 5: (collected alongside biochemistry)	7 days after 1 st fosfomycin intravenous dose

***Note: Subjects will be allocated to only one of each sampling timeframe**

⁺ **PK** timepoints may be subject to change based on emerging data

Samples will be collected into heparinised tubes, centrifuged and the separated plasma stored at minus 80°C. Haematology, Biochemistry and Electrolytes will be measured in real time, and results returned immediately to assist clinical care.

If a lumbar puncture is conducted and processed in the laboratory for clinical reasons, residual CSF will be stored at minus 80°C to assess CSF antimicrobial penetration.

Samples will be securely stored on site in the KEMRI-CGMRC in Kilifi. Following export approval by SERU, samples will be packaged and shipped according to IATA regulations by a reputable courier, such as World Courier to Analytical Services International Ltd. At St. George's Hospital, London and University College London for analysis. Pharmacokinetic assay results will be returned to Kenya. Samples may be stored for up to 5 years. Additional analyses beyond those described in this protocol: assaying antimicrobial drug levels and haematology, biochemistry/liver function will first require further approval by SERU. Remaining samples will be destroyed by incineration according to GCP after 5 years.

	SCREENING	BASELINE	←--TREATMENT PHASE--→					FOLLOW-UP
PROCEDURES			Daily until discharge	Day 0	48 hours	Day 7	Discharge	Day 28 + 7 days
Informed Consent	X							
Demographics	X							
Medical History	X		X				X	X
Physical Examination	X		X				X	X
Vital Signs (incl. wt)	X		X				X	X
PK Sampling				X	X [#]	X [^]		
Haematology, Biochemistry and Electrolytes	X				X [#]	X [^]		
Eligibility Assessment	X							
Allocation		X						
Dispensing Trial Drugs		X	X	X				
Tolerability Questionnaire						X	X	
Nappy Swab		X					X	
Adverse Event Assessment	X	X	X	X	X	X	X	X

*Or when tolerating oral medication

[#]Acceptable time point: within 12 hours (either side) of 48 hours since commencing IV fosfomycin

[^]Acceptable time point: within 24 hours (either side) of day 7 since commencing IV fosfomycin

x. Provisions for data verification and validation

Clinical data will be collected prospectively, supervised by a consultant paediatrician investigator, and overseen by the coordinating team in Kilifi. Data will be monitored for integrity and completeness weekly by the data manager. The study will be monitored by the Sponsor. For the PK study, a comprehensive study initiation visit will be done at which all staff will be trained in protocol specific procedure and check that all trial logistics are in place. A site initiation visit, then routine monitoring will be conducted during PK study. The monitor's role is part of the quality system that will ensure that all participants have duly completed informed consent; entries relating to eligibility, consent and data collected on the CRF are source-verified; and that staff on the study are following standard operating procedures (SOPs) which are in accordance with the protocol.

Clinical Trial Governance:

An independent DSMB will have an advisory role to safeguard the interests of trial's participants, investigators and sponsor; to assess the safety of the trial's intervention, and to monitor the trial's overall conduct, and protect its validity and credibility. Its recommendations will be addressed by the Sponsor to the study team. The DSMB operations will be facilitated by the Sponsor. The DSMB will usually be convened in a quarterly basis, by teleconference. The chair may also call for ad hoc or emergency meetings. The DSMB will report to the Sponsor usually within 2 weeks of a meeting, copied to the trial statistician. Unless the DSMB is recommending that the trial protocol be changed, the letter to the Sponsor should not usually reveal any confidential information. If the DSMB has serious concerns about a Study team decision, a meeting of these groups should be held, chaired by an external expert not directly involved with the trial.

Safety reporting

i. Assessment of Safety:

Neonates will be reviewed every day by study clinicians, working together with the hospital team. All adverse events will be documented and reported.

Safety will be assessed through routine monitoring of adverse events. In addition, evaluation of haematology and blood chemistry parameters, regular measurement of vital signs and physical examinations will be conducted as per the protocol and clinical indication. The frequency, severity, seriousness and causality assessments of AEs will be described, as well as frequency of SAEs or AEs that lead to treatment discontinuation. AEs will be collated for both patient groups in the CRF.

ii. Protocol Violations:

Any protocol violations will be reported to the Sponsor (DNDi), to an independent DSMB, and to the Ethics Committee and PPB.

iii. Laboratory examinations

Haematology parameters (CBC) will be analysed at screening, on days 2 and day 7 (if baby remains as inpatient) as is normally clinically indicated (plus any additional investigations as clinically indicated). Biochemistry and electrolytes parameters will be analysed at screening, on day 2 and day 7 (if baby remains as inpatient). Additional samples may be done if clinically indicated. Samples will be analysed at the adjacent KWTRP Clinical Trials Laboratory using standardized equipment. Approximately 0.5ml of blood will be collected for each study investigation.

Abnormal Lab parameters will be assessed for clinical significance. If the abnormality is judged clinically significant, an adverse event must be reported.

iv. Adverse event definitions and reporting

The definition of adverse events, adverse drug reactions, serious adverse event/reactions, or suspected unexpected serious adverse reactions (SUSARs) is outlined below:

TERM	DEFINITION
Adverse Event (AE)	Any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment ^A
Adverse Drug Reaction (ADR)	A response to a (investigational or authorized) medicinal product which is noxious and unintended.
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)	Any untoward medical occurrence or effect that at any dose which: Results in death Is life-threatening Requires hospitalization or prolongation of existing hospitalization Results in persistent or significant disability or incapacity Is a congenital anomaly or birth defect Is considered medically important/clinically significant ^C
Non-Serious Adverse Event / Non-Serious Adverse Drug Reaction	An adverse event or adverse drug reaction that does not meet the criteria listed above for a serious adverse event/serious adverse drug reaction

TERM	DEFINITION
Unexpected Adverse Reaction (UAR)	An adverse reaction, the nature or severity of which is not consistent with the SPC for Fosfocina, suspension (250mg/5ml) Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, InfectoPharm
Suspected Unexpected Serious Adverse Reaction (SUSAR)	An adverse reaction that is unexpected (not consistent with the SPC for Fosfocina suspension [250mg/5ml] Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, (InfectoPharm) and meets the definition of a serious adverse event/reaction

Adverse event:

Any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether considered related to the IMP.

What is not an AE?

- Medical conditions present at the initial study visit, that do not worsen in severity or frequency during the study, are not considered as AE.
- Lack of efficacy of the IMP is not considered as AE.

Laboratory/procedures abnormalities considered as an AE:

Laboratory/procedures abnormalities (or worsening in severity or frequency of pre-existing abnormalities) should be assessed as “clinically significant” if they meet AT LEAST ONE of the following conditions:

- The abnormality suggests a disease and/or organ toxicity AND this abnormality was not present at the screening visit or is assessed as having evolved since the screening visit
- The abnormality results in discontinuation of the study drug
- The abnormality requires medical intervention or concomitant therapy

When reporting an abnormal laboratory/procedure result, a clinical diagnosis should be recorded rather than the abnormal value itself, if available (for example, “anaemia” rather than “low haemoglobin”). For every laboratory assessment, the investigator will evaluate if the lab test is normal or abnormal. If abnormal, the investigator will assess if this finding is clinically significant or not. If a lab parameter is abnormal and clinically significant, it should be reported as an adverse event, after comparison with the previous value (AE).

v. Eliciting Adverse Event information

The investigator will report all directly observed AEs and all AE spontaneously reported by the parents/guardians using concise medical terminology. In addition, at follow-up visit the parents/guardians will be asked a generic question such as “Since you were discharged from hospital, has your child had any health problems?” Information on AEs will be evaluated by a physician.

All AEs must be evaluated with regards to severity (Clinical intensity), causality (with each study drug) and for seriousness (regulatory definition for reporting).

vi. Adverse Event reporting period

The adverse events reporting period begins upon subject enrolment in the trial (after signature of informed consent and ends 28 days (4 weeks) after the first dose of study drug(s) is administered.

vii. Anticipated Events in neonatal setting:

Anticipated events listed below are relatively common in this patient group due to low birth weight, possible birth asphyxia and concomitant disease processes.⁴⁶ Anticipated events in this patient population (babies under 28 days) defined in the table below will be recorded and reported in the CRF session “Anticipated Events”.

These anticipated events must be assessed by the investigators with regards to the definition of adverse event, in the context of neonatal setting.

Anticipated events associated with neonatal setting, but which are **not assessed as “AEs”** (not an untoward medical occurrence taking into account the newborn pre-existing conditions and common neonatal setting/conditions) will be reported on the CRF **but not as AEs (or SAEs)**.

Anticipated events which are **more severe or more frequent than expected in this neonatal setting** will be reported as **AEs, and assessed for severity, causality and seriousness as any other AE**. If classified as AEs, they must be reported as AEs in the CRF and, if matching any seriousness criteria, on CRF AE and SAE form.

All anticipated events, not matching the AE definition will be provided to DSMB as part of the quarterly line listings reviewed by the DSMB and then forwarded to SERU/OXTREC and PPB.

They will not be reported in an expedited manner unless they are assessed as both AEs and serious.

ANTICIPATED EVENTS IN NEONATAL SETTING
Necrotising enterocolitis (diagnostic radiological/surgical changes)
Intracranial abnormality on cranial ultrasound scan (parenchymal haemorrhage or focal white matter injury)
Patent ductus arteriosus
Pulmonary haemorrhage
Severe anaemia requiring transfusion (due to ABO incompatibility, prematurity or haemorrhage)
Jaundice requiring phototherapy or exchange transfusion
Congenital birth defect diagnosed during admission
Fracture secondary to birth trauma
Apnoea
Infection (positive blood culture with clinical signs)*
Persistent derangement of liver function tests (beyond 36 weeks CGA)
Abnormal muscle tone, posturing or convulsions (secondary to suspected birth asphyxia)
An episode of Hypoglycaemia (defined as per the World Health Organization, ≤ 2.6 mmol/L)⁴⁷

* Both infections other than condition for inclusion in trial and, in case of infections linked to the sepsis episode that is the reason of the participant's inclusion in the trial, worsening (e.g. septic shock) and relapse.

viii. Adverse Event Recording:

All AEs will be recorded on the AE CRF and reported as a listing at the end of the study.

In the CRF, a given AE will be recorded one time per subject, and the severity will be assessed and recorded as the maximum level reached during an episode. If several distinct episodes of the same condition occur, their number will be recorded in the CRF. In addition, the causal relationship between the onset of each AE and each study drug IMP will be assessed.

Information on adverse events will be evaluated by a physician. Each adverse event will be classified by the investigator for severity (ix), causality (x) and also as serious or non-serious (xi). This “seriousness” classification will determine the regulatory reporting procedure (reporting form and timelines) for the AE.

ix. Grading of Adverse Event severity

Toxicities and adverse events will be graded for severity to describe the maximum severity of the adverse event according to the DAIDS grading scales (version 2.1, March 2017; Available at: <https://rsc.tech-res.com/docs/default-source/safety/daids-ae-grading-table-mar2017.pdf?sfvrsn=6>).

In case of AEs that are not described in the DAIDS AE grading system, the investigator will use the terminology “mild”, “moderate”, “severe” or “life-threatening” to describe the maximum severity of the adverse event. These severity grades are defined as follows:

MILD	Does not interfere with subject's usual functions
MODERATE	Interferes to some extent with subject's usual functions

SEVERE	Interferes significantly with subject's usual functions
LIFE-THREATENING	The subject is at risk of death at the time of the AE it does not refer to an AE that hypothetically might have caused death if more severe.

It is to be noted there exists a distinction between severity and seriousness of adverse events. A severe adverse event is not necessarily a serious event.

x. Adverse Event causality assessment

For both serious and non-serious AEs, the investigator is required to assess the causal relationship between the AE and the study drug, i.e. to determine whether there exists a reasonable possibility that the study drug caused or contributed to the adverse event, or evidence to suggest a causal relationship.

To help investigators with the decision binary tree in the evaluation of causality, as per the CIOMS VI group recommendation, the investigators will consider the following before reaching a decision:

- Medical history
- Lack of efficacy/worsening of existing condition
- Study medications
- Other medications (concomitant or previous)
- Withdrawal of study medication, especially following trial discontinuation / end of study medication
- Erroneous treatment with study medication (or concomitant)
- Protocol related procedure

The terms for reporting are:

Definitely related	The adverse event and administration of IMP are related in time, and a direct association can be demonstrated.
Probably related	The adverse event and administration of IMP are reasonably related in time, and the adverse event is more likely explained by study agent than other causes
Possibly related	The adverse event and administration of IMP are reasonably related in time, and the adverse event can be explained equally well by causes other than IMP
Unlikely related	A potential relationship between IMP and the adverse event could exist (i.e. the possibility cannot be excluded), but the adverse event is most likely explained by causes other than the IMP
Not related	The adverse event is clearly explained by another cause not related to the IMP

Adverse Drug Reaction (ADR):

A response to a (investigational or authorized) medicinal product which is noxious and unintended.

Response in this context means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility.

The definition implies a reasonable possibility of a causal relationship between the event and the investigational medicinal product. This means that there are **facts (evidence) or arguments** to suggest a causal relationship (see definition of causality below).

With regards to safety reporting definition, “not related” corresponds to “not related, unlikely related” and “related” (AE related to any study drug at any dose) corresponds to “possibly related, probably related and definitely related”.

xi. Grading of Adverse Event seriousness

A serious Adverse event (SAE) is an Adverse Event (AE) which:

- **results in death**

i.e. causes or contributes to the death.

- **is life-threatening**

in this context refers to an AE in which the patient was **at immediate risk of death at the time of the AE**; it does not refer to an AE that hypothetically might have caused death if more severe.

- **requires in-patient hospitalization or prolongation of existing hospitalization**

i.e. the AE requires at least an overnight admission or prolongs a hospitalization beyond the expected length of stay. Hospital admissions for surgery planned before study entry, for social reasons, for any elective surgery (i.e. plastic surgery) or for normal disease management (including treatment adjustment) are NOT to be considered as SAE according to this criterion (i.e. if the protocol or the standard management of the disease under study requires planned hospitalization).

- **results in persistent or significant disability or incapacity**

i.e. the AE resulted in a substantial disruption of the subject's ability to conduct normal activities.

- **is a congenital anomaly / birth defect (Not applicable in this study)**

i.e. an AE outcome in a child or foetus of a subject exposed to the Investigational Medicinal Product (or marketed medicinal product (Note: to be only added for marketed drug)) before conception or during pregnancy.

- **is an important medical event, i.e. is medically significant**

Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious events, such as important medical events that might not be immediately life-threatening or result in death or hospitalization but might jeopardize the patient or might require intervention to prevent one of the other outcomes listed above. In addition, any suspected transmission via a medicinal product of an infectious agent is also considered a SAE.

xii. Serious Adverse Event Reporting:

All Serious AEs (SAE) will be reported immediately (no later than within 24h of knowledge by the investigator) to the Sponsor, and within 24-48 hours of knowledge by the Investigator to the Ethics Committees (SERU and OxTREC) (whether or not the event is considered study drug-related), using the SAE report form. This includes a description of the event, onset date and type, duration, severity, relationship to each study drug, outcome, measures taken and all other relevant clinical and laboratory data.

In support of investigator, the Sponsor will report the SAE (using the SAE report form) to PPB and DSMB within 2 working days of awareness by investigator.

The initial report will be followed by submission of additional information (follow-up SAE form) as it becomes available.

Any follow-up reports will be submitted within 5 working days. In addition to documenting the SAE on the SAE report form, the SAE will also be documented on the AE CRF and all medications used to treat the SAE will be documented on the concomitant treatments CRF.

The sponsor will assess the causality of every SAE with each study drug.

In addition, the Sponsor will assess the expectedness of every SAE reported as "definitely/probably/possibly related" (therefore an adverse reaction) by the investigator or assessed the Sponsor as "related", with each study drug, and as per following definitions.

- **Unexpected Adverse Reaction (UAR):**

An adverse reaction, the nature or severity of which is not consistent with the SPC for Fosfocina, suspension (250mg/5ml) Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, InfectoPharm

- **Suspected Unexpected Serious Adverse Reaction (SUSAR)**

An adverse reaction that is unexpected (not consistent with the SPC for Fosfocina, suspension [250mg/5ml] Laboratorios ERN; or Fomicyt, 40mg/ml powder for solution for infusion, InfectoPharm) and meets the definition of a serious adverse event/reaction.

The Sponsor will report every SUSARs or Fatal SARs or other SAEs (CIOMS-I regulatory format) to PPB, Ethics Committees (SERU and OxTREC) and DSMB as follows:

- Fatal/Life-threatening SUSARs within 7 calendar days (+follow-up within 8 days) of knowledge by Sponsor
- Fatal SARs in 7 calendar days from knowledge by Sponsor
- Other SUSARs/SAEs within 15 calendar days of knowledge by Sponsor

xiii. Adverse event follow-up

All participants with AEs will receive treatment for those events and be followed up until they are resolved, or the investigator assesses them as chronic or stable, or the subject participation in the study ends (i.e., until a final report is completed for that subject) and care is ongoing.

In addition, all SAEs and those non-serious AEs assessed by the investigator as related (related/probably related/possibly related) to the investigational medication will continue to be followed even after the subject participation in the study is over. Such events will be followed until they resolve or until the investigator assesses them as chronic or stable. Resolution of such events will be documented on the CRF.

xiv. Withdrawal criteria:

A subject should be withdrawn from the study treatment if, in the opinion of the investigator, it is medically necessary, or if it is the wish of the parent/guardian. If a patient is withdrawn from the study before the full course of the treatment is completed, the physician will make all necessary arrangements to ensure that the subject receives the appropriate treatment for the relevant medical condition (i.e. with medication/s currently recommended by national guidelines). Should a patient require second-line or alternative antimicrobials, they will not be removed from the study as this will not impact the fosfomycin PK data.

If a subject does not return for the follow-up assessments at D28, every effort will be made to contact their parents/guardian. In any circumstance, every effort should be made to document subject outcome, if possible. If the subject withdraws consent, no further evaluations should be performed and no attempts should be made to collect additional data, except for safety data, which should be collected if possible and in accordance with consent.

If a subject is withdrawn from the study, the reason will be noted on the CRF. If a subject is withdrawn from the study because of a treatment limiting adverse event, thorough efforts will be made to clearly document the outcome of AE.

Data Safety Monitoring Board:

A Data Safety Monitoring Board (DSMB), composed of 3 members independent of the investigator and sponsor, will be set up prior to study initiation. The DSMB monitors the study in order to ensure that harm is minimized, and benefits maximized for the study subjects. They will review the study data at pre-determined intervals and issue recommendations about the study. The data and intervals will be agreed prior to, or soon after, the study initiation and documented in the DSMB Charter.

Quality Assurance and Quality Control Procedures

i. Investigator's file:

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents include:

- Investigator's Site File
- Subject clinical source documents
- Screening / enrolment logs.

The Investigator's Site File will contain the protocol/protocol amendments, CRF and query forms, REC and regulatory approval with correspondence, sample informed consent, drug accountability records, staff curriculum vitae, authorization forms and other appropriate documents and correspondence.

ii. Case report forms (CRFs):

For all participants, a standardized daily record will be used from admission (enrolment), and the study specific information will be captured in the respective CRF, and subsequently into the trial database. At discharge, the date, vitals status and weight will be recorded. Clinical data will be collected prospectively, supervised by a consultant paediatrician investigator to ensure data completeness and accuracy. Data that are derived should be consistent with the source documents or the discrepancies will be explained. All CRF data will be anonymized

(identified by study patient number only). The study will be reviewed by the Sponsor CRA. Study monitors will raise queries on data discrepancies, and these will be corrected by the study investigator against verified source information.

The investigators will ensure the accuracy, completeness, legibility, and timelines of all data reported to the sponsor in the CRFs and any other additional information that is required. The investigator is responsible for keeping all consent forms, screening forms, CRF and the completed subject identification code list in a secure location.

iii. Source documents:

The verification of the CRF data will be by direct inspection of source documents. Source documents include subject hospital/clinic records, physician's and nurse's notes, appointment book, original laboratory reports, letters, and subject screening and enrolment logs. The Investigator / designee will record the date of each subject's visit together with a summary of their status and progress in the study. The investigator will maintain source documents for possible review and/or audit by DNDi, Ethics Committees and/or Regulatory Authorities.

Indicate the identification of any data to be recorded directly on the CRFs (i.e. no prior written or electronic record of data), and to be considered to be source data. (Chapter 6: Clinical trial protocol and protocol amendment(s) § 6.4.9, CPMP/ICH/135/95 Topic E6)

iv. Record Retention:

The sponsor will keep all study documents on file for at least 25 years after completion or discontinuation of the study, at a secure facility contracted by the DNDi Nairobi offices, within Kenya. After that period of time the documents may be destroyed with prior permission from DNDi, subject to local regulations. Should the investigator wish to assign the study records to another party or move them to another location, DNDi will be notified in advance.

v. Monitoring, audits and inspections:

The investigators will permit representatives of DNDi, designated clinical monitors and representatives of Ethics Committees or Regulatory Authorities to review all CRFs, medical records, laboratory work sheets and to assess the status of drug storage, dispensing and retrieval at any time during the study. The Investigator's File and corresponding source documents for each subject will be made available provided that subject confidentiality is maintained in accordance with local regulations. The monitoring, audits or inspections are for the purpose of verifying the adherence to the protocol and to ensure the study is conducted according to GCP. It is important that the investigators and other trial site staff are available at these visits.

vi. Protocol Amendments:

The principal investigator will ensure that the study protocol is strictly adhered to throughout, and that all data are collected and recorded correctly on the CRF. All protocol modifications must be documented in writing. Any protocol amendment must be approved and signed by the sponsor and the Principal investigator and is to be submitted to the appropriate IEC for information and approval in accordance with local requirements, and to regulatory agencies if required. Approval by IEC (and Regulatory Authority, if applicable) must be awaited before any changes can be implemented, except for changes necessary to eliminate an immediate hazard to trial subjects, or when the change involves only logistical or administrative aspects of the trial [e.g. change in clinical monitor[s], change of telephone number[s]].

The protocol amendment can be initiated by either sponsor or by any Principal investigator. The investigator will provide in writing the reasons for the proposed amendment and will discuss with the medical coordinator and sponsor.

Data Sharing

The results of this work will be accessible with no financial barriers, by contributing to open source initiatives such as public databases and open access journals in a timely fashion. Permission to utilize anonymized data will be by application to the Data Governance Committee at CGMR-C who will ensure that appropriate ethical approval is in place for any new analysis. Explanation of this eventuality will be included in the participant Information and Consent Form (ICF).

Intellectual property

Any intellectual property rights that arise from the work will be safeguarded according to DNDi's IP policy and current KEMRI guidelines and the Industrial Property Act of 2001, sections 32, 58 and 80. The scientific and intellectual contributions of all persons involved in the research will be appropriately acknowledged in all publications and presentations arising from the work.

Ethical Considerations

The experimental protocol for this study has been designed in accordance with the general ethical principles outlined in the Declaration of Helsinki and ICH guidelines for Good Clinical Practice (International Committee for Harmonization). DNDi assures that it will comply with all applicable state, local and foreign laws for protecting the rights and welfare of human subjects. This protocol and any protocol amendments will be reviewed / approved by the KEMRI Scientific and Ethical Review Unit, Nairobi and the Oxford Tropical Research Ethics Committee, Oxford, UK. The study will be registered on www.clinicaltrials.gov.

Participation in research is voluntary and consent must be given with free will of choice, and without undue inducement. The parent/legal guardian must have sufficient knowledge and understanding of the nature of the proposed research, the anticipated risks and potential benefits, and the requirements of the research to be able to make an informed decision.

i. Human Subjects

First do no harm

ii. Risks

The study will be performed in a patient group who may potentially benefit from the treatment. Fosfomycin is licensed for use in neonates throughout Europe and is used to treat resistant UTIs among adults in Europe and the USA. Adverse events are reported to be rare, and monitoring of renal function, sodium and potassium levels should pre-empt major adverse clinical outcomes from occurring.

The risks of blood drawing include pain and thrombophlebitis. These will be minimized by careful aseptic technique according to a standard SOP. No more than 1ml/kg of blood will be drawn for research at any one time, and no more than a total of 2.5ml will be drawn for research during the entire study. DNDi has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the performance of the study.

iii. Benefits to the Patients and Community as a whole

Additional clinical staff will be recruited and will undertake study duties and assist in care, adding to the staff available for clinical care on the wards. For babies who do not improve on the currently recommended standard-of-care, we will provide second-line antibiotics free of charge if they are required. This study contributes to knowledge informing the appropriate use of antimicrobials, thus benefiting the whole community both at a local and international level.

iv. Confidentiality

On enrolment, participants will be issued with a unique identifying number and names recorded on CRFs and in the database as initials only. All clinical data will be held confidentially, and the investigator will ensure that subjects' anonymity will be maintained, and their identities protected from unauthorized parties. No documents containing patient identity will be submitted to the sponsor. The investigator will maintain documents for submission to sponsor authorized representatives, and the subject's signed written consent forms, in strict confidence.

v. Community Engagement Strategy

Community engagement will commence prior to the study with a stakeholders meeting involving Ministry of Health County staff and relevant national Government authorities and policy makers. This will be facilitated by the study sponsor, with attendance by investigators. Ongoing community engagement will be through regular meetings with the community involving KEMRI-Community Representatives and County Government Health and hospital management teams. At these meetings, information and feedback will be given and received.

vi. Stakeholder information giving

We will engage key individuals whom patients may receive information from, including nurses and all ward staff. We will expand ongoing communication activities about research to include this study in order to support parents and guardians receiving information on the study, before being asked for consent.

vii. Individual informed consent process

Written consent will be required for all data and samples taken for research purposes. Consenting will be done in a separate area to ensure privacy and the opportunity to ask questions and discuss concerns in the paediatric ward, high dependency unit or in casualty once the decision to admit has been made. It is the responsibility of the investigator / designee to obtain written informed consent for each individual participating in this study, after adequate presentation of the aims, methods, anticipated benefits, and potential hazards of the study. The written

informed consent document will be translated into the local language (Swahili and Giriama). If needed, the person will be given time to discuss the information received with other members of the family before deciding to consent, providing this does not extend beyond the time identified for inclusion in the study as per the inclusion criteria. The subject or parent/guardian will be asked to provide written and signed consent. Parents or legal guardians will be able to consent separately for participation in the study, storage of data and samples for future research, and export of samples for investigations that cannot currently be conducted in Kenya. Where the attending clinician judges that the child is so severely ill that adequate communication with the parent or legal guardian is not possible, the child will be excluded from participation. If the parent /guardian is illiterate, a literate witness must sign (this person should have no connection to the research team and the sponsor, and, if possible, should be selected by the participant). The witness shall attest that they have provided information accurately to the parent/guardian and this was understood; a thumbprint of the parent/guardian must be provided to attest to this. If new safety information results in significant changes in the risk/benefit assessment, the consent form should be reviewed and updated if necessary. All subjects (including those already being treated) should be informed of the new information, given a copy of the revised form and give their consent to continue in the study.

viii. Training / support for those involved in community engagement and administering consent
Clinical officers, nurses and field workers will be trained in providing information and administering the consent procedure, following a standard operating procedure in the local language of participants, using didactic learning and role plays. In addition, all investigators will complete relevant courses in Good Clinical Practice ethical training specifically addressing research involving human subjects.

ix. Feedback of information
This study will be undertaken with the medical and nursing unit staff and the hospital consultants, who have been involved in its design and will be essential in its implementation. Information arising from the study will be fed back through hospital-wide meetings. Study results will be disseminated to study staff, hospital staff and local communities through meetings targeting respective groups. Results will also be published in peer-reviewed journals and presented at local and international meetings or conferences.

x. Animal Subjects
N/A

Expected Application of the Results

The results will contribute to both local and international knowledge regarding the appropriate use of antimicrobials in neonates with presumed sepsis and help in the design of a subsequent multi-centre, large-scale randomized clinical trial to determine the risks and benefits (in terms of mortality and antimicrobial resistance) of an updated antibiotic schedule, particularly where multidrug resistant bacteria are prevalent.

References

- 1 Lawn J, Blencowe H, Oza S, You D, Lee A. Every Newborn: Progress, Priorities, and Potential beyond Survival. *Lancet* 2014; **384**: 189–205.
- 2 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000–2013; with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet* 2014; **385**: 430–40.
- 3 Shah D, Doyle L, Anderson P, et al. Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. *J Pediatr* 2008; **153**: 170–5.
- 4 The World Health Organization. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources. 2013. <http://apps.who.int/iris/bitstream/10665/43206/1/9241546700.pdf>.
- 5 Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics- systematic review and meta-analysis. *Arch Dis Childhood* 2013; **98**: 146–54.
- 6 Le Doare J, Heath, P. and Sharland, M. KB. Systematic review of antibiotic resistance rates among gram-negative bacteria in children with sepsis in resource-limited countries. *J Paediatr Infect Dis Soc* 2014; **4**: 11–20.
- 7 Folgori L, Livadiotti S, Carletti M, et al. Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary paediatric hospital during a 12-month period. *Pediatr Infect Dis J* 2014; **33**: 929–32.
- 8 Delhi Neonatal Infection Study (DeNIS). Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. *Lancet Glob Heal* 2016; **4**: e752–60.
- 9 Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: A worldwide challenge. *Lancet* 2016; **387**: 168–75.
- 10 The World Health Organization. Critically important antimicrobials for human medicine. 3rd Revis. 2011.
- 11 Hendlin D, Stapley M, Jackson H, Wallick A, Miller A, Wolf F. Phosphonomycin. A new antibiotic produced by strains of *Streptomyces*. *Science* (80-) 1969; **166**: 122–3.
- 12 Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. *Int J Infect Dis* 2011; **15**: e732–9.
- 13 Falagas M, Vouloumanou E, Samonis G, Vardakas K. Fosfomycin. *Clin Microbiol Rev* 2016; **29**: 321–47.
- 14 Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. *Int J Antimicrob Agents* 2016; **47**: 269–85.
- 15 Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. *Infect Dis Ther* 2015; **4**: 433–58.
- 16 Baquero F, Hortelano JG, Navarro M, et al. Antibiotherapy of *Serratia marcescens* septicemia in children. *Chemotherapy* 1977; **23 Suppl 1**: 416–22.
- 17 Corti N, Sennhauser FH, Stauffer UG, Nadal D. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. *Arch Dis Child* 2003; **88**: 512–6.
- 18 Llorens J, Lobato A, Olay T. The passage of fosfomycin into the cerebrospinal fluid in children's meningitis. *Chemotherapy* 1977; **23 Suppl 1**: 189–95.
- 19 Careddu P, Borzani M, Scotti L, Varotto F, Garlaschi L, Fontana P. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. *Chemioterapia* 1987; **6**: 290–4.

- 20 Principi N, Corda R, Bassetti D, Varese LA, Peratoner L. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. *Chemotherapy* 1990; **36 Suppl 1**: 41–5.
- 21 Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children's lower urinary tract infections. *Eur Urol* 1987; **13 Suppl 1**: 119–21.
- 22 Nutrition A et al. for the EC on. Enteral Nutrient Supply for Preterm Infants: Commentary From the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Committee on Nutrition. *Hepatol Nutr* 2010; **50**: 85–91.
- 23 Group K et al. for the PNGW. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric. *J Pediatr Gastroenterol Nutr* 2005; **41**: S1–S4.
- 24 Nash P. Potassium and Sodium Homeostasis in the Neonate. *Neonatal Netw* 2007; **26**: 125–8.
- 25 Akçam M. Oral fructose solution as an analgesic in the newborn: A randomized, placebo-controlled and masked study. *Pediatr Int* 2004; **46**: 459–62.
- 26 Bueno M, Yamada J, Harrison D, et al. A systematic review and meta-analyses of nonsucrose sweet solutions for pain relief in neonates. *Pain Res Manag* 2013; **18**: 153–61.
- 27 Taylor CG, Mascaros E, Roman J, et al. Enteropathogenic *E. coli* gastroenterocolitis in neonates treated with fosfomycin. *Chemotherapy* 1977; **23 Suppl 1**: 310–4.
- 28 Rossignol S, Regnier C. [Fosfomycin in severe infection in neonatology]. *Ann Pediatr (Paris)* 1984; **31**: 437–44.
- 29 Guillois B, Guillemin MG, Thoma M, Sizun J, Monnery JL, Alix D. [Neonatal pleuropulmonary staphylococcal infection with multiple abscesses of the liver]. *Ann Pediatr (Paris)* 1989; **36**: 681–4.
- 30 Gouyon JB, Francois C, Semama D, Sandre D, Duez JM, Portier H. [Nosocomial *Staphylococcus epidermidis* and *Staphylococcus aureus* septicemias in neonates]. *Ann Pediatr (Paris)* 1990; **37**: 21–5.
- 31 Algubaisi S, Buhner C, Thomale U-W, Spors B. Favorable outcome in cerebral abscesses caused by *Citrobacter koseri* in a newborn infant. *IDCases* 2015; **2**: 22–4.
- 32 Li G, Standing J, Bielicki J, et al. The potential role of fosfomycin in neonatal sepsis caused by multidrug resistant bacteria. *Publ* 2016.
- 33 Guggenbichler JP, Kienel G, Frisch H. [Fosfomycin, a new antibiotic drug (author's transl)]. *Pediatr Padol* 1978; **13**: 429–36.
- 34 Molina MA, Olay T, Quero J. Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period. *Chemotherapy* 1977; **23 Suppl 1**: 217–22.
- 35 Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. *Infection* 1990; **18 Suppl 2**: S65–9.
- 36 Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profile of fosfomycin trometamol. *Chemotherapy* 1993; **39**: 297–301.
- 37 Guibert M, Magny JF, Poudenx F, Lebrun L, Dehan M. [Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration]. *Pathol Biol (Paris)* 1987; **35**: 750–2.
- 38 Suzuki S, Murayama Y, Sugiyama E, Sekiyama M, Sato H. [Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function]. *Yakugaku Zasshi* 2009; **129**: 829–42.
- 39 Traummüller F, Popovic M, Konz K-H, Vavken P, Leithner A, Joukhadar C. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. *Clin Pharmacokinet* 2011; **50**: 493–503.
- 40 Patel S, Balfour J, Bryson H. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. *Drugs* 1997; **53**: 637–56.

- 41 Duez J, Mousson C, Siebor E, et al. Fosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infections. *Clin Med Rev Ther* 2011; **3**: 123–42.
- 42 Borgia M, Longo A, Lodola E. Relative bioavailability of fosfomycin and of trometamol after administration of single dose by oral route of fosfomycin trometamol in fasting conditions and after a meal. *Int J Clin Pharmacol Ther Toxicol* 1989; **27**: 411–17.
- 43 WHO | Antimicrobial resistance: a priority for global health action. *Bull World Heal Organ* 2015; **93**: 437–512.
- 44 Sarnat H, Sarnat M. Neonatal encephalopathy following fetal distress: A clinical and electroencephalographic study. *Arch Neurol* 1976; **33**: 696–705.
- 45 Lu C, Liu C, Huang Y, et al. Antimicrobial Susceptibilities of Commonly Encountered Bacterial Isolates to Fosfomycin Determined by Agar Dilution and Disk Diffusion Methods. *Antimicrob Agents Chemother* 2011; **55**: 4295–4301.
- 46 Morgan C, Herwitker S, Badhawi I, et al. SCAMP: standardised, concentrated, additional macronutrients, parenteral nutrition in very preterm infants: a phase IV randomised, controlled exploratory study of macronutrient intake, growth and other aspects of neonatal care. *BMC Pediatr* 2011; **11**.
- 47 The World Health Organization. Hypoglycaemia of the Newborn: Review of the Literature. 1997 DOI:WHO/CHD/97.1 / WHO/MSM/97.1.

Patient Information Sheets and Informed Consent Forms**A study measuring the levels of an additional antibiotic (fosfomycin) to treat severe infections in newborns (NeoFosfo)**

KEMRI-Wellcome Trust, Kilifi, Kenya	James Berkley (Principal Investigator), Phoebe Williams, Christina Obiero, Neema Mturi, Claire Gordon, Johnstone Thitiri, Mwanamvua Boga, Sheila Murunga, Joseph Waichungo
KEMRI CCR & CREATES, Strathmore University, Nairobi	Martin Ongas
St George's Hospital, University of London, UK	Mike Sharland, Julia Anna Bielicki, Karin Kipper
University College, London, UK	Joseph Standing
Medical Research Council Clinical Trials Unit at University College London, UK	Sarah Walker
GARDP, Geneva, Switzerland	Sally Ellis
Study Sponsor	Drugs for Neglected Diseases Initiative

We are speaking with you today to give you information about a research study, answer any questions you may have and ask for your consent for your child's participation by signing this form (or for those who cannot write, to select a witness to help them through the consenting process and give a thumb print). Participation in research is voluntary; you are free to decide if you want your child to take part or not. A copy of the signed/thumb printed consent form will be given to you to keep if you agree to participate in this study.

Your child is being admitted to hospital where you will receive the best treatment available at this hospital. As part of normal standard care, these things are usually done:

There will be an admission blood test to check your baby's kidney and liver function, as well as for an infection in the blood; and usually a test for infection in the spinal fluid using a needle;

For sick babies with presumed infections, antibiotic medications are always given into their bloodstream (via a vein).

What is this research about?

Currently, all sick babies admitted to hospital with a presumed infection are treated with two antibiotics. However, bacteria are increasingly becoming resistant to the antibiotics that are normally used. This may make it harder for babies to recover from their illnesses. In Africa, other drugs that work are expensive, and may themselves cause the bacteria to become resistant. New alternatives are therefore needed. One drug that might be able to be used as an alternative is 'fosfomycin'. This drug is already used in Europe and America to treat infections in adults and children and is cheaply available, however we need more information to help us understand how fosfomycin should be used in babies. To help find this out, we want to add fosfomycin to the usual antibiotics we give to provide us with information about how much fosfomycin is in a baby's blood after a dose is given. This will help us know what doses are effective for babies with infection. The people conducting this research have been carefully trained on the research and on ensuring the rights and safety of participants.

Who is carrying out this study?

The Kenya Medical Research Institute is part of the Ministry of Health that carries out research with the aim of finding better ways of preventing and treating illness in the future, for everybody's benefit. One health problem we are trying to discover more about is how best to treat newborn babies with serious infections.

What will it involve for me/my child?

This research will involve 120 children, 60 of whom will receive fosfomycin together with the standard antibiotics and the other 60 will just receive the standard antibiotics which are normally given. We will put your baby into a group by chance, like tossing a coin. Your baby will have an equal chance of being in either group.

The doctors and nurses will open a closed envelope which tells them which group your baby will be in. They cannot themselves choose which group your baby will be in.

If your child is assigned to the group receiving fosfomycin, we are asking:

To give your child the standard treatment (two antibiotics), plus fosfomycin as an extra (third) antibiotic for up to one week;

To take a small amount of blood, about half a teaspoon (2.5ml in **total**) for this research at five different times while your baby is in hospital (0.5ml, or a few drops, each time). We will use these samples to check the amount of antibiotics present in your baby's blood and conduct routine tests to check their blood cells, kidney and liver function;

To take a swab from your baby's nappy when they are admitted and discharged from hospital, to check if there are changes to the type of bacteria in their stool;

If your treating Doctor decides that your baby needs a lumbar puncture to check for an infection in the fluid surrounding the brain, we will send any leftover fluid from this test to a lab in England to check the levels of antibiotic present;

To come for a follow-up, visit after 28 days to check if your baby is well. We will pay your transport fare and compensate you for your time (KSh300) for this visit.

Everything else that is done during your stay in hospital will be part of normal tests and treatment requested by doctors. If your baby becomes ill or you are concerned about their health before this follow-up appointment, you may call 0740 310 773 or bring your baby to the ward/clinic for review (and any necessary treatment) by a clinician.

Are there any risks from my child's participation?

KEMRI's priority for every patient is his/her care. The drug being studied is already licensed and in use by adults and children in Europe and other parts of the world, but not yet in Kenya. Your child will be closely observed for any side effects. Occasionally reported side effects include a mild rash or stomach upset, while rare side effects include an allergic reaction or changes to the level of salts in the blood. These are unlikely to occur and may also occur with other antibiotics. Your baby will be closely monitored and treated for any side effects they may develop while participating in the study.

The blood samples for measuring the level of the drug will be taken using a small plastic tube that is like the one that the drugs are given through. If your child needs further blood tests as part of their care, these can be done at the same time. Taking blood can cause a small amount of pain, bruising, swelling, discomfort or a very small chance of infection. We will use a careful procedure to help prevent these from occurring. The use of a cotton swab to collect a sample from your child's nappy poses no risk to your child.

Are there any benefits for me/my child's participation into this study?

Your child will be reviewed daily by one of our study clinicians, together with the regular hospital staff. We will provide alternative antibiotics at no cost if they are needed. We will also provide an extra clinical review 3 weeks after your baby has been discharged from hospital, and you are welcome to contact us at any point or bring your baby to see us at the ward prior to this if you have any concerns in regard to your baby. There is no other direct benefit to your baby in participating. The research aims to benefit society by helping to improve care for children in the future.

What will happen if I do not agree to participate?

If you do not want your baby to take part, no blood samples for research will be taken; but the Doctor may still wish to test your child's blood for regular clinical care. If you agree to participate now, you can still change your mind at any time and withdraw your child from the study. This will not affect your child's care now or in the future.

What will happen to the samples?

All the information and samples collected will be held confidentially. Individual names are removed from all samples and replaced by codes, so that samples can only be linked to the children by people closely concerned with the research. Some of the research tests that will be done on the blood will be done in Kilifi. However, for

some tests that cannot be done in Kenya, part of the sample will be sent overseas (to the United Kingdom) to identify the levels of antibiotics in your baby's blood.

Who will be able to access my child's information in this study?

All information on participants collected in this study will be stored in a confidential manner in locked, secured cabinets and password-protected computers, and will only be accessible to authorized study personnel. Data will be stored to the end of the study, and clinical monitors and regulatory authorities (such as the Kenyan Pharmacy and Poisons Board or Ethics Committee) may check this information to ensure the study is being conducted correctly. In the future, information collected or generated during this study may be used to support new research by other researchers in Kenya and other countries on questions about child health. In all cases, we will only share information with other researchers in ways that do not reveal individual participants' identities. Any future research using information from this study must first be approved by a local or national expert committee to make sure that the interests of participants and their communities are protected. Samples will be stored for up to 5 years.

Who has authorized this research to take place?

All research at KEMRI has to be approved before it begins by an independent ethical review board, the Scientific and Ethical Review Unit in Nairobi and the Oxford University Tropical Research Ethics Committee in the UK, who look carefully at planned work. They must agree that the research is important, relevant to Kenya and follows nationally and internationally agreed research guidelines. This includes ensuring that all participants' safety and rights are respected.

What if I have any questions?

You may ask any of our staff questions at any time. You can also contact the research team using the contacts below:

0740 210 773: KEMRI - STUDY-SPECIFIC MOBILE LINE (LOCAL LANGUAGE SPEAKER)

If you want to ask someone independent about this research, please contact:

Community Liaison Manager, KEMRI Wellcome Trust Research Programme, P.O. Box 230, Kilifi. Telephone: 041 7522 063, Mobile 0723 342 780 or 0705 154 386

Or

The Head, KEMRI Scientific and Ethics Review Unit, P. O. Box 54840-00200, Nairobi;

Telephone numbers: 0717 719477; 0776 399979 Email address: seru@kemri.org

[ENGLISH] A study measuring the levels of an additional antibiotic (fosfomycin) to treat severe infections in newborns (NeoFosfo)

I, being the parent/guardian of, _____ (name), have had the research explained to me. I have understood all that has been read and had my questions answered satisfactorily.

Please place a tick in each box below:

- ☐ I agree / do not agree (delete as appropriate) for my child to take part in this research
- ☐ I agree / do not agree (delete as appropriate) to samples being stored for future research
- ☐ I agree / do not agree (delete as appropriate) to samples being exported to measure blood drug levels

I understand that I can change my mind at any stage, and it will not affect me or my baby in any way.

Parent/guardian's signature: _____ **Date** _____

Parent/guardian's name: _____ **Time** _____

(Please print name)

I certify that I have followed the study SOP to obtain consent from the [participant]. She/he apparently understood the nature and the purpose of the study and consents to participation in the study. She has been given opportunity to ask questions which have been answered satisfactorily.

Designee/investigator's signature: _____ **Date** _____

Designee/investigator's name: _____ **Time** _____

(Please print name)

Only necessary if the participant cannot read:

I *attest that the information concerning this research was accurately explained to and apparently understood by the subject and that informed consent was freely given by the participant.

Witness' signature: _____ **Date** _____

Witness' name: _____ **Time** _____

(Please print name)

***A witness is a person who is independent from the trial or a member of staff who was not involved in gaining the consent.**

Thumbprint of the subject as named above if they cannot write:



THE PARTICIPANT SHOULD NOW BE GIVEN A SIGNED COPY TO KEEP

[SWAHILI]: Utafiti wa kupima viwango vya dawa nyongeza dhidi ya bakteria (fosfomycin) kwa kutibu maambukizi makali kwa watoto wachanga (NeoFosfo)

Taasisi	Watafiti
KEMRI-Wellcome Trust, Kilifi, Kenya	James Berkley (Mtafiti mkuu), Phoebe Williams, Neema Mturi, Claire Gordon, Johnstone Thitiri, Mwanamvua Boga, Christina Obiero, Sheila Murunga, Joseph Waichungo
KEMRI CCR & CREATES, Strathmore University, Nairobi	Martin Ongas
St George's Hospital, University of London, UK	Mike Sharland, Julia Anna Bielicki, Karin Kipper
University College, London, UK	Joseph Standing
Medical Research Council Clinical Trials Unit at University College London, UK	Sarah Walker
GARDP, Geneva, Switzerland	Sally Ellis
Mfadhili wa utafiti	Drugs for Neglected Diseases Initiative

Tunazungumza na wewe kutoa habari kuhusu utafiti, kujibu maswali yako na tuombe ruhusa yako ya kushirikisha mtoto wako kwa kusaini fomu hii, au kwa wale ambao hawawezi kuandika, kupata shahidi atakaye wasaidia kupitia utaratibu wa kuomba idhini na kuweka alama ya dole gumba. Kushiriki katika utafiti ni hiari; uko huru kuamua kama unataka mtoto wako kushiriki katika utafiti au la. Utapewa nakala ya fomu ya idhini yenye sahihi/alama ya dole gumba uiweke ikiwa unakubali kushiriki katika utafiti huu.

Mtoto wako amelazwa hospitali ambako utapata matibabu bora yanayopatikana katika hospitali hii. Mambo haya yanafanywa kwa kawaida kama sehemu ya huduma ya kawaida:

Kutakuwa na sampuli ya damu wakati wa kulazwa kuangalia jinsi figo na ini zinavyofanya kazi na kwa maambukizi katika damu na kwa kawaida uchunguzi wa maambukizi kwenye maji ya uti wa mgongo inayofanyika kwa kutumia sindano.

Kwa watoto wagonjwa wanaokisiwa kuwa na maambukizi, dawa dhidi ya bakteria huingizwa kwenye damu yao (kupitia mishiya).

Je utafiti huu unahusu nini?

Kwa sasa watoto wote wachanga wanaolazwa hospitali wakidhaniwa kuwa na maambukizi hutibiwa kwa dawa dhidi ya bakteria aina mbili. Hata hivyo, bakteria wanazidi kuwa sugukwa dawa zinazotumika kwa kawaida. Hii inaweza kufanya iwe vigumu kwa watoto wachanga kupona kutoka kwa magonjwa. Hapa Afrika, dawa mbadala zinazofanya kazi ni ghali na pia zinaweza kufanya bakteria kuwa sugu. Kwa hivyo, dawa mpya mbadala zinahitajika. Dawa moja inayoweza kutumika kama mbadala ni 'fosfomycin'. Dawa hii inatumika bara Uropa na Amerika kutibu maambukizi katika watu wazima na watoto na iko rahisi kupatikana, Hata hivyo tunahitaji habari zaidi ili kutusaidia kuelewa jinsi 'fosfomycin' inastahili kutumika kwa watoto wachanga. Ili kutusaidia kujua hili, tungependa kujumuisha fosfomycin kwa dawa za kawaida dhidi ya bakteria tunazopeana ili kutupatia habari kuhusu kiwango cha fosfomycin kilicho kwenye damu ya mtoto mchanga baada ya kupewa kiwango chadawa (dozi?). Hii itatusaidia kujua ikiwa viwango ni vya sawa kwa watoto wachanga walio na maambukizi.

Ni nani anayefanya utafiti huu?

Shirika la utafiti la KEMRI Wellcome Trust ni sehemu ya wizara ya afya linalofanya utafiti kwa lengo la kutafuta njia bora za kukinga na kutibu magonjwa kwa siku za usoni kwa manufaa ya watu wote. Tatizo moja la kiafya ambalo tunajaribu kujifunza zaidi ni jinsi ya kutibu vyema watoto wachanga wenye maambukizi makali. Watu wanaofanya utafiti huu wamepata mafunzo kwa uangalifu na wanahakikisha haki na usalama wa wanaoshiriki vinaheshimiwa.

Utafiti huu utahusisha watoto 120, 60 ambao watapewa fosfomycin pamoja na dawa za kawaida na wengine 60 wataendelea tu kupewa dawa za kawaida ambazo hupewa kwa kawaida. Mtoto wako yuko na nafasi sawa ya kuwa kwenye moja wapo ya makundi haya. Tutamuweka mtoto wako kwenye kungi kwa njia ya bahati na sibu, kama vile kurusha sarafu.. Madaktari na wauguzi watafungua bahasha zilizofungwa ambazo zinaonyesha mtoto wako atakuwa kundi gani. Hawana njia ya kuchagua kundi ambalo mtoto wako ataingia.

Je, itahusisha nini kwangu/mtoto wangu?

Ikiwa mtoto wako atawekwa kwa kundi la wanaopewa fosfomycin, tunauliza:

Kumpa mtoto wako matibabu ya kawaida (dawa 2 dhidi ya bakteria – antibiotiki?); na kuongeza fosfomycin, kama dawa ya ziada (ya tatu) kwa wiki moja.

Kuchukua kiwango kidogo cha damu, kama nusu ya kijiko cha chai (mililita 2.5 **jumla**) kwa utafiti huu mara tano wakati tofauti mtoto wako akiwa hapa hospitalini (mililita 0.5, au matone machache, kila wakati). Tutatumia sampuli hizi kuangalia kiwango cha dwa dhidi ya bakteria kilichoko kwenye damu ya mtoto wako na kufanya vipimo vya kawaida kuangalia kuangalia chembechembe za damu, figo na ini vinavyofanyakazi.

Kuchukua sampuli ya choo kutoka kwa mtoto wako atakapokuwa amelazwa na watakapotolewa hospitali, kuangaliaa iwapo kuna mabadiliko ya aina ya bakteria katika choo chao.

Iwapo daktari wako anayetibu mtoto ataamua ya kwamba mtoto wako anahitaji kutolewa maji ya mti wa mgongo kuangalia maambukizi ya maji yanayozunguka ubongo tutatuma mabaki ya maji kutoka kwa utafiti huu kwa mahabara iliyoko Uingereza ili kuangalia kiwango cha dawa dhidi ya bakteria kilichoko.

Uje kwa ziara za ufuatiliizi baada ya siku 28 ili kuangalia kama mtoto wako yuko salama Tatalipia usafiri wako na kufidia muda wako (Shilingi 300) kwa kila ziara.

Kila kitu kingine ambacho kitafanywa wakati uko hospitali itakuwa sehemu ya vipimo vya kawaida na matibabu vinavyo ulizwa na madaktari.

Ikiwa mtoto wako atakupwa mgonjwa, au una wasi wasi kuhusu afya yake kabla ya tarehe ufuatiliizi wa mwezi wa kwanza, unaweza kupiga simu **0740310773** timu watafiti iliyoapanwa hapa chini au umlete mtoto wako kwa wodi/kliniki kwa ukaguzi (na matibabu yoyote yanayohitaji) daktari.

Je, kuna madhara yoyote kwa mtoto wangu kushiriki?

Kipao mbele cha KEMRI kwa kila mgonjwa ni uangalizi wake. Dawa inayotafitiwa tayari imeidhinishwa kutumika katika watu wazima na watoto huko bara Uropa na semehu nyengine za ulimwengu, lakini bado hapa Kenya. Mtoto wako atafuatiliwa kwa ukaribu kwa madhara yoyote kutokana na dawa hii. Mara chache, madhara ambayo yameripotiwa yanajumuisha vipele na kuumwa na tumbo madhara nadra ni kama mabadiliko ya kiwango cha chumvi kwenye damu. Haya yanauwezekano mchache kutokea, na hata yanafanyika hata kwa dawa nyengine dhidi ya bakteria. Mtoto wako atafuatiliwa kwa ukaribu na atibiwe madhara yoyote yahayoweza kutokea wakati akishiriki kwenye utafiti

Sampuli ya damu ya vipimo vya kiwango cha dawa zitachukuliwa kutumia mrija mdogo wa plastiki ambayo ni kama zile zitumikazo kupitisha dawa. Ikiwa mtoto wako anahitaji vipimo zaidi vya damu kama sehemu ya huduma yake, hivi vitafanywa wakati mmoja. Kuchukua damu kutoka mkononi kunaweza kusababisha maumivu machache, mkwaruzo, kufura au uwezekano mdogo wa kupata maambukizi. Tutatumia utaratibu wa makini ili kuzuia haya. Utumizi wa kifaa cha pamba kuchukua sampuli ya choo kutoka kwa kibinda cha mtoto wako hakuna hatari yoyote kwa mtoto wako.

Je, kuna manufaa kwangu/mtoto wangu kwa kushiriki katika utafiti huu?

Mtoto wako atachunguzwa kila siku na mmoja wa daktari wa utafiti, pamoja na wafanyikani wa kawaida wa hospitali. Tutatoa dawa mbadala dhidi ya bakteria bila kuhitaji malipo zaidi. Pia tutapeana ukaguzi wa kimatibabu wiki tatu baada ya mtoto wako kuruhusiwa kuenda nyumbani, na unaweza kututafuta wakati wowote, au kumleta mtoto wako wadini kabla haya ikiwa una wasi wasi wowote kuhusu mtoto wako. Hakuna

manufaa mengine ya moja kwa moja kwa kushiriki. Utafiti huu unalenga kunufaisha jamii kwa kuboresha huduma kwa watoto siku za usoni.

Je, kutafanyika nini nikikataa kushiriki?

Ikiwa hutaki mtoto wako ashiriki, hakuna sampuli za damu zitachukuliwa kwa utafiti, hata hivyo madaktari bado watahitaji kupima damu ya mtoto wako kama ilivyo kawaida kwa huduma. Ukikubali kushiriki sasa, unaweza kubadilisha mawazo yako wakati wowote na kumuondoa mtoto wako kutoka kwa utafiti na hakuna sampuli ya damu au habari za utafiti zaidi ambazo zitachukuliwa. Hii haitaathiri huduma kwa mtoto wako sasa wala siku za usoni.

Je, nini kitafanyika kwa sampuli?

Habari zote na sampuli zitakazokusanywa zitawekwa katika hali ambayo haiwafikii wengine. Majina ya watu binafsi yanatolewa kutoka kwa sampuli zote na yabadilishwe na nambari maalum (codes), kuhakikisha kwamba sampuli zinaweza tu kuambatanishwa na watu wanaohusika na utafiti kwa ukaribu. Baadhi ya vipimo vitakavyofanywa kwenye sampuli ya damu vitafanywa hapa Kilifi. Hata hivyo kwa baadhi ya vipimo ambavyo haviwezi kufanywa Kenya, baadhi ya sampuli zitatumwa ng'ambo nchi ya Uingereza ili kutambua viwango vya dawa dhidi ya bakteria vilivyo katika damu ya mtoto wako. Sampuli zinaweza kuhifadhiwa kwa hadi miaka mitano.

Ni nani atakayefikia habari kunihusu mimi/mtoto wangu katika utafiti huu?

Habari zote kuhusu washiriki katika utafiti huu zitahifadhiwa katika hali ambayo haziwezi kufikia wengine, katika kabati zilizofungwa na komputa zinazohitaji neno siri kufunguliwa zinazofikiwa tu na wafanyikazi walioidhinishwa. Habari zitahifadhiwa hadi mwisho wa utafiti na uchambuzi; na wakaguzi wa tafiti za kimatibabu au wakaguzi wengine na mamlaka za udhibiti (kama vile Bodi ya Kenya ya Dawa na Sumu au Kamati ya Maadili) wanaweza kukagua habari ili kuhakikisha utafiti unafanywa sawa. Ripoti yoyote au jarida kuhusu utafiti huu hazitatumia majina au vitambulishi vya mshiriki.

Siku za usoni, habari zitakazokusanya wakati wa utafiti huu zitatumika kusaidia tafiti mpya zitakazofanywa na watafiti wengine nchini Kenya na nchi zengine kuhusu maswali ya afya ya mtoto. Katika hali zote, tutasambaza tu habari katika njia ambayo haidhihirishi vitambulisho binafsi vya washiriki. Kwa mfano, tutaondoa habari ambazo zinaweza kutambulisha watu, kama vile majina yao na kule wanakoishi, na tubadilishe na nambari maalum (codes). Kisha, tafiti zozote za siku zijazo zitakazotumia habari kutoka kwa utafiti huu lazima kwanza ziidhinishwe na kamati za wataalam za Kilifi na za kitaifa ili kuhakikisha kwamba maslahi ya washirikina jamii zao yanalindwa.

Ni nani ameidhinisha utafiti huu?

Tafiti zote za KEMRI ni lazima ziidhinishwe kabla kuanza na kamati iliyo huru ya KEMRI ya kukagua maadili, Kitengo cha Sayansi na Maadili huko Nairobi na Kamati ya Chuo Kikuu cha Oxford ya Maadili ya utafiti huko Uingereza, zinazoangalia kwa makini mpangilio wa kazi. Ni lazima wakubali kwamba utafiti ni muhimu, wafaa Kenya na unafuata taratibu zinazokubalika kitaifa na kimataifa. Hii ni pamoja na kuhakikisha kwamba usalama na haki za washiriki zinaheshimika.

Je nikiwa na maswali yoyote?

Uko huru kumuuliza maswali mfanyaji kazi wetu yeyote wakati wowote. Pia unaweza kuwasiliana na kundi la utafiti kutumia anwani zifuatazo:

0715 938 077 KEMRI – Nambari ya mradi wa utafiti (Mtu anayezungumza lugha ya hapa)

Ukitaka kumuuliza mtu huru kuhusu utafiti huu tafadhali wasiliana na:

Meneja wa kitengo cha uhusiano mwema na jamii, Shirika la utafiti la KEMRI Wellcome Trust, S. L. Posta 230, Kilifi. Simu: 0723 342 780 au 041 7522 063

Na

Kiongozi, Kitengo cha kukagua sayansi na maadili cha KEMRI, S. L. Posta 54840-00200, Nairobi; Nambari ya simu: 0717 719477; 0776 399979 Barua pepe: seru@kemri.org

Utafiti wa kupima viwango vya nyongeza vya dawa dhidi ya bakteria (fosfomycin) kutibu maambukizi makali katika watoto wachanga (NeoFosfo)

Mimi, nikiwa mzazi/mlezi wa _____ (jina la mtoto),] nimeelezewa utafiti huu. Nimeelewa yote yaliyosomwa/elezwa na maswali yangu yamejibiwa kikamilifu.

- ☐ Ndio nakubali kumruhusu mtoto wangu kushiriki kwenye utafiti huu
- ☐ Ndio nakubali sampuli zihifadhiwe na zitumike kwa utafiti wa siku za usoni
- ☐ Ndio nakubali sampuli zisafirishwe ng'ambo kupima viwango vya dawa katika damu

Naelewa kwamba naweza kubadilisha nia wakati wowote na haitaniathiri mimi/mtoto wangu kwa njia yoyote.

Sahihi ya mhusika/ mzazi/mlezi: _____ **Tarehe:** _____

Jina la mhusika/ mzazi/mlezi: _____ **Saa:** _____

(tafadhali andika jina kwa herufi kubwa)

Ninathibitisha kwamba nimefuata muongozo wa utafiti wa kuchukua idhini kutoka kwa mshiriki. Ni wazi kuwa ameelewa asili na madhumuni ya utafiti na amekubali kushiriki katika utafiti. Amapewa nafasi ya kuuliza maswali ambayo yamejibiwa kikamilifu.

Sahihi ya mwakilishi/ mtafiti: _____ **Tarehe** _____

Jina la mwakilishi/mtafiti: _____ **Saa** _____

(Tafadhali andika jina kwa herufi kubwa)

Ni muhimu tu kama mshiriki hawezi kusoma

Ninathibitisha kwamba habari kuhusu utafiti huu zimeelezwa kikamilifu na ni dhahiri kuwa mshiriki ameelewa na kwamba idhini imetolewa kwa hiari na mshiriki.

Sahihi ya shahidi: _____ Tarehe _____


Jinan a shahidi: _____ Saa _____

(Tafadhali andika jina kwa herufi kubwa)

*Shahidi ni mtu ambaye yuko huru kutokana na utafiti au mfanyakikazi ambaye hakuhusika katika kupata idhini.

Alama ya kidole gumba cha mzazi kama alivyotajwa hapo juu ikiwa hawezi kuandika:

MSHIRIKI/MZAZI/MLEZI SASA APEWE NAKALA ILIYOWEKWA SAHIHI AHIFADHI



[GIRIAMA]: Utafiti wa kupima viwango zha dawa ya nyongeza dhidi ya bakteria (fosfomycin) kahi za kutibu maambukizi makali kahi za ahoho atsanga (NeoFosfo)

Taasisi	Atafiti
KEMRI-Wellcome Trust, Kilifi, Kenya	James Berkley (Mutafti mubomu), Phoebe Williams, Neema Mturi, Claire Gordon, Johnstone Thitiri, Mwanamvua Boga, Christina Obiero, Sheila Murunga, Joseph Waichungo
KEMRI CCR & CREATES, Strathmore University, Nairobi	Martin Ongas
St George's Hospital, University of London, UK	Mike Sharland, Julia Anna Bielicki, Karin Kipper
University College, London, UK	Joseph Standing
Medical Research Council Clinical Trials Unit at University College London, UK	Sarah Walker
GARDP, Geneva, Switzerland	Sally Ellis
Mufadhili wa utafiti	Drugs for Neglected Diseases Initiative

Funazungumuza na uwe kumboza habari kuhusu utafiti, kujibu maswali gakwako na fovoye ruhusayo kwa ushiriki wa mwanao na kusaini fomu ii, hedu kwa aryahu ambao kamadima kwandhika, kupata shahidhi andiye asaidhia kukirira utharathibu wa kuvoya idhini na kungiza alama ya dzalagumbe. Kushiriki kahi za utafiti ni hiari; uhuru kuamua kala undahenza mwanao kushiriki kahi za utafiti uu ama la. Undagerwa fomu ya idhini yenye saini /alama ya dzalagumbe iriyochapishwa undapewa ili uenderere kala unakubali kushiriki kahi za utafiti uu.

Mwanao alazwa kahi za sipitali ambaho andahokera matibabu madzo gapatikanago kahi za sipitali ii. Here sehemu ya huduma ya kawaida mambo gathuwago nikukala ganahendwa:

Fundahala sampuli ya mulatso wakati wa kulazwa kolola jinsi figo na ini zihendazho kazi na kwa maambukizi kwa damu na kwa kawaida uchunguzi wa maambukizi kwenye madzi ga utafiti wa utu wa mingo ihendekayo kuumira shindano.

Kwa ahoho akongo ambao manakisiwa kukala na maambukizi, dawa dhidi ya bakteria nikungizwa kahi za mulatso wa kwao kukirira mishipani.

Utafiti uno unahusu noni?

Ana atsanga osini Mario malazwa sipitali na manakisiwa kukala mana maambukizi nikukala manatibiwa na dawa mbiri dhidi ya kidudu cha bakteria ilazhwayo kukirira mishipani. Hata vizho, vidudu zha bakteria vinaenderera kukala na sugu ya dawa dhidi yao ambazo zinahumika kwa kawaida. Ii inadima kureha ugumu wa ahoho kuhola kula kwa makongo gao. Kahi za Afrika, dawa mbadala ambazo zinadima kuhenda kazi zi gali na pia zinadima kusababisha vidudu zha bakteria kukala sugu. Kwa vizho, dawa mbisha mbadala inahitajika. Dawa ambayo inadima kuhumika here dawa mbadala ni 'fosfomycin'. Dawa ii inahumika kuko Ulaya na Marekani kutibu maambukizi kwa atu azima na ahoho na inapatikana kwa bei rahisi lakini kaidzaanza kuhumika Kenya. Funahitaji habari zaidi ili zifusaidie kuelewa kuhusu mahumizi ga fosfomycin kahi za ahoho a Kenya. Ili kumanya vivi, funahenza fungehenza kungeza fosfomycin kahi za dawa za kawaida dhidi ya bakteria ili fupate habari kuhusu kiwango cha 'fosfomycin' kahi za mulatso wa mwana mutsanga baada ya kiwango maalumu cha dawa kulazhwa. Iii indafusaidia kumanya kala kiwango kicho ni sawa kwa ana atsanga enye maambukizi.

Ni hani ahendaye utafiti uno?

Shirika ra utafiti ra afya ra Kenya ni shirika kahi za wizara ya afya rihendaro utafiti kwa lengo ra kutafuta ngira mbidzo za kuchinga na kutibu makongo siku za usoni kwa manufaa ga kila mumwenga. Tatizo mwenga raho ra kiafya ambaro funajeza kudzfundisha zaidi ni jinsi ya kutibu ahoho atsanga enye maambukizi makali.

Utafiti uu undahusisha ahoho 120, 60 mandahokera fosfomycin hamwenga na dawa ya kawaida na o angine 60 mandahokera yo dawa ya kawaida hakeye ambayo kwa kawaida nikukala inalazhwa. Fundahumira bahasha zidzifungwa ili fumuike mwanao kwa kundi mwenga kahi za go makundi mairi ga utafiti kwa ngira mabayo inalazha nafasi sawa ya kukala kahi za kundi rorosi. II inamaanisha fundamwika mwanao kahi za kundi kwa ngira ilazhayo nafasi ya sawa ya kuikwa kahi za kundi mwenga, here muchezo wa kuzungulusha shilingi. Mwanao andakala na nafasi sawa ya kukala kahi za kundi rorosi. Madaktari na auguzi kamana ngira ya kumutsagula mwanao kukala kahi za kundi rorosi.

Indahusisha noni kwangu/kwa mwanangu?

Kala mwanao adzaikwa kahi za kundi rihokeraro fosfomycin, funauza:

Kumupa mwanao matibabu ga kawaida (dawa mbiri dhidi ya bakteria), nay a hahu ya nyongeza fosfomycin kwa wiki mwenga kwa jumula;

Kuhala kiwango kithithe cha mulatso, here nisu kujiko cha chai (mililita 2.5 **kwa jumula**) kwa ajili ya utafiti uu kwa mara 5 wakati mwanao akikala sipitali (mililita 5, hedu madeswe machache, kila wakati). Fundahumira sampuli zizi kulola kiwango cha dawa dhidi ya bakteria kahi za mulatso wa mwanao na kuhenda vipimo zha chembechembe za mulatso wa kwao na viryahu figo na maini vihendazhokazi.

Kuhala sampuli kukirira kuangusa kibinda cha mwanao wakati kala adzalazwa sipital na kumbozwa sipitali, kulola kala kuna mabadiliko kahi za aina ya bakteria kahi za choo cha kwakwe;

Kala daktari akutibuye andaamua kukala mwanao anahitaji kumbozwa sampuli ya madzimadzi ga mongoni ili kulola maambukizi kwa go madzimadzi kazungukago wongo, fundahuma madzimadzi gaga gandigokala gadzasala kula kwa kipimo kiki kwa maabara ga ng'ambo ili kulola kiwango cha dawa dhidi ya bakteria;

Kudza kwa ziara ya thuwirizi baada ya siku 28 ili kulola kala mwanao kana utu, hedu kala wakala na wasiwasi wowose ho mbereni. Fundariha tikiti ya kwako na fidia ya muda wa kwako (shilingi 300) kwa ziara ii.

Mambo mengine gosi gandigohendwa wakati undokala sipitali gandakala sehemu ya vipimo na matibabu ga kawaida gamalwago ni dakitari.

Mwanao akikala mukongo hedu kala una wasiwasi kuhusu afya ya kwakwe kabla ya siku iriyopangwa ya uthuwirizi ya mwezi muwenga, undapiga simu kwa namba **0740310773** hedu umurehe mwanao wadini/kliniki kwa ukaguzi wa daktari.

Kuna madhara gogosi kwa kushiriki kwa mwanangu?

Jambo ra muhimu kwehu kwa kila mushiriki ni huduma ya kwakwe. Dawa huichunguzayo yaidhinishwa kare na inahumika kwa atu azima na ahoho ko Ulaya na sehemu nyingine za dunia, lakini si Kenya. Mwanao andathuwirizwa kwa uhehi ili kulola madhara gogosi ga dawa. Mara kwa mara, madhara ambago gaonewa na kuripotiwa ni harara na kubujika tumbo (na madhara ambago ni nadra sana mabadiliko kahi za kiwango cha munyu kahi za mulatso) ela gaga si rahisi koneka na pia ganadima gakaoneka na dawa dhidi ya bakteria nyingine. Mwanao andathuwirizwa kwa uhehi na agerwe matibabu ga madhara gogosi gadimago kumbola wakati akishiriki kahi za utafiti uu.

Sampuli za mulatso za kupima kiwango cha dawa zindahalwa kwa kuhumira muridza muthithe wa plastiki ambao ni here uryahu ambao dawa zinangizirwa. Kala mwanao andahitaji vipimo zha mulatso zaidi here sehemu ya huduma ya kwakwe, vivi vinadima vikahendwa wakati mumwenga. Kumboza damu kunadima kukasababisha maumivu vichache, kuvarurwa, kubujika na uwezekano muthithe wa maambukizi. Fundahumira utaratibu kwa kumakinika ili kusaidhia kuchinga mambo gaga. Mahumizi ga kapamba wakati wa kuhala sampuli kula kwa kibinda cha mwanao kakusababisha madhara gogosi kwa mwanao.

Kuna manufaa gogosi kwangu/kwa mwanangu kwa kushiriki kahi za utafiti uno?

Mwanao andaguliwa kila siku ni mumwenga wa daktari wehu wa utafiti, hamwenga na muhenzi wa kazi wa sipitali. Fundalazha dawa mbadala dhidi ya vidudu zha bakteria bila mariho kala zindahitajika. Pia fundalazha ukaguzi wa ziada wa kimatibabu wiki 3 baada ya mwanao kumbozwa sipitali, na unaruhusiwa kuwasiliana nasi

wakati wowosi hedu umurehe mwanao ili humuhudumie kuku wodini kabla ya siku ii kala una wasiwasi wowosi kuhusu mwanao. Kakuna manufaa mengine ga mwenge kwa mwenge kwako kwa kushiriki, lakini undafusaidhia kuboresha huduma kwa ahoho siku zidzazo.

Kundakalani nikikahala kushiriki?

Kushiriki kahi za utafiti ni hiari. Uhuru kuamua kala unamala kushiriki kahi za utafiti uu hedu kwenzi. Kala kwenzi mwanao ashiriki, sampuli za damu za utafiti kazindahalwa, idzaho daktarin anadma akamala kumupima mwanao mulatso here kawaida kwa huduma ya kwao. Ukikubali kushiriki vikara, unadima ukagaluza maazogo wakati wowosi na umumboze mwanao kula kwa utafiti na kakuna sampuli ya damu ya zaidi hedu habari za utafiti zindizohalwa. Iii kaindaathiri huduma ya afya ya mwanao vikara na siku zidzazo.

Sampuli zindahendwadze?

Habari zosi na sampuli zindizokusanywa zindaikwa kwa hali ambayo atu anhine kama nadima kuzifikirira. Madzina gam utu binafsi ganambozwa kula kwa sampuli na gabadilishwe na nambari maalumu, ili sampuli zidime kuambatanishwa na ahoho ni atu ambao manahusika na utafiti kwa uheho hakeye. Baadhi ya vipimo zha utafiti ambazho vindahendwa kahi za mulatso vindahendwa Kilifi. Hat vizho, kwa vipimo ambazho kavidima kuhendwa Kenya, sehemu ya sampuli indahumwa ng'ambo kuko Ulaya ili kutambua kiwango cha dawa dhidi ya bakteria kahi za mulatso wa mwanao. Sampuli zinadima kuikwa hadi miaka mitsano.

Ni hani andedima kufikira habari za mwanangu kahi za utafiti uno?

Habari zosi za ashiriki zindizokusanywa kahi za utafiti uu zindahifadhiwa kwa hali ambayo kazindaafikira atu angine kahi za kabati zidzizofungwa na komputa zihitajizo namba maalumu kuvugulwa na zindafikirwa ni atu madzoidhinishwa kahi za utafiti. Habari zindahifadhiwa muhadi utafiti na uchambuzi ugame; na akaguzi a kimatibabu na enye mamlaka ya kisheria (here Bodi ya madawa na sumu ya Kenya [Kenyan Pharmacy and Poisons Board] hedu kamati za maadili) manadima makalola habari zizi ili kuhakikisha utafiti unahendwa sawasawa. Ripoti yoyosi hedu uchapishaji kuhusu utafiti uu kaundahumira dzina ra mushiriki hetu vitambulishi vya kwakwe.

Siku za usoni, habari zindizokusanywa hedu zimbolanazo na utafiti uu zinadima zikahumika kusaidhia tafiti mbisha za utafiti angine haha Kenya na tsi nyingine kuhusu maswali kuhusu afya ya muhoho. Kahi za hali zosi, fundalazha habari kwa utafiti angine kwa angira ambazo kazidima kugunula vitambulishi binafsi zha ashiriki. Kwa mufano, fundausa habari ambazo zinadima kumanyisa atu, here madzina gao na maishiko na fubadilishe habari zizi na namba maalumu. Tafiti zosi za siku zidzazo zihumirazo habari kula kwa utafiti uu ni lazima kwanza ziidhinishwe ni kamati za kitaalamu za haha Kilifi na ya kitaifa ili kuhakikisha kukala maslahi ga ashiriki na jamii zao ganarindwa.

Ni hani adzeruhusu utafiti uno uhendeke?

Tafiti zosi za KEMRI ni sharti ziidhinishwe kabla kuanza ni Bodi huru ya ukaguzi wa maadili, kitengo cha kukagua sayansi na maadili kuko Nairobi na Oxford University Tropical Research Ethics iriyo Uingereza, zilolazo kwa makini mpangilio wa kazi. Ni lazima makubali kukala utafiti ni muhimu, unafaa Kenya na unathuwa mulongozo ukubalikao kitaifa na kimataifa. Iii ni hamwenga na kuhakikisha usalama na haki za ashiriki vinaheshimika.

Je nikikala na swali rorosi?

Unadima ukamuza muhenzi wa kazi wehu yeyosi waswali wakati wowosi. Unadima pia ukawasiliana na kundi ra utafiti kwa kuhumira anuani ithuwayo:

0715 938 077 KEMRI – Nambari ya mradi wa utafiti (Mtu anenaye lugha zha haha)

Ukimala kumuza mutu huru chochosi kuhusu utafiti uu tafadhali wasiliana na:

Meneja wa kitengo cha uhusiano mudzo na jamii, KEMRI Wellcome Trust Research Programme, S. L. Posta 230, Kilifi. Simu: 041 7522 063, Rununu 0723 342 780 hedu 0705 154 386

Hedu

Kiongozi, Kitengo cha kukagua sayansi na maadili cha KEMRI, S. L. Posta 54840-00200, Nairobi; Nambari ya Simu: 0717 719477; 0776 399979 Barua pepe: seru@kemri.org

MSHIRIKI/MZAZI/MLEZI SASA APEWE NAKALA ILIYOWEKWA SAHIHI

Utafiti wa kupima viwango zha dawa ya nyongeza dhidi ya bakteria (fosfomycin) kahi za kutibu maambukizi makali kahi za ahoho atsanga (NeoFosfo)

Mimi nikikala ni muzhazi/murezi wa, _____ (dzina), nidzaelezerwa kuhusu utafiti uu. Nidzaelewa gosi gadzigoshomwa na maswali gangu gajibiwa kikamilifu.

- ☐ Nakubali mwanangu ashiriki kahi za utafiti uu
- ☐ Nakubali sampuli zihifadhiwe kwa tafiti za siku zidzazo
- ☐ Nakubali sampuli zisafirishwe ng'ambo ili kupima viwango zha dawa kahi za mulatso

Ninaelewa kwamba nadima kugaluzwa maazo ganu wakati wowosi na kaindaniathiri mimi hedu mwanangu kizhozhosi.

Sahihi ya muzhazi/murezi: _____ **Tarehe** _____

Dzina ra muzhazi/murezi: _____ **Saa** _____

(Tafadhali ndhika dzina kwa herufi bomu)

Ninathibitisha kukala nidzathuwiriza utaratibu wa kuvoya idhini wa utafiti uu ili kuvoya idhini kula kwa mushiriki. Ni wazi kukala adzaelewa hali na lengo ra utafiti na alazha idhini ya kushiriki kahi za utafiti. Adzagerwa nafasi ya kuuza maswali ambago gajibiwa kikamilifu.

Sahihi ya mtafiti/muwakilishi: _____ **Tarehe** _____

Dzina ra mtafiti/muwakilishi: _____ **Saa** _____ Tafadhali ndhika dzina kwa herufi bomu)

Ni muhimu tu kala mushiriki kadima kushoma:

*Ninathibitisha kukala habari kuhusu utafiti uu zaelezwa kwa usahihi na ni wazi kukala zaeleweka kwa mushiriki na kukala idhini yalazhwa kwa hiari ni mushiriki.

Sahihi ya shahidi: _____ **Tarehe** _____

Dzina ra shahidi: _____ **Saa** _____

(Tafadhali ndhika dzina kwa herufi bomu)

***Shahidi ni utu ariyehuru kula kwa utafiti hedu muhenzi wa kazi ambaye kahisikire na kuvoya idhini**

Alama ya dzalagumbe la mushiriki here adzohadzwa ho dzulu kala kadima kundhika:

MUSHIRIKI VIKARA NI AGERWE NAKALA IDZIYOIKWA SAHIHI ADZIIKIRE



Randomised Controlled Trial of Fosfomycin in Neonatal Sepsis: Safety and Pharmacokinetics

Supplement 2

Additional methods and results

Table of Contents

Supplementary Methods2

 Study Site and Population2

 Screening and Enrolment of Study Participants2

 Procedures2

 Study Treatment2

 Clinical Definitions3

 Safety Assessment and Follow up3

 PK Sample Processing and Measurement3

Supplementary Figures4

 Figure S1: Outline of study procedures4

 Figure S2. Plasma concentration-time curves for A: IV and B: oral fosfomycin administered at 100mg/kg/dose twice daily.5

Supplementary Tables6

 Table S1: Baseline laboratory test parameters by treatment arm6

 Table S2: Blood and CSF culture results by treatment arm7

 Table S3: Standard-of-care (SOC) antibiotic changes and day 2 sample collection8

 Table S4: Serious and non-serious AEs by treatment arm, severity and MedDRA coding classification9

 Table S5. Anticipated adverse events by treatment arm.....13

 Table S6: AE outcome at study termination excluding events that either resolved or occurred in neonates who died14

 Table S7 Simulated Steady State PK Summary – Sub-populations15

References16

Supplementary Methods

Study Site and Population

Kilifi County Hospital (KCH) is a Level IV government health facility located along the Kenyan coast that serves a mostly rural population including patient referrals from within Kilifi county and surrounding counties. The Kenya Medical Research Institute – Wellcome Trust Research Programme (KWTRP) is located at KCH. The paediatric ward has a dedicated neonatal unit with 3 incubators and 21 cots while the high dependency unit (HDU) has 4 incubators and 12 cots, with capacity to accommodate more neonates within the main HDU ward which has six beds. Mechanical ventilation and central venous lines for monitoring and parenteral feeding are not available at KCH. Treatment of sick neonates at KCH is done according to the Kenya national paediatric guidelines.¹

Screening and Enrolment of Study Participants

All neonates requiring admission to KCH were screened at presentation to the ward and this was enhanced by the use of an electronic-based data management system (Kilifi Integrated Data Management System). Assessment of eligibility was done by qualified clinicians and included a medical history, clinical examination, and review of admission complete blood count (CBC) and biochemistry results which were done for all admissions as part of routine care. Inclusion and exclusion criteria are outlined in the manuscript and **Supplement 1** (trial protocol). Gestational age was estimated using the Ballard Maturational Assessment.² Screening procedures were done in parallel with admission procedures, prioritizing the latter to ensure that treatment of sick neonates was not delayed. Trained study staff undertook the informed consent process with parents or legal guardians of neonates who were found to be eligible for study inclusion and those who provided consent for study participation were transferred to the HDU for continued treatment, randomization to treatment arm and additional study procedures.

Procedures

All neonates had blood samples for CBC, clinical biochemistry, blood slide for malaria parasites, and blood culture taken at admission as part of routine investigations. A lumbar puncture (LP) was performed as indicated according to Kenya national paediatric guidelines¹ in neonates lacking contraindications of an LP.³ All trial participants were reviewed daily by trained clinicians until discharge. Concomitant medication administered as a result of ongoing illness or adverse events (AEs) was documented in appropriate case report forms (CRFs). Blood samples for CBC and biochemistry were obtained at baseline (at admission as part of clinical care), 48 hours and 7 days for those still hospitalized. Additional samples were taken if clinically indicated. To minimize the number of times SOC-F participants underwent venepuncture, collection of blood samples for safety assessment was done at the same time as pharmacokinetics (PK) sample collection. CBC and biochemistry tests were measured using Coulter AcT 5Diff CP (Beckman Coulter, Inc. USA) and iLab Aries (Instrumentation Laboratory, USA) respectively at the KWTRP laboratory, and results were reviewed in real time for patient care. Blood samples for culture were collected and processed in BACTEC Peds Plus/F bottles with a BACTEC 9050 instrument (Becton Dickinson, Oxford, UK). Positive samples were sub-cultured on standard media by routine microbiological techniques as previously described.⁴ Cerebrospinal samples were collected, processed and cultured as previously described and organisms identified using standard methods.^{5,6}

Study Treatment

SOC antibiotics (ampicillin [50mg/kg/dose twice daily if age ≤ 7 days or thrice daily if > 7 days] plus gentamicin [3mg/kg or 5mg/kg once daily for participants < 2 kg or ≥ 2 kg respectively] were prescribed according to WHO⁷ and Kenya national paediatric guidelines.¹ Second line antibiotics were prescribed according to guidelines, or in response to culture results.

Two formulations of fosfomycin were administered in this study as follows:

1. Fomicyt™ 40 mg/ml solution powder for infusion (Infectopharm GmbH)
 - i. Supplied in clear type-II glass bottles with a rubber stopper (bromobutyl rubber) and pull-off cap containing 2g fosfomycin (in 100 ml bottle)
 - ii. IV dose was prescribed as 100mg /kg bodyweight, twice daily for 2 days or until the participant was able to take oral fosfomycin.
 - iii. The solution was prepared for infusion by dissolving 2g fosfomycin powder in 50ml of 5% or 10% dextrose infusion.
 - iv. IV fosfomycin was administered as a slow push.
 - v. Each bottle was dispensed to a single participant and used for one dose only.

2. Fosfocina® 250mg/5ml powder for oral suspension (Laboratorios ERN S.A)
 - i. The suspension is presented in glass bottles with a quantity sufficient to prepare 120ml of solution.
 - ii. The oral dose was 100mg/kg bodyweight, twice daily for up to 5 days.
 - iii. The oral suspension was prepared by filling the bottle with water to the level marked with an arrow and shaking it well before use.
 - iv. Oral fosfomycin was administered via syringe, spoon or nasogastric tube.
 - v. Once reconstituted the bottle would be stored under temperature monitoring conditions between 2 and 8°C. Each bottle was dispensed to a single participant and used for 24 hours only (2 doses).

Clinical Definitions

Hypoglycaemia was defined as a random blood sugar ≤ 2.6 mmol/L as measured using ILab Aries (Instrumentation Laboratory, USA) or Accu-Check bedside glucometer (Roche, USA). Thrombocytopenia was defined as a platelet count $< 150 \times 10^3/\mu\text{L}$, and hypothermia as axillary body temperature $< 35.5^\circ\text{C}$. Oxygen saturation $< 90\%$ in room air or while receiving oxygen support was considered as hypoxia. A participant was in respiratory distress if observed to have at least two of the following: tachypnoea (respiratory rate ≥ 60 breaths/minute), grunting, and chest wall indrawing. Diarrhoea was defined as presence of at least three loose motions in 24 hours, and a participant would be in shock if they presented with cool peripheries, a rapid and weak pulse, and delayed capillary refill time > 2 seconds. Definite meningitis was defined as: i) positive cerebrospinal (CSF) culture; or ii) positive CSF latex agglutination test; or iii) positive CSF Gram stain microscopy; or iv) CSF leukocyte count ≥ 20 cells/ μL plus positive blood culture for known pathogen. Possible meningitis was defined as CSF leukocyte count ≥ 20 cells/ μL and negative blood culture. Clinically suspected sepsis was based on clinician's judgement at admission following WHO and Kenya national guidelines. Culture-confirmed sepsis was defined as a positive blood culture in the presence of clinical features suggestive of sepsis.

Safety Assessment and Follow up

All solicited and unsolicited AEs were evaluated for severity, seriousness and causality with each study treatment. Abnormal laboratory parameters were reported if found to be clinically significant e.g. suggesting a new or worsening pre-existing disease and/or organ toxicity, leading to discontinuation of medication, or requiring medical intervention. AEs were prospectively recorded and coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 22.0. Severity was classified according to Division of AIDS Table for Grading of Adult and Paediatric Adverse Events (DAIDS) version 2.1. AE grading not described on the DAIDS scale was done as follows: mild (does not interfere with participant's usual functions), moderate (interferes to some extent with usual functions), severe (interferes significantly with usual functions), life-threatening (participant is at risk of death at the time of the AE), or death.


Day 28 visit was conducted at the study clinic for most participants. Non-attenders were contacted by phone and/or home tracing. Families were invited to make unscheduled visits in case of illness after hospital discharge up to day 28.

PK Sample Processing and Measurement

Plasma and cerebrospinal fluid (CSF) samples were centrifuged at 3,000RPM (1351 RCF) for 5 minutes then separated and frozen at -80°C within 30 minutes of collection. Samples were shipped to Analytical Services International Ltd., St. Georges University of London, UK. Fosfomycin concentration in plasma and CSF samples was assessed via an in-house validated Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) assay, including for frozen storage stability. The lower limit of quantification for plasma and CSF was 5mg/L and 1mg/L respectively. Assay methodology and fosfomycin stability data are described elsewhere.⁸


Supplementary Figures

Figure S1: Outline of study procedures



Abbreviations: LP, lumbar puncture; CPR, cardiopulmonary resuscitation; HIE, hypoxic ischaemic encephalopathy; SOC, standard of care; IV, intravenous; PK, pharmacokinetic.

Figure S2. Plasma concentration-time curves for A: IV and B: oral fosfomycin administered at 100mg/kg/dose twice daily.



Supplementary Tables

Table S1: Baseline laboratory test parameters by treatment arm

Parameter	SOC (n=59)	SOC-F (n=61)	Overall (n=120)
Haematology			
Haemoglobin (g/dL)	16 (2.9)	16 (2.3)	16 (2.6)
MCV (fl)	102 (9.0)	101 (8.0)	101 (8.5)
WBC (x10 ³ /μL)	16 (7.7)	16 (7.9)	16 (7.7)
Neutrophils (x10 ³ /μL)	7.5 (4.3)	7.6 (5.2)	7.6 (4.8)
Lymphocytes (x10 ³ /μL)	5.9 (3.6)	5.5 (4.3)	5.7 (4.0)
Monocytes (x10 ³ /μL)	1.3 (0.9)	1.4 (1.0)	1.4 (0.9)
Eosinophils (x10 ³ /μL)	0.3 (0.2)	0.3 (0.3)	0.3 (0.2)
Basophils (x10 ³ /μL)	1.1 (1.5)	1.0 (1.0)	1.1 (1.2)
Platelets (x10 ³ /μL)	248 (118)	268 (143)	258 (132)
Chemistry			
Creatinine (μmol/L)	92 (28)	89 (24)	90 (26)
Sodium (mmol/L)	135 (4.1)	136 (5.3)	136 (4.7)
Potassium (mmol/L)	4.3 (0.6)	4.3 (0.7)	4.3 (0.7)
AST (U/L)	91 (58)	82 (47)	86 (52)
ALT (U/L)	38 (35)	28 (20)	32 (28)
ALP (μmol/L)	225 (113)	224 (83)	225 (97)
Albumin (g/dL)	37 (4.6)	35 (5.0)	36 (4.9)
Total bilirubin (μmol/L)	58 (57)	78 (79)	68 (70)
Calcium (mmol/L)	2.3 (0.2)	2.3 (0.2)	2.3 (0.2)
Magnesium (mmol/L)	3.0 (13)	0.8 (0.2)	0.8 (8.9)
Phosphate (mmol/L)	1.9 (0.5)	2.1 (0.8)	2.0 (0.7)
Glucose (mmol/L)	3.7 (2.1)	3.4 (1.5)	3.6 (1.8)
Urea (mmol/L)	4.0 (3.4)	3.8 (2.1)	3.9 (2.8)
GGT (U/L)	119 (89)	116 (80)	117 (84)
Data are mean (sd). Abbreviations: g/dL, gram/decilitre; MCV, mean corpuscular volume; fl, femtoliters; WBC, white blood cell; μL, microliter; μmol/L, micromole/litre; mmol/L, mmol/litre; U/L, units/litre; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase. Missing parameters: i) All haematological parameters (2 SOC and 1 SOC-F [sample obtained but clotted]) ii) Chemistry parameters (insufficient samples due to low sampling volume or haemoconcentration): Creatinine (1 SOC), ALT (22 SOC, 15 SOC-F), AST (21 SOC, 14 SOC-F), ALP (21 SOC, 13 SOC-F), Albumin (20 SOC, 10 SOC-F), total bilirubin (1 SOC-F), calcium (23 SOC, 12 SOC-F), magnesium (22 SOC, 18 SOC-F), phosphate (22 SOC, 15 SOC-F), glucose (3 SOC, 4 SOC-F), urea (23 SOC, 19 SOC-F), GGT (24 SOC, 16 SOC-F). 1 SOC participant missed serum creatinine at enrolment resulting in a protocol deviation. However, serum creatinine was 107 μmol/L a few hours after enrolment, 101 μmol/L at 48 hours, and 78 μmol/L prior to discharge.			

Table S2: Blood and CSF culture results by treatment arm

	SOC (n=59)		SOC-F (n=61)	
Isolate	CSF culture	Blood culture	CSF culture	Blood culture
Pathogen				
<i>Acinetobacter</i> spp.	0	1 ^a	0	0
<i>Streptococcus</i> Group B	0	0	0	1 ^b
Presumed non-significant				
<i>Bacillus</i> spp.	1	0	0	1
<i>Corynebacterium</i> spp.	0	2	0	0
<i>L. adecarboxylata</i>	0	0	0	1
<i>S. epidermidis</i>	0	0	0	1
<i>S. haemolyticus</i>	0	5	0	2
<i>S. hominis</i>	0	3	0	4
Data are n				
^a <i>Acinetobacter</i> spp. susceptible to gentamicin;				
^b <i>Streptococcus</i> Group B susceptible to penicillin.				

Table S3: Standard-of-care (SOC) antibiotic changes and day 2 sample collection

No.	1 st line antibiotics	Date started	Date switched (specify)	Indication for antibiotics/change	Date of day 2 samples	Date IV SOC treatment stopped	Date fosfomycin stopped
<i>SOC 1</i>	Amp + gent	07May18	08May18 (clox + gent)	Septic skin lesions	09May18	13May18	N/A
<i>SOC 2</i>	Amp + gent	07Jul18	08Jul18 (ceftriaxone)	Meningitis	09Jul18	21Jul18	N/A
<i>SOC 3</i>	Amp + gent	23Jul18	N/A	Skin infection	25Jul18	26Jul18	N/A
<i>SOC 4</i>	Amp + gent	24Jul18	24Jul18 (ceftriaxone)	Clinical deterioration	26Jul18	02Aug18	N/A
<i>SOC 5</i>	Ceftriaxone	24Aug18	N/A	Suspected meningitis	26Aug18	27Aug18	N/A
<i>SOC 6</i>	Amp + gent	24Sep18	27Sep18 (ceftriaxone)	Clinical deterioration	27Sep18	03Oct18	N/A
<i>SOC 7</i>	Amp + gent	05Oct18	07Oct18 (ceftriaxone)	Possible meningitis	07Oct18	18Oct18	N/A
<i>SOC 8</i>	Amp + gent	06Oct18	14Oct18 (ceftriaxone)	Clinical deterioration	08Oct18	20Oct18	N/A
<i>SOC 9</i>	Amp + gent	01Nov18	02Nov18 (ceftriaxone)	Meningitis	04Nov18	15Nov18	N/A
<i>SOC 10</i>	Amp + gent	01Nov18	02Nov18 (ceftriaxone)	Suspected meningitis	04Nov18	14Nov18	N/A
<i>SOC 11</i>	Amp + gent	03Nov18	09Nov18 (ceftriaxone)	Clinical deterioration	06Nov18	13Nov18	N/A
<i>SOC 12</i>	Amp + gent	07Nov18	09Nov18 (ceftriaxone)	Clinical deterioration	09Nov18	13Nov18	N/A
<i>SOC 13</i>	Amp + gent	08Nov18	15Nov18 (ceftriaxone)	Clinical deterioration	11Nov18	19Nov18	N/A
<i>SOC 14</i>	Amp + gent	23Nov18	27Nov18 (ceftriaxone)	Bacteraemia	26Nov18	02Dec18	N/A
<i>SOC 15</i>	Clox + gent	08Jan19	N/A	Skin infection	10Jan19	11Jan19	N/A
<i>SOC-F 1</i>	Amp + gent	03May18	03May18 (ceftriaxone)	Bacteraemia, meningitis	05May18	16May18	09May18
<i>SOC-F 2</i>	Amp + gent	06Jun18	07Jun18 (ceftriaxone)	Clinical deterioration	08Jun18	11Jun18	12Jun18
<i>SOC-F 3</i>	Amp + gent	24Jul18	25Jul18 (ceftriaxone)	Clinical deterioration	NA (died)	25Jul18	25Jul18
<i>SOC-F 4</i>	Amp + gent	13Aug18	17Aug18 (ceftriaxone)	Possible meningitis	15Aug18	23Aug18	19Aug18
<i>SOC-F 5</i>	Amp + gent	29Oct18	01Nov18 (ceftriaxone)	Clinical deterioration	31Oct18	02Nov18	03Nov18
<i>SOC-F 6</i>	Amp + gent	29Oct18	29Oct18 (cefotaxime)	Clinical deterioration, hyperbilirubinemia	31Oct18	01Nov18	01Nov18
<i>SOC-F 7</i>	Amp + gent	02Nov18	05Nov18 (ceftriaxone)	Meningitis	04Nov18	16Nov18	09Nov18
<i>SOC-F 8</i>	Amp + gent	06Nov18	09Nov18 (ceftriaxone)	Clinical deterioration	08Nov18	13Nov18	09Nov18
<i>SOC-F 9</i>	Amp + gent	24Nov18	25Nov18 (ceftriaxone)	Clinical deterioration	27Nov18	29Nov18	29Nov18
<i>SOC-F 10</i>	Amp + gent	03Dec18	04Dec18 (ceftriaxone)	Clinical deterioration	06Dec18	06Dec18	07Dec18
Abbreviations: SOC, Standard-of-care; SOC-F, Standard-of-care plus fosfomycin; amp, ampicillin; gent, gentamicin; clox, cloxacillin; N/A, not applicable.							

Table S4: Serious and non-serious AEs by treatment arm, severity and MedDRA coding classification

	SOC (n=34)						SOC-F (n=25)					
DAIDS Grade	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Blood and lymphatic system disorders												
Anaemia	1	1	0	1	0	3	0	1	0	0	0	1
Neutropenia	0	0	1	0	0	1	0	0	0	0	0	0
Thrombocytopenia	0	2	2	0	0	4	0	2	1	0	0	3
Cardiac disorders												
Bradycardia	2	0	0	0	0	2	2	0	0	0	0	2
Congenital, familial and genetic												
Atrial septal defect	0	0	0	0	0	0	0	1	1 ^a	0	0	2
Congenital intestinal malformation, aggravated	0	0	0	0	1 ^a	1	0	0	0	0	0	0
Patent ductus arteriosus	0	0	0	0	0	0	0	1	0	0	0	1
Tetralogy of Fallot, aggravated	0	0	0	0	0	0	0	0	0	0	2 ^a	2
Eye disorders												
Conjunctivitis	1	0	0	0	0	1	1	0	0	0	0	1
Eye discharge	1	0	0	0	0	1	0	0	0	0	0	0
Gastrointestinal disorders												
Abdominal distension	0	1	0	0	0	1	0	0	0	0	0	0

	SOC (n=34)						SOC-F (n=25)					
DAIDS Grade	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Diarrhoea	0	0	0	0	0	0	0	1	0	0	0	1
Vomiting	0	0	0	0	0	0	1	0	0	0	0	1
General disorders and administrative site conditions												
Fever neonatal	0	1 ^b	0	0	0	1	0	0	0	0	0	0
Hypothermia	4	0	0	0	0	4	2	0	0	0	0	2
Oedema	0	1	0	0	0	1	0	0	0	0	0	0
Hepatobiliary disorders												
Jaundice	2	0	0	0	0	2	0	0	0	0	0	0
Infections and infestations												
Acrodermatitis	1	0	0	0	0	1	1	0	0	0	0	1
Lower respiratory tract infection	0	1	0	0	0	1	0	0	0	0	0	0
Meningitis neonatal	0	0	1	0	0	1	0	0	0	0	0	0
Neonatal sepsis, aggravated	0	0	0	0	2	2	0	0	0	0	1 ^a	1
Pneumonia	0	1 ^b	1 ^b	0	0	2	0	0	0	0	0	0
Skin infection	2	0	0	0	0	2	0	0	0	0	0	0
Upper respiratory tract infection	1	0	0	0	0	1	1	0	0	0	0	1

	SOC (n=34)						SOC-F (n=25)					
DAIDS Grade	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Investigations												
Hepatic enzyme increased	0	1	1	0	0	2	0	0	0	0	0	0
Metabolism and nutrition disorders												
Failure to thrive	1	0	0	0	0	1	0	0	0	0	0	0
Hypoglycaemia neonatal	2	0	2	2	0	6	0	1	2	2	0	5
Hypokalaemia	2	0	0	0	0	2	1	2	0	0	0	3
Nervous system disorders												
Neonatal seizure	0	0	1	0	1	2	0	1	2	0	0	3
Reproductive system and breast disorders												
Vaginal haemorrhage	1	0	0	0	0	1	0	0	0	0	0	0
Respiratory, thoracic and mediastinal disorders												
Infantile apnoea	0	0	0	1	1 ^a	2	0	0	0	0	0	0
Neonatal asphyxia	0	0	0	0	0	0	0	0	1	0	1 ^a	2
Skin and subcutaneous tissue disorders												
Dermatitis, diaper	0	0	0	0	0	0	1	0	0	0	0	1
Rash	1	0	0	0	0	1	2	0	0	0	0	2
Skin lesion	1	0	0	0	0	1	0	0	0	0	0	0

	SOC (n=34)						SOC-F (n=25)					
DAIDS Grade	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total
Total	23	9	9	4	5	50	12	10	7	2	4	35
Data are n												
*Worsening of pre-existing conditions and those resulting in death included: Tetralogy of Fallot (2 SOC-F); congenital intestinal malformation (1 SOC); birth asphyxia (1 SOC-F); worsening neonatal sepsis together with atrial septal defect (1 SOC-F); birth asphyxia and infantile apnoea (1 SOC)												
‡Three SOC participants were re-admitted to hospital and discharged home alive (pneumonia [n=2] and febrile illness of unknown origin [n=1])												

Table S5. Anticipated adverse events by treatment arm

	SOC (n=59)	SOC-F (n=61)	All (n=120)
Anaemia	2	0	2
Atrial Septal Defect	0	1	1
Congenital intestinal malformation	1	0	1
Hypoglycaemia	6	4	10
Infantile apnoea	1	0	1
Jaundice	2	0	2
Meningitis neonatal	1	0	1
Neonatal asphyxia	0	2	2
Neonatal seizure	2	3	5
Neonatal sepsis	1	1	2
Patent Ductus Arteriosus	0	1	1
Tetralogy of Fallot	0	2	2
Total	16	14	30
Data are n			

Table S6: AE outcome at study termination excluding events that either resolved or occurred in neonates who died

Outcome	SOC (n=17)	SOC-F (n=10)
Resolving (n=5)	Anaemia (1)	Acrodermatitis (1)
	Conjunctivitis (1)	Rash (1)
	Eye discharge (1)	
Not resolved (n=20)	Anaemia (1)	Atrial septal defect (2)
	Acrodermatitis (1)	Hypokalaemia (1)
	Failure to thrive (1)	Patent ductus arteriosus (1)
	Hepatic enzyme increased (2)	Thrombocytopenia (3)
	Neutropenia (1)	
	Oedema (1)	
	Rash (1)	
	Skin lesion (1)	
	Skin infection (2)	
	Thrombocytopenia (2)	
Resolved with sequelae (n=2)	Thrombocytopenia (1)	Hypokalaemia (1)
Data are n		

Table S7 Simulated Steady State PK Summary – Sub-populations

Regimen	Group	AUC48-72 (hr*mg/L)			Cmin (mg/L)			Cmax (mg/L)			T>MIC (hr)		
		P5	P50	P95	P5	P50	P95	P5	P50	P95	P5	P50	P95
100_IV	1	2962.5	5554.6	10019.0	34.2	126.6	304.9	379.3	497.8	687.7	24.0	24.0	24.0
150_IV	1	4443.8	8331.9	15028.4	51.2	189.9	457.3	568.9	746.6	1031.6	24.0	24.0	24.0
200_IV	1	5925.0	11109.3	20037.9	68.32	253.2	609.7	758.6	995.5	1375.4	24.0	24.0	24.0
100_PO	1	1115.2	2542.9	4968.8	38.8	95.8	200.5	51.0	113.3	218.6	24.0	24.0	24.0
200_PO	1	2230.3	5085.8	9937.6	77.7	191.5	401.1	102.0	226.6	437.2	24.0	24.0	24.0
300_PO	1	3345.5	7628.7	14906.4	116.5	287.3	601.6	153.0	340.0	655.7	24.0	24.0	24.0
100_IV	2	1256.5	2086.9	3606.5	1.8	13.8	56.9	308.6	385.2	478.8	9.8	17.0	24.0
150_IV	2	1884.7	3130.3	5409.7	2.7	20.7	85.4	462.9	577.8	718.2	11.8	20.4	24.0
200_IV	2	2512.9	4173.8	7212.9	3.5	27.5	113.9	617.2	770.4	957.5	13.2	22.6	24.0
100_PO	2	464.5	959.9	1890.0	13.4	30.4	66.3	23.0	46.1	86.0	0.0	22.1	24.0
200_PO	2	929.1	1919.9	3779.9	26.8	60.8	132.5	45.9	92.2	172.0	19.0	24.0	24.0
300_PO	2	1393.6	2879.8	5669.9	40.1	91.2	198.8	68.9	138.3	258.0	24.0	24.0	24.0
100_IV	3	1659.3	3056.4	5508.1	6.4	38.3	120.6	325.2	413.4	517.4	13.4	24.0	24.0
150_IV	3	2488.9	4584.6	8262.2	9.5	57.4	180.8	487.8	620.1	776.1	16.2	24.0	24.0
200_IV	3	3318.5	6112.8	11016.2	12.7	76.5	241.1	650.4	826.8	1034.8	18.0	24.0	24.0
100_PO	3	646.3	1392.7	2817.2	20.2	47.7	104.9	30.8	64.4	125.7	0.0	24.0	24.0
200_PO	3	1292.6	2785.5	5634.4	40.4	95.5	209.7	61.6	128.7	251.4	24.0	24.0	24.0
300_PO	3	1938.9	4178.2	8451.6	60.6	143.2	314.6	92.4	193.1	377.0	24.0	24.0	24.0
100_IV	4	2271.0	3883.8	6805.8	17.5	63.6	173.0	345.9	438.5	567.4	18.6	24.0	24.0
150_IV	4	3406.5	5825.7	10208.7	26.2	95.4	259.6	518.8	657.7	851.1	22.2	24.0	24.0
200_IV	4	4541.9	7767.6	13611.6	34.9	127.3	346.1	691.7	877.0	1134.9	24.0	24.0	24.0
100_PO	4	860.8	1792.9	3500.4	28.5	63.9	132.7	40.2	80.9	154.8	19.1	24.0	24.0
200_PO	4	1721.7	3585.8	7000.8	57.0	127.8	265.5	80.5	161.8	309.6	24.0	24.0	24.0
300_PO	4	2582.5	5378.7	10501.2	85.5	191.7	398.2	120.7	242.6	464.4	24.0	24.0	24.0
Abbreviations: AUC, area under concentration-time curve; C, plasma concentration; min, minimum; max, maximum; T>MIC, fraction of time plasma concentrations exceeds the MIC (minimum inhibitory concentration); mg, milligram; L, litre; hr, hour; P5, 5 th percentile; P50, median; P95, 95 th percentile; IV, intravenous; PO, oral; WT, weight; PNA, postnatal age. T>MIC assumes MIC=32mg/L Group 1: WT >1.5kg + PNA ≤7days Group 2: WT >1.5kg + PNA >7days Group 3: WT ≤1.5kg + PNA ≤7days Group 4: WT ≤1.5kg + PNA >7days													

References

1. MOH. Basic Paediatric Protocols for ages up to 5 years. Fourth ed, February 2016.
2. Ballard JL, Khoury JC, Wedig K, et al. New Ballard Score, expanded to include extremely premature infants. *The Journal of pediatrics* 1991;119(3):417-23. doi: 10.1016/s0022-3476(05)82056-6 [published Online First: 1991/09/01]
3. Schulga P, Grattan R, Napier C, et al. How to use... lumbar puncture in children. *Arch Dis Child Educ Pract Ed* 2015;100(5):264-71. doi: 10.1136/archdischild-2014-307600 [published Online First: 2015/06/25]
4. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. *The New England journal of medicine* 2005;352(1):39-47. doi: 10.1056/NEJMoa040275 [published Online First: 2005/01/07]
5. Berkley JA, Mwangi I, Mellington F, et al. Cerebral malaria versus bacterial meningitis in children with impaired consciousness. *QJM : monthly journal of the Association of Physicians* 1999;92(3):151-7. [published Online First: 1999/05/18]
6. Mwaniki MK, Talbert AW, Njuguna P, et al. Clinical indicators of bacterial meningitis among neonates and young infants in rural Kenya. *BMC infectious diseases* 2011;11:301. doi: 10.1186/1471-2334-11-301 [published Online First: 2011/11/03]
7. WHO. Pocket book of hospital care for children: Guidelines for the management of common childhood illnesses. Second ed: World Health Organization, 2013:412.
8. Kane Z, Gastine S, Obiero C, et al. IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. *The Journal of antimicrobial chemotherapy* 2021;76(7):1855-64. doi: 10.1093/jac/dkab083 [published Online First: 2021/04/16]

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Intravenous and Oral Fosfomycin in Hospitalised Neonates with Clinical Sepsis: An Open-label, Safety and Pharmacokinetic study (neoFosfo)

**STATISTICAL ANALYSIS PLAN
(SAP)**

 2 Drugs for Neglected Diseases <i>initiative</i>	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
---	--	-------------------------	--------------------

SIGNATURES:

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Dr. Raymond Omollo, Head of Data Centre & Statistician

Institution Drugs for Neglected Diseases *initiative*

Address P.O. Box 20778-00202 Nairobi, Kenya

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Prof. Sarah Walker, Statistician

Institution University College, London, UK

Address

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Erika Correia, Clinical Research Associate

Institution GARDP

Address Chemin Louis Dunant, 15, 1202 Geneva, Switzerland

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Dr. Borna Nyaoke, Clinical Trial Manager

Institution GARDP

Address P.O. Box 20778-00202 Nairobi, Kenya

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Sally Ellis, Project Leader

Institution GARDP

Address Chemin Louis Dunant, 15, 1202 Geneva, Switzerland

Signature _____ **Date (dd/mmm/yyyy)** _____

Name Prof James A Berkley, PI

Institution KEMRI/Wellcome Trust Research Programme

Address P.O. Box 230-80108 Kilifi, Kenya

DNDi 2 AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
---	------------------------------------	------------------	-------------

Table of CONTENTS

Table of CONTENTS 3

List of Tables 5

List of Figures 6

Abbreviations..... 7

1. Scope 8

2. Protocol Summary..... 9

3. Trial Objectives and endpoints 10

 3.1. Trial Objectives10

 3.1.1. General Objective10

 3.1.2. Specific Objectives10

 3.2. Trial Endpoints10

 3.2.1. Primary endpoint.....10

 3.2.2. Secondary endpoints.....10

4. Trial Design 10

 4.1. Study design10

 4.2. Study duration11

 4.3. Study Population11

 4.3.1. Selection of Subjects11

 4.3.2. Inclusion criteria11

 4.3.3. Exclusion criteria11

 4.4. Sample Size Determination12

5. Study Assessments 12

 5.1. Schedule of events.....12

 5.2. Assessment of Safety.....14

 5.2.1. Safety Reporting14

 5.2.2. Clinical Laboratory assessments14

 5.2.3. Anticipated Events in neonatal setting14

6. Planned Analysis 15

 6.1. Interim Analysis15

 6.2. Final Analysis15

7. Statistical Methods..... 16

 7.1 Data Transformation16

DNDi 2 AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
---	------------------------------------	------------------	-------------

7.2

Baseline Data.....

16

7.3

Analyses set.....

16

7.4

Safety Analysis

16

7.5

Biological Parameters

17

7.5.1

Shift tables

17

7.5.2

Graphical representations

17

7.6

Software

17

8.

Results

18

8.1.

Trial Profile

18

8.2.

Patient Characteristics and baseline comparisons

18

8.3.

Exploratory Analysis

23

8.3.1.

Graphical representations

23

8.3.2.

Change in Lab values

24

8.5.

Safety Analysis: Adverse Events

26

References

39

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

List of Tables

Table 1: Anticipated Events in Neonatal Setting	15
Table 2: Baseline demographic characteristics by the treatment group	19
Table 3: Baseline anthropometric and vital signs by the treatment group	19
Table 4: Baseline clinical symptoms by the treatment group	20
Table 5: Past medical history and concomitant illness by the treatment group	20
Table 6: Baseline summary of haematological parameters by treatment group	20
Table 7: Baseline summary of blood chemistry parameters by treatment group	21
Table 8: Baseline summary of Blood Gas parameters by treatment group	23
Table 9: Plasma Sodium Concentrations	25
Table 10: Creatinine	25
Table 11: Potassium Concentrations	25
Table 12: ALT	25
Table 13: Number of patients experiencing adverse events	26
Table 14. Serious adverse events listing	27
Table 15. Treatment discontinuation: AE and other reasons	27
Table 16. Serious and non-serious AEs by relationship to study medication	27
Table 17. Serious and non-serious AEs by severity	27
Table 18: Anticipated events by the treatment group	28
Table 19: Shift table for Haemoglobin	29
Table 20: Shift table for White Blood Cells	30
Table 21: Shift table for Neutrophils	31
Table 22: Shift table for Lymphocytes	32
Table 23: Shift table for Platelets	33
Table 24: Shift table for Sodium	34
Table 25: Shift table for SGOT/AST	35
Table 26: Shift table for Alkaline Phosphatase	36
Table 27: Shift table for Creatinine	37

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	------------------------------------	------------------	-------------

List of Figures

Figure 1: Schedule of Events	13
Figure 2: Participant Flow	18
Figure 3: Time trajectories for heart rate (bpm)	23
Figure 4: Box plot for heart rate (bpm)	23
Figure 5: Time trajectories for respiratory rate (bpm)	23
Figure 6: Box plot for respiratory rate (bpm)	23
Figure 7: Time trajectories for temperature (°C)	23
Figure 8: Box plot for temperature (°C)	24
Figure 9: Time trajectories for SaO₂ (%)	24
Figure 10: Box plot for SaO₂ (%)	24
Figure 11: Time trajectories for White cell count (x10³/μL)	24
Figure 12: Box plot for White cell count (x10³/μL)	24
Figure 13: Scatter plot for White cell count (x10³/μL)	24
Figure 14: Time trajectories for SGPT/ALT (U/L)	24
Figure 15: Box plot for SGPT/ALT (U/L)	24
Figure 16: Scatter plot for SGPT/ALT (U/L)	24
Figure 17: Time trajectories for Creatinine (μmol/L)	24
Figure 18: Box plot for Creatinine (μmol/L)	24
Figure 19: Scatter plot for Creatinine (μmol/L)	24
Figure 20: Time trajectories for Sodium (mmol/L)	24
Figure 21: Box plot for Sodium (mmol/L)	24
Figure 22: Scatter plot for Sodium (mmol/L)	24
Figure 23: Time trajectories for Potassium (mmol/L)	24
Figure 24: Box plot for Potassium (mmol/L)	24
Figure 25: Scatter plot for Potassium (mmol/L)	24

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Abbreviations

AE	: Adverse Event
ALT	: Alanine Aminotransferase
AMR	: Antimicrobial Resistance
ANOVA	: Analysis of Variance
AST	: Aspartate Aminotransferase
BW	: Birth Weight
CBC	: Complete Blood Count
CGMR-C	: Centre for Geographic Medicine Research-Coast
CI	: Confidence Interval
CNS	: Central Nervous System
CONSORT	: Consolidated Standards of Reporting Trials
CRE	: Creatinine
CRF	: Case Report Form
DAIDS	: Division of AIDS
EMLc	: Essential Medicines List for Children
GNB	: Gram Negative Bacteria
Hb	: Haemoglobin
HIE	: Hypoxic Ischaemic Encephalopathy
IQR	: Inter-Quartile Range
IV	: Intravenous injection
KEMRI	: Kenya Medical Research Institute
LMICs	: Low and Middle-Income Countries
MCV	: Mean Corpuscular Volume
MDR	: Multi Drug Resistant
MedDRa	: Medical Dictionary for Regulatory Activities
PCO ₂	: Partial Pressure of Carbon Dioxide
PK	: Pharmacokinetic
PO ₂	: Partial Pressure of Oxygen
SAE	: Serious Adverse Event
SaO ₂	: Oxygen Saturation
SAP	: Statistical Analysis Plan
SAR	: Statistical Analysis Report
SD	: Standard Deviation
SOC	: Standard of Care
TBIL	: Total Bilirubin
WBC	: White Blood Cells
WHO	: World Health Organization

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

1. Scope

This Statistical Analysis Plan (SAP) provides a description of the planned analyses and reporting for an open-label trial on safety and Pharmacokinetics of fosfomycin in Hospitalised Neonates with Clinical Sepsis in Kilifi, Kenya (*protocol v2.0 dated 13th April 2018: Safety and Pharmacokinetics of Fosfomycin in Hospitalised Neonates with Clinical Sepsis*). The main changes described in protocol amendment version 2.0 include the following:

- Allow flexibility in the sample size i.e. approximately 120 babies will be enrolled
- Collect information on the tolerability of oral Fosfomycin
- Change entry criteria from 4 hours after initiating ampicillin and gentamicin to 24 hours after initiation of ampicillin and gentamicin

Other changes were procedural clarifications or corrections of inconsistencies identified in the first version of the protocol.

Since the primary objective of the trial is on the PK of fosfomycin, this SAP mainly focuses on the analyses of secondary objectives i.e.:

- a) Difference in mean plasma sodium concentrations at 48 hours and at day 7 or discharge date between the two arms and
- b) Difference in the rate of adverse events from enrolment to day 28 between the two arms.

The analysis plan for the PK and antimicrobial resistance (AMR) susceptibility sub-study of this trial will be reported separately.

Any additional or unplanned analyses not specified in this SAP will be clearly identified as such in the Statistical Analysis Report (SAR) and any other manuscripts for publication produced from the trial.

The following documents have also been considered in the process of developing this SAP:

- Clinical Research Protocol for the trial
- Case Report Forms (CRFs) for the trial

The details on the conduct of this trial, the operational aspects of clinical assessments and timing for patients in this trial can also be found in the Clinical Research Protocol.

Any changes to this SAP will be approved by those listed on the signature page.

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	------------------------------------	------------------	-------------

2. Protocol Summary

Antimicrobial resistance (AMR) has become a major issue in global health. Despite progress in the reduction of under 5 mortality rates in recent decades, the proportion of neonatal deaths occurring within this age group has increased, with almost one quarter of all neonatal deaths occurring due to serious bacterial infections. Common bacteria causing neonatal sepsis are now exhibiting widespread resistance to several classes of antibiotics. There is an urgent need to discover new, effective treatments and re-evaluate existing therapeutic agents to treat infections potentially caused by multi-drug resistant (MDR) pathogens. Gram-negative bacteria (GNB) predominate as the cause of neonatal sepsis and are increasingly associated with high rates of resistance to the currently recommended WHO empirical therapy regimen of ampicillin/penicillin and gentamicin. There is therefore a need to develop an updated empiric regimen with improved efficacy in the context of increasing MDR sepsis in neonates. New antimicrobials under development will be expensive once licenced, and there are currently no planned trials to assess their efficacy in neonates in low- and middle-income countries (LMICs).

One potential strategy is utilising an existing off-patent (and therefore affordable) antibiotic available in intravenous and oral formulations – fosfomycin. Fosfomycin has a wide spectrum of activity against Gram-positive and Gram-negative bacteria causing neonatal sepsis. It is mainly used for resistant urinary tract infections in adults but has licenced neonatal and paediatric doses in Europe (though dosing regimens vary between countries). Both oral and IV formulations are available. A large clinical trial to assess the efficacy of a fosfomycin plus an aminoglycoside combination (compared to the current WHO recommended ampicillin and gentamicin) is anticipated, including sites in Kenya. The ultimate aim is for fosfomycin to be included in the WHO essential medicines list for children (EMLc) and be available for use in developing countries, where rates of resistance to ampicillin and gentamicin have been estimated at over 40%. The first steps before this trial are to clarify the pharmacokinetics (PK) and safety profile of fosfomycin in neonates, as well as generate further information regarding local patterns of bacterial susceptibility to fosfomycin. The aim of this study is to fulfil both these steps. Fosfomycin (IV and oral) PK will be investigated among 60 neonates admitted to hospital provided with standard of care and fosfomycin. They will also be monitored to compare adverse events with 60 other neonates receiving standard of care only (without PK sampling).

In addition to this trial, the laboratory at KEMRI CGMR-C, previously archived bacterial isolates have been tested for their sensitivity to fosfomycin; and are collecting data and samples from trial participants to determine the faecal carriage of antimicrobial resistance, including to fosfomycin, at admission and discharge.

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	------------------------------------	------------------	-------------

3. Trial Objectives and endpoints

3.1. Trial Objectives

3.1.1. General Objective

To understand the fosfomycin pharmacokinetics, safety and antimicrobial susceptibility of local invasive bacterial species.

3.1.2. Specific Objectives

The specific objectives of the trial are to;

- Estimate the PK disposition parameters of IV and PO fosfomycin in neonates
- Assess the safety of fosfomycin, particularly with regards to possible elevation of sodium after 48 hours of IV fosfomycin administration in neonates
- Estimate the oral bioavailability of fosfomycin in neonates
- Generate preliminary data on the safety of oral fosfomycin in neonates
- Generate a recommended dosing schedule for future IV and PO fosfomycin trials

Note:

Since the primary objective of the trial is on the PK of fosfomycin, this SAP focuses on the analyses of secondary objectives i.e.:

- Difference in mean plasma sodium concentrations at 48 hours and at day 7 or discharge date between the two arms and
- Difference in the rate of adverse events from enrolment to day 28 between the two arms

3.2. Trial Endpoints

3.2.1. Primary endpoint

Estimation of the pharmacokinetic disposition and absorption parameters of IV and oral fosfomycin in neonates with clinical sepsis with sufficient precision such that a dose schedule can be recommended for a future efficacy trial.

3.2.2. Secondary endpoints

- Plasma sodium concentrations taken at 48 hours and at 7 days or at discharge.
- Adverse events (any grade) experience during 28 days after enrolment in the study

4. Trial Design

4.1. Study design

This is an open label, safety and pharmacokinetic study among neonates admitted to a rural hospital in Kenya and eligible for IV antibiotics under current national guidelines. Approximately 120 patients will be randomized 1:1 to standard-of-care antibiotics plus a 7-day course of fosfomycin (up to n=60 to achieve at least 45

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

complete PK sample sets); or standard of care (n=60) antibiotics only (ampicillin 50mg/kg twice daily and gentamicin (3mg/kg for babies<2kg or 5mg/kg for babies>2kg) once daily for 7 days, as per Kenyan treatment guidelines).

4.2. Study duration

The study duration for each participant is 28 days from enrolment.

4.3. Study Population

4.3.1. Selection of Subjects

The following eligibility criteria were designed to select subjects for whom the protocol treatment is considered appropriate.

4.3.2. Inclusion criteria

Subjects must meet **all** the following three inclusion criteria to be eligible for enrolment into the study:

- Patients aged 0 to 28 days inclusive.
- Weight >1500g
- Born (an estimated)>34 weeks gestation (calculated as per the Ballard Maturation Assessment)
- Admitted to hospital and eligible to receive IV antibiotics, according to national guidelines

4.3.3. Exclusion criteria

The presence of **any** of the following will exclude a subject from study enrolment:

- Baseline sodium level ≥ 150 mmol/L
- Baseline creatinine ≥ 150 micromol/L
- Presenting with severe (grade 3) Hypoxic Ischaemic Encephalopathy (HIE), defined as per Sarnat and Sarnat⁴⁴ as a stuporous, flaccid infant (with or without seizure activity) with suppressed brainstem and autonomic functions and absent reflexes
- Requiring cardiopulmonary resuscitation on admission
- Jaundice requiring exchange transfusion
- Admitted as a transfer after an overnight inpatient stay at another hospital
- Known allergy or contraindication to fosfomycin
- A specific clinical indication for another class of antibiotic (other than the nationally recommended standard of care)
- More than 24 hours after initiating ampicillin plus gentamicin (one dose of gentamicin), which allows for administration of these first line antibiotics not to be delayed by study procedures
- Concurrent participation in another clinical trial
- Attending clinician's judgement that the child is so severely ill that adequate communication about the study with the parent or legal guardian is not possible
- Not planning to remain resident in the county for the next 28 days
- Lack of consent

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

4.4. Sample Size Determination

Sample size has been calculated to ensure that the following PK parameters can be estimated with sufficient precision such that a dose schedule can be recommended for a future efficacy trial:

- Clearance (CL)
- Central volume (V)
- Oral bioavailability (F)

Precision limits were set to 20%, and the power to estimate parameters with 95% confidence intervals within these limits was assessed by simulation-estimation. The simulation model consisted of an adult disposition model, with age and size scaling down to neonates, with added first-order absorption and assumed bioavailability. Six sampling time points were chosen to cover the dose intervals (3 early, 3 late) and the simulated population was randomly assigned age and weight combinations across the range expected for neonates. Parallel and cross over (IV/oral) designs were considered, with a range of 2-4 samples per patient. Power for sample size was greatest for the cross-over design. For the cross-over design, a minimum of 45 subjects contributing the complete set of 4 samples each (allocated early and late sample following the first IV and PO dose) are required to provide power of >85% to estimate all parameters within 20% precision limits. We estimate that up to 25% of subjects will not provide complete sample sets (either due to missing samples or withdrawal), so plan to recruit approximately 60 subjects to ensure 45 complete sample sets. If all 60 subjects provide complete sample sets, power would rise to 96%. Recruitment will continue until 45 patients in fosfomycin arm have a complete set of PK samples.


5. Study Assessments

5.1. Schedule of events

A schedule of events identifying the timing of required assessments and investigations (Figure 1).

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Figure 1: Schedule of Events



 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

5.2. Assessment of Safety

5.2.1. Safety Reporting

Safety will be assessed through routine monitoring of adverse events. In addition, evaluation of hematology and blood chemistry parameters, regular measurements of vital signs and physical examinations will be conducted as per the protocol and clinical indication.

The frequency, severity, seriousness and causality assessments of AEs (for each study drug) will be described, as well as frequency of SAEs or AEs that lead to treatment discontinuation.

AEs will be collated for each treatment groups in the CRF. The adverse events reporting period begins upon subject enrolment in the trial (after signature of informed consent and ends 28 days + 7 days (4 weeks) after the first dose of study drug(s) is administered.

5.2.2. Clinical Laboratory assessments

Hematology parameters (CBC, WBC with differential and platelets) will be analyzed at screening, on days 2 and 7 (if baby remains inpatient) as is normally clinically indicated (plus any additional investigations as clinically indicated). Biochemistry and electrolytes parameters will be analysed at screening, on day 2 and day 7 (if baby remains as inpatient). Additional samples may be done if clinically indicated.

5.2.3. Anticipated Events in neonatal setting

Anticipated events are relatively common in this patient group due to low birth weight, possible birth asphyxia and concomitant disease process (*protocol page 28*).

- Anticipated events associated with neonatal setting, but which are **not assessed as "AEs"** (not an untoward medical occurrence taking into account the new born pre-existing conditions and common neonatal setting/conditions) will be reported on the CRF **but not as AEs (or SAEs)**.
- Anticipated events which are **more severe or more frequent than expected in this neonatal setting** will be reported as **AEs, and assessed for severity, causality and seriousness as any other AE**. If classified as AEs, they must be reported as AEs in the CRF and, if matching any seriousness criteria, on CRF AE and SAE form.

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Table 1: Anticipated Events in Neonatal Setting

ANTICIPATED EVENTS IN NEONATAL SETTING
Necrotising enterocolitis (diagnostic radiological/surgical changes)
Intracranial abnormality on cranial ultrasound scan (parenchymal haemorrhage or focal white matter injury)
Patent ductus arteriosus
Pulmonary haemorrhage
Severe anaemia requiring transfusion (due to ABO incompatibility, prematurity or haemorrhage)
Jaundice requiring phototherapy or exchange transfusion
Congenital birth defect diagnosed during admission
Fracture secondary to birth trauma
Apnoea
Infection (positive blood culture with clinical signs)*
Persistent derangement of liver function tests (beyond 36 weeks CGA)
Abnormal muscle tone, posturing or convulsions (secondary to suspected birth asphyxia)
An episode of Hypoglycaemia (defined as per the World Health Organization, ≤ 2.6 mmol/L) ⁴⁷

* Both infections other than condition for inclusion in trial and, in case of infections linked to the sepsis episode that is the reason of the participant's inclusion in the trial, worsening (e.g. septic shock) and relapse.

6. Planned Analysis

6.1. Interim Analysis

There is no interim analysis planned for this trial

6.2. Final Analysis

The planned final analyses will be performed only after the last patient has completed assessments scheduled for the day 28 and the database has been cleaned and locked.

Every effort will be made to collect all data as per the schedule of assessments. Where missing data occurs either because of withdrawal of consent, lost to follow-up or omitted due to investigator oversight, the analysis will capture the missing information and summaries will be provided based on available data set. Patients who withdraw consent will be excluded from trial analyses from the time they withdraw. It is assumed that when missing data occurs it will be at random.

Any additional analyses performed to provide support for planned analyses but not identified in this SAP will be documented and reported in the SAR and clearly identified as unplanned analyses in the report.

Results from the final analyses will be reviewed by the trial team prior to completion of the statistical analysis report (SAR).

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

7. Statistical Methods

7.1 Data Transformation

There is no data transformation specified in the protocol. However, any data transformations or derived variables that become necessary during analysis will be documented in the STATA analysis programs and described in the SAR and manuscripts developed from the trial.

7.2 Baseline Data

To present baseline data, summaries for continuous variables will include: n, mean, standard deviation (SD), median and interquartile range and other summaries (e.g. minimum, maximum) will be used as appropriate.

Binary and categorical data will be summarized using frequencies and proportions. Reported percentages will be rounded and reported to a single decimal place (xx.x%).

7.3 Analyses set

All patients enrolled in the trial and who have received at least one dose of the trial medication will be included in the safety analysis.

7.4 Safety Analysis

The mean difference (95%CI) in plasma sodium, creatinine, potassium and ALT values between 48 hours and day 7 and baseline will be calculated, by treatment arm. Formal testing for a difference between arms will be done using ANOVA comparing the average 48 hour and day 7 absolute values, adjusting for baseline values.

Additionally, safety for each regimen will be based on the incidence of adverse events and laboratory test abnormalities by treatment group.

The following data summaries of adverse events will be documented for each treatment arm:

- i. The number (%) of patients experiencing a SAE
- ii. The number (%) of patients experiencing a serious adverse drug reaction (SADR), where an adverse drug reaction (ADR) means that the relation to a study drug was recorded by the investigator
- iii. The number (%) of patients experiencing an AE (whether serious or not)
- iv. The number (%) of patients experiencing an ADR (whether serious or not)
- v. The median (range) number of ADR per patient (whether serious or not).
- vi. The number of patients (%) whose treatment was stopped due to an AE or other pre-specified reason.

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

7.5 Biological Parameters

7.5.1 Shift tables

Shift tables will be used to present changes between baseline and D2 and baseline and D7 (if available). Categorizations will be made into normal, grade 1, grade 2, grade 3, grade 4 and grade 5 according to DAIDS toxicity tables. The number of patients in each category will be given.

7.5.2 Graphical representations

Descriptive analyses of the biological parameter data will include the following visual presentations:

- i) Box and whisker plots will be created showing the distribution of biological parameters of interest at each measurement time point. The y-axis will show the values of each parameter on the original measurement scale. The x-axis will show the measurement times in terms of treatment day (i.e. day 0 (baseline), 2 and 7 (if available))
- ii) Scatterplots of hematological parameters with baseline values on the x-axis and D2, D7 (if available) values on the y-axis for.
- iii) Scatterplots for sodium with baseline values on the x-axis and D2, D7 if available on the y-axis.
- iv) Line graphs showing values over time as individual lines for each patient connecting measurements at baseline and all subsequent measurements up to and D7 (if available). There will be one graph per parameter.

7.6 Software

Analysis for this SAP will be done using STATA version 15.1


DNDi 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	---------------------------------	------------------	-------------

8. Results

8.1. Trial Profile

All patients who provide informed consent will be accounted for in the SAR trial from initial screening for eligibility to completion of the final analysis through a CONSORT flow diagram (Figure 2). The summary will include number by treatment group for patient’s population and reasons for trial withdrawal.

Figure 2: Participant Flow



8.2. Patient Characteristics and baseline comparisons

A summary of enrolled patients based on eligibility criteria at the two timepoints (before and after protocol amendment) will be provided.

Demographic and other baseline characteristics will be summarized by treatment group. Categorical variables will be summarized by frequencies and percentages. Percentages will be calculated according to the number of patients for whom data are available. Where values are missing, the denominator, which will be less than the number of patients assigned to the treatment group, will be reported either in the body or a footnote in the summary table. Continuous variables will be summarized in terms of mean and standard deviation as well as quartiles.

Additionally, examination (protocol section 6) feeding practices (protocol section 12), Birth history (protocol section 11), clinicians’ impression of risk (protocol section 9) and suspected

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

initial diagnosis (*protocol section 8*) will be reported as part of list of listings in the appendices.

Table 2: Baseline demographic characteristics by the treatment group

Parameter	Statistic	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Age (days)	N			
	Mean (SD)			
	Median (IQR)			
Sex, n (%)	Female			
	Male			
Estimated gestational age	Range (min-max)			

SOC=standard of care

Table 3: Baseline anthropometric and vital signs by the treatment group

Parameter	Statistic	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Weight (grams)	Mean (SD)			
	Median (IQR)			
	Median (IQR)			
Head circumference (cm)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Length (cm)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Axillary Temperature (°C)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Heart rate (bpm)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Respiratory rate (bpm)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			

SOC=standard of care; SD=standard deviation; IQR=inter quartile range

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Table 4: Baseline clinical symptoms by the treatment group

	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Clinical Symptoms and signs			
Fever			
Difficulty breathing			
Rash			
Vomiting			
Altered consciousness			
Not feeding			
Lethargy			
Seizures			
Other signs			

SOC=standard of care

Table 5: Past medical history and concomitant illness by the treatment group

	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Past medical history			
Respiratory			
General			
Infection			
CNS e.g. seizures			

SOC=standard of care

Table 6: Baseline summary of haematological parameters by treatment group

Parameter	Statistic	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Hb (g/dL)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
MCV (fl)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
WBC (x10 ³ /μL)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Neutrophils (x10 ³ /μL)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Lymphocytes (x10 ³ /μL)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Monocytes ($\times 10^3/\mu\text{L}$)	Range (min-max) Mean (SD) Median (IQR)
Eosinophils ($\times 10^3/\mu\text{L}$)	Range (min-max) Mean (SD) Median (IQR)
Basophils ($\times 10^3/\mu\text{L}$)	Range (min-max) Mean (SD) Median (IQR)
Platelets ($\times 10^3/\mu\text{L}$)	Range (min-max) Mean (SD) Median (IQR)

SOC=standard of care; SD=standard deviation; IQR=inter quartile range

Table 7: Baseline summary of blood chemistry parameters by treatment group

Parameter	Statistic	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Creatinine (CRE) ($\mu\text{mol/L}$)	Range (min-max) Mean (SD) Median (IQR)			
Sodium (mmol/L)	Range (min-max) Mean (SD) Median (IQR)			
Potassium (mmol/L)	Range (min-max) Mean (SD) Median (IQR)			
Alanine transaminase (ALT) (U/L)	Range (min-max) Mean (SD) Median (IQR)			
Aspartate aminotransferase (AST) (U/L)	Range (min-max) Mean (SD) Median (IQR)			
Alkaline Phosphatase ($\mu\text{mol/L}$)	Range (min-max) Mean (SD) Median (IQR)			
Albumin (g/dL)	Range (min-max) Mean (SD) Median (IQR)			
Total bilirubin (TBIL) ($\mu\text{mol/L}$)	Range (min-max) Mean (SD) Median (IQR)			
Calcium (mmol/L)	Range (min-max) Mean (SD) Median (IQR)			
Magnesium (mmol/L)	Range (min-max) Mean (SD)			

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	------------------------------------	------------------	-------------

Phosphate (U/L)

Median (IQR)
Range (min-max)
Mean (SD)
Median (IQR)

SOC=standard of care; SD=standard deviation; IQR=inter quartile range

A summary on positive blood or CSF culture at admission will be reported here.

A summary of the relevant clinical events will be reported here.

 2 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Table 8: Baseline summary of Blood Gas parameters by treatment group

Parameter	Statistic	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
PH	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
PO ₂ (mmHg/kpa)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
PCO ₂ (mmHg/kpa)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Bicarb (mmol/L)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Chloride (mmol/L)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			
Lactate (mmol/L)	Range (min-max)			
	Mean (SD)			
	Median (IQR)			

SOC=standard of care; SD=standard deviation; IQR=inter quartile range

A summary of the results of CSF/Blood culture (including sensitivity) will be captured here.

8.3. Exploratory Analysis

Box plot and profile plots will be used in exploring data distributions as well as identifying possible outliers. Exploratory analysis will also involve subgroup and subset analysis. The shift tables will be used in exploring the change in lab values at during and post-treatment visits from the baseline.

8.3.1. Graphical representations

Descriptive analyses of the biological parameter data will include box plots, scatter plots and line graphs where appropriate. Box plots will be created showing the distribution of biological parameters of interest at each measurement time point for two regimens side-by-side. Line graphs showing values over time as individual lines for each patient connecting measurements at baseline and all subsequent measurements. The following are the planned graphs by treatment group;

Figure 3: Time trajectories for heart rate (bpm)

Figure 4: Box plot for heart rate (bpm)

Figure 5: Time trajectories for respiratory rate (bpm)

Figure 6: Box plot for respiratory rate (bpm)

Figure 7: Time trajectories for temperature (°C)

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Figure 8: Box plot for temperature (°C)

Figure 9: Time trajectories for SaO₂ (%)

Figure 10: Box plot for SaO₂ (%)

Figure 11: Time trajectories for White cell count (×10³/μL)

Figure 12: Box plot for White cell count (×10³/μL)

Figure 13: Scatter plot for White cell count (×10³/μL)

Figure 14: Time trajectories for SGPT/ALT (U/L)

Figure 15: Box plot for SGPT/ALT (U/L)

Figure 16: Scatter plot for SGPT/ALT (U/L)

Figure 17: Time trajectories for Creatinine (μmol/L)

Figure 18: Box plot for Creatinine (μmol/L)

Figure 19: Scatter plot for Creatinine (μmol/L)

Figure 20: Time trajectories for Sodium (mmol/L)

Figure 21: Box plot for Sodium (mmol/L)

Figure 22: Scatter plot for Sodium (mmol/L)

Figure 23: Time trajectories for Potassium (mmol/L)

Figure 24: Box plot for Potassium (mmol/L)

Figure 25: Scatter plot for Potassium (mmol/L)

8.3.2. Change in Lab values

Lab shift tables (See Tables in appendix) will be used to present changes in lab values between baseline and subsequent visits. Categorizations will be made into grade 1, grade 2, grade 3 and grade 4 according to DAIDS toxicity tables. The number of patients in each category and percentage change from baseline will be given.

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

8.4. Safety Analyses: Sodium, Creatinine & Potassium

Table 9: Plasma Sodium Concentrations

48 hours	Sodium plasma concentration	Mean Difference	p-value*
	Mean (SD)		
Std, n=			
Std+Fosfo, n=			
Day 7	Mean (SD)		
Std, n=			
Std+Fosfo, n=			

* p-value from ANOVA test of difference at (48hr or day 7) between arms, adjusting for baseline values

Table 10: Creatinine

48 hours	Creatinine	Mean Difference	p-value*
	Mean (SD)		
Std, n=			
Std+Fosfo, n=			
Day 7	Mean (SD)		
Std, n=			
Std+Fosfo, n=			

* p-value from ANOVA test of difference at (48hr or day 7) between arms, adjusting for baseline values

Table 11: Potassium Concentrations

48 hours	Potassium	Mean Difference	p-value*
	Mean (SD)		
Std, n=			
Std+Fosfo, n=			
Day 7	Mean (SD)		
Std, n=			
Std+Fosfo, n=			

* p-value from ANOVA test of difference at (48hr or day 7) between arms, adjusting for baseline values

Table 12: ALT

48 hours	ALT	Mean Difference	p-value*
	Mean (SD)		
Std, n=			
Std+Fosfo, n=			
Day 7	Mean (SD)		
Std, n=			
Std+Fosfo, n=			

* p-value from ANOVA test of difference at (48hr or day 7) between arms, adjusting for baseline values

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

8.5. Safety Analysis: Adverse Events

Table 13: Number of patients experiencing adverse events

	SOC	SOC + Fosfo	Overall
Number enrolled and receiving at least one dose			
Number of patients with at least one SAE: n (%)			
Total*			
Adverse drug reaction (ADR) related to std or fosfomycin			
Not related to study drug			
Patients with at least one AE (serious or not): n (%)			
Total*			
Adverse drug reaction (ADR) related to std or fosfomycin			
Not related to study drug			
Patients with at least one ADR (serious or not) by intensity: n (%)			
Mild			
Moderate			
Severe			
Life threatening			
Death			
Patients whose treatment was stopped due to an AE (serious or not): n (%)			
Total			
Adverse drug reaction (ADR) related to std or fosfomycin			
Not related to study drug			
Patients with anticipated AE's (related and unrelated)			
Median			
Range			
Number of non-ADR per patient			
Median			
Range			
Number of ADR per patient			
Median			
Range			
Total person days at risk†			
Unadjusted rate per day (95% CI)			
Patients experiencing ≥1 DAIDS grade 3 or 4 ADR, n (%)			

AE=Adverse Event; ADR=Adverse Drug Reaction; SAE=Serious Adverse Event; SOC=Standard of care

*rows do not necessarily add to the total number of patients as a single patient may have AE's in multiple rows.

†time at risk is from day 1 to 28 or day of death if before D28.

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Additional summary detail on ADR if on oral or IV fosfomycin will be provided here.

Table 14. Serious adverse events listing

ID	Onset day (Study Day)	System Organ Class	MedDRA Preferred Term	Relation to study drug*	Intensity	Outcome

*indicate which drug if available

Table 15. Treatment discontinuation: AE and other reasons

ID	Days administered (total dose)	System Organ Class	MedDRA Preferred Term	Corresponding laboratory parameter value	Relation to study Drug*	Intensity	Rescue medication administered (Yes/No)

*indicate which drug if available

Table 16. Serious and non-serious AEs by relationship to study medication

System Organ Class	Preferred MedDRA Term	NR	ADR

Note: Data are numbers of AE rather than number of patients with an AE of each type

Table 17. Serious and non-serious AEs by severity

System Organ Class	Preferred MedDRA Term	Grade 1 n (%) []	Grade 2 n (%) []	Grade 3 n (%) []	Grade 4 n (%) []	Grade 5 n (%) []

Note: Data are number of patients (percent of patients) [number of events].

 DNDi AFRICA Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V2	22-Feb-2019
--	--	-------------------------	--------------------

Table 18: Anticipated events by the treatment group

	SOC (n=)	SOC + Fosfo (n=)	Overall (n=)
Necrotising enterocolitis (diagnostic radiological/surgical changes)			
Intracranial abnormality on cranial ultrasound scan (parenchymal haemorrhage or focal white matter injury)			
Patent ductus arteriosus			
Pulmonary haemorrhage			
Severe anaemia requiring transfusion (due to ABO incompatibility, prematurity or haemorrhage)			
Jaundice requiring phototherapy or exchange transfusion			
Congenital birth defect diagnosed during admission			
Fracture secondary to birth trauma			
Apnoea			
Infection (positive blood culture with clinical signs)*			
Persistent derangement of liver function tests (beyond 36 weeks CGA)			
Abnormal muscle tone, posturing or convulsions (secondary to suspected birth asphyxia)			
An episode of Hypoglycaemia (defined as per the World Health Organization, ≤ 2.6 mmol/L)			

SOC=standard of care

*** Both infections other than condition for inclusion in trial and, in case of infections linked to the sepsis episode that is the reason of the participant's inclusion in the trial, worsening (e.g. septic shock) and relapse.**

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 19: Shift table for Haemoglobin

Baseline (Day 0) n =		Day 2 n =						Day 7 n =					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 20: Shift table for White Blood Cells

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 21: Shift table for Neutrophils

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 22: Shift table for Lymphocytes

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 23: Shift table for Platelets

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 24: Shift table for Sodium

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 25: Shift table for SGOT/AST

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

Table 26: Shift table for Alkaline Phosphatase

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

 Drugs for Neglected Diseases initiative	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
--	------------------------------------	--------------------	-----------

Table 27: Shift table for Creatinine

Baseline (Day 0)		Day 2						Day 7					
Grade		Normal	1	2	3	4	5	Normal	1	2	3	4	5
SOC	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
SOC + Fosfo	Normal	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	1	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	2	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	3	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	4	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
	5	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)

SOC=standard of care

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

A list of listings for additional assessments will be provided here including concomitant medication as well as individual patient data listings on;

- i. adverse events
- ii. Laboratories (Hematology, Biochemistry)
- iii. Vital signs
- iv. Physical exams
- v. Demographics
- vi. Protocol deviation

	Statistical Analysis Plan (SAP)	NEO_FOSFO_SAP_V0.1	18-Mar-19
---	--	---------------------------	------------------

References

1. Protocol: Safety and Pharmacokinetics of Fosfomycin in Hospitalised Neonates with Clinical Sepsis v2.0 dated 13th April 2018